Targeting metastatic colorectal cancer with PLGA nanoparticles carrying MACC1 siRNA by Ana Rita Fortunato Sousa
 
 
 
 
 
 
 
MESTRADO EM ONCOLOGIA 
ESPECIALIZAÇÃO EM ONCOLOGIA MOLECULAR 
Targeting metastatic colorectal 
cancer with PLGA nanoparticles 
carrying MACC1 siRNA 
Ana Rita Fortunato Sousa 
M 
2018 
 
 
 
 
 
 
 
A
n
a
 R
it
a
 S
o
u
s
a
. T
a
rg
e
tin
g
 m
e
ta
sta
tic co
lo
re
cta
l ca
n
ce
r            
w
ith
 P
L
G
A
 n
a
n
o
p
a
rticle
s ca
rryin
g
 M
A
C
C
1
 siR
N
A
 
M
.ICBA
S 2018 
T
a
rge
tin
g m
e
ta
sta
tic
 c
o
lo
re
c
ta
l c
a
n
c
e
r w
ith
 
P
L
G
A
 n
a
n
o
p
a
rtic
le
s c
a
rry
in
g
 M
A
C
C
1
 siR
N
A
 
A
n
a
 R
ita
 F
o
rtu
n
a
to
 So
u
sa
 
IN
S
T
IT
U
T
O
 D
E
 C
IÊ
N
C
IA
S
 B
IO
M
É
D
IC
A
S
 A
B
E
L
 S
A
L
A
Z
A
R
 
 
 
 
 
 
Ana Rita Fortunato Sousa 
 
 
Targeting metastatic colorectal cancer with PLGA nanoparticles carrying 
MACC1 siRNA 
 
 
 
 
Dissertação de Candidatura ao grau de Mestre em Oncologia 
– Especialização em Oncologia Molecular, submetida ao 
Instituto de Ciências Biomédicas Abel Salazar da 
Universidade do Porto.  
 
 
 
 
Orientador: Prof. Doutor Bruno Filipe Carmelino Cardoso 
Sarmento  
 
Professor Auxiliar do Instituto Universitário de Ciências da 
Saúde, Cooperativa de Ensino Superior Politécnico e 
Universitário e Coordenador do Grupo Nanomedicines and 
Translational Drug Delivery do Instituto de Engenharia 
Biomédica /Instituto de Investigação e Inovação em Saúde - 
Universidade do Porto.  
 
 
 
 
Co-orientadora: Professora Doutora Maria José Cardoso 
Oliveira  
 
Professora Afiliada da Faculdade de Medicina da 
Universidade do Porto e Coordenadora do Grupo Tumour 
Microenvironment Interactions do Instituto de Engenharia 
Biomédica /Instituto de Investigação e Inovação em Saúde - 
Universidade do Porto. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“A imaginação é mais importante do que o conhecimento.  
O conhecimento é limitado.  
A imaginação envolve o mundo”. 
Albert Einstein (1879-1955) 
 
  
 i 
 
Acknowledgments 
Firstly, I want to thank to my supervisor, Professor Bruno Sarmento for receiving me in his 
group, for his good mood and patience for teaching me, and for his effort on moving the 
group forward, improving the visibility of our work. Thank you for training us to be 
autonomous people and at the same time favouring social activities to promote good work 
relationships, remembering us to help each other. To my co-supervisor, Professor Maria 
José Oliveira, I want to thank all her care for me and for giving me a very good example of 
what is like to be a hard-working woman with passion for science, with no time to spend, 
and still, time to hear everyone with attention and always available to do everything for her 
students. At both I want to let my sincere thank you for giving me an opportunity to work in 
this field and learn from you, even starting with no experience and being so stressed and 
serious all the time. For hearing my problems and suggestions, even with so few time to 
share. 
To Professor Kerry Chester from University College London (UCL), I want to acknowledge 
for being available to provide the anti-CEA antibody fragment, essential for the execution of 
this dissertation.  
I want to leave my institutional acknowledgments to the Director of the Oncology Master, 
Professor Carmen Jerónimo, to the Instituto de Ciências Biomédicas Abel Salazar (ICBAS), 
to the Instituto Português de Oncologia do Porto (IPO-Porto) and to the Universidade do 
Porto (UP) for giving me the chance to ingress in this master programme. Is necessary also 
to gratefully acknowledge the financial support obtained from the project NORTE-01-0145-
FEDER-000012, supported by Norte Portugal Regional Operational Programme (NORTE 
2020), under the PORTUGAL 2020 Partnership Agreement, through the European 
Regional Development Fund (ERDF). The present work was also supported by FEDER - 
Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - 
Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 
2020, and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/ 
Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the project "Institute 
for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274). I am 
grateful for the funding received from the CESPU/IINFACTS under the project NanoCEA-
CESPU-2018.  
To the Nanomedicines and Translational Drug Delivery group at Instituto de Inovação e 
Investigação em Saúde da Universidade do Porto (I3S), I want to leave my HUGE thank 
you, as every single person there helped me and teach me something important. Namely, I 
must thank to Patrick Kennedy, for teaching me all the molecular biology possible to learn 
 ii 
 
in so short time, for teaching me working with love, for his time, patience and suggestions, 
so important for the development of my work. To Ana Vanessa Oliveira, for teaching me in 
the more final steps of my work, for her patience, suggestions and good mood. To all the 
awesome GIRLS that I met in that group, I will not name people because all were important 
for me! For staying with me and hearing me even with all my negativity issues, for dancing 
with me, making me smile, teaching me, and finally, for making that place a more peaceful 
one with lots of beauty and style. I am really grateful for meeting you all!  
I also must thank to the people from the Tumour Microenvironment Interactions from I3S, 
because they also helped me in the more initial important steps of my work, namely to 
Ângela Costa and Patrícia Cardoso.  
To my university friends, namely my Daniela, for taking care of me and being for so long 
the only person that I could trust in this city. To my GIRLS from Covilhã, Carolina, Inês 
and Cátia, thank you is not enough for everything that you have done for me. I will try to 
be as good friend for you all, like you have been for me all this time.  
To my friends from Alcobaça, the ones that I wish I could spend more time with, thank you 
for waiting for me and not giving up on me.   
To my boy, my Adriano, thank you for all your patience, understanding, advices, love, and 
mostly, for not giving up on me and remember me that are things more important in life. 
To my parents, the ones who teach me the values of the hard work in the land and in the 
pigs, the ones who I wish that could understand me more. Without them, without what I 
learn from them, I would not be able to reach this final year of my master. They supported 
me financially, but more important than that, they teach me how to be a good person and a 
good worker. They gave me love all this time though other ways, and now I understand that 
better and I love them very much. I hope they feel proud of me, even if I don’t follow their 
dreams. To my beautiful godson, Duarte, for waiting so patiently for me, for his love, and 
for being the only one who I can play with. To my brother, sister and to my Catarina, thank 
you for remembering me that work is not everything, for giving me all the physical love I 
need, for supporting me at distance, for being such amazing persons. I have no words to 
all of you. 
I want to thank God, for giving health to me and to the ones that I care about.  
This work is specially dedicated to my parents, brother, sister and to my Catarina. 
 
iii 
Contents 
Acknowledgments ............................................................................................................... i 
Figures List ........................................................................................................................ v 
Tables List ........................................................................................................................ vi 
Abbreviations List ............................................................................................................ vii 
Abstract ........................................................................................................................... xii 
Resumo .......................................................................................................................... xiv 
I. Introduction .................................................................................................................. 1 
Cell surface molecules highly expressed on CRC ............................................................. 6 
Carcinoembryonic antigen as a target for CRC-directed therapies .................................... 9 
Nanoparticles: An opportunity for safe drug delivery ........................................................12 
CEA-targeting nanotechnologies......................................................................................14 
Small interfering RNA as an oncological therapy .............................................................23 
Pharmacokinetics of siRNA and in vivo challenges ..........................................................28 
Nanosystems for siRNA delivery in metastatic CRC ........................................................31 
MACC1 contribution for metastasis in colorectal cancer ..................................................37 
II. Aims of the Dissertation ............................................................................................41 
III. Materials and Methods .............................................................................................43 
IV. Results ......................................................................................................................54 
1. Selection of CEA & MACC1 most expressing CRC cell lines .......................................55 
2. Silencing efficiency of MACC1 in SW480 cell line ........................................................56 
3. Physicochemical characterization of nanoformulations ................................................58 
4. Evaluation of siRNA complexation with spermidine ......................................................60 
5. Physicochemical characterization of functionalized nanoformulations ..........................62 
6. Cell Uptake Studies .....................................................................................................64 
V. Discussion .................................................................................................................76 
VI. Conclusions and Future Perspectives ....................................................................85 
VII. References ...............................................................................................................89 
VIII. Appendices .............................................................................................................99 
 iv 
 
Immunofluorescence assay for evaluation of CEA localization in SW480 and HCT-116 cells
 ...................................................................................................................................... 100 
Cell interaction studies with anti-CEA scFv by flow cytometry analysis (FACS) ............. 101 
Evaluation of CEA recognition by Cy7.5-scFv and functionalized PLGA-FITC nanoparticles 
by FACS ........................................................................................................................ 102 
Physical-chemical characterization of functionalized nanoparticles  ................ 103 
Cytotoxicity evaluation by metabolic activity assay (MTT) and LDH release assay ........ 104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
Figures List 
Figure 1. Schematic representation of two major pathways followed by colorectal cancer..
 ......................................................................................................................................... 3 
Figure 2. The carcinoembryonic antigen cell adhesion molecules (CEACAM) family ......10 
Figure 3. Structure of conventional whole immunoglobulin and antibody fragments ........18 
Figure 4. Most common reaction chemistries to conjugate antibodies to other structures 
 ........................................................................................................................................22 
Figure 5. Small interfering RNA (siRNA) structure ...........................................................25 
Figure 6. siRNA post-transcriptional silencing mechanism ..............................................27 
Figure 7. Chemical structures of important polymers .......................................................35 
Figure 8. MACC1 impact on the tumorigenesis progression of colorectal cancer ............39 
Figure 9. MACC1 as a key regulator of HGF-MET pathway in CRC. ...............................40 
Figure 10. General scheme of nanoparticles production and functionalization carrying the 
siRNA/spermidine complex ..............................................................................................47 
Figure 11. Representation of the functionalization protocol through maleimide chemistry.
 ........................................................................................................................................50 
Figure 12. Evaluation of CEA and MACC1 expression in seven colorectal cancer cell lines 
through Western Blot analysis .........................................................................................56 
Figure 13. Western blot analysis of MACC1 silencing in SW480 colorectal cancer cells 
through silencing with MACC1 siRNA. .............................................................................57 
Figure 14. TEM images of the nanoformulations .............................................................60 
Figure 15. Polyacrylamide gel electrophoresis (PAGE) of siRNA complex-loaded 
nanoformulations and siRNA complexes. .........................................................................62 
Figure 16. Confocal microscopy evaluation of uptake studies performed ........................67 
Figure 17. ImageStream®X analysis of uptake studies performed ....................................75 
Figure 18. Immunofluorescence assay for cell-surface CEA detection in HCT-116 and 
SW480 colorectal cancer cells ....................................................................................... 100 
Figure 19. Preliminary FACS analysis to evaluate scFv interaction in SW480 (CEA 
expressing CRC cell line) ............................................................................................... 101 
Figure 20. Preliminary study of the CEA recognition ability of scFv-Cy7.5 and of 
functionalized NPs made with PLGA-FITC polymer were evaluated by flow cytometry 
analysis (FACS) in SW480 cells .................................................................................... 102 
Figure 21. Enzyme-linked immunosorbent assay (ELISA) of different formulations ....... 103 
Figure 22. Evaluation of the toxicity of the nanoformulations and of free siRNA ............ 104 
 
 
 vi 
 
Tables List 
Table 1. Evaluation of the pathological stage of the colorectal cancer. Adapted from [10]. 4 
Table 2. Prognostic groups according to AJCC/UICC 7th edition. Adapted from [10]........ 4 
Table 3. Treatment options sorted by colorectal cancer stage. Adapted from [10, 12]. ..... 5 
Table 4. Nanoparticle-based targeting systems to promising cell surface molecules for 
gastrointestinal cancer treatment and monitorization. ....................................................... 8 
Table 5. CEA-targeted nanosystems for monitorization and therapeutic applications. .....19 
Table 6. Differences between several RNA interference tools for silencing purposes in 
cancer. .............................................................................................................................26 
Table 7. Co-encapsulants to improve the encapsulation of siRNA in PLGA nanoparticles 
suitable for oncological therapy. .......................................................................................36 
Table 8. Scheme of samples analysed in the cell uptake experiments. ...........................52 
Table 9. Nanoparticles characterization at different surfactant pH. ..................................58 
Table 10. Nanoparticles characterization and association efficiency evaluation. ..............59 
Table 11. Nanoparticles production and scFv-Rhodamine conjugation efficiency evaluation.
 ........................................................................................................................................63 
Table 12. Nanoparticles production using FITC- PLGA polymer. .....................................64 
Table 13. Characterization of functionalized nanoparticles at several scFv ratios and 
conjugation efficiency (CE) determination by ELISA direct method. ............................... 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
Abbreviations List 
A  
Ac-BSA Acetylated bovine serum albumin 
ADCC Antibody-dependent cell-mediated cytotoxicity 
AE Association efficiency 
AFP Alpha fetoprotein 
AgNCs Silver nanoclusters 
AGO2 Endonuclease argonaute-2 
AJCC American joint cancer committee 
Akt Protein kinase B 
APC Adenomatous polyposis coli 
AuNPs Gold nanoparticles 
  
B  
BCL-2 B-cell lymphoma 2 gene 
BRAF BRAF protooncogene 
BSA Bovine serum albumin 
  
C  
CA 19-9 Carbohydrate antigen 19-9 
Cbl-b Casitas-B-lineage lymphoma protein-b 
CCR5 C-C chemokine receptor type 5 
CDR Complementary-determining regions 
CD44v6 Cluster of differentiation 44 variant 6 
CD66e Cluster of differentiation 66e 
CE Conjugation efficiency 
CEA Carcinoembryonic antigen 
CEACAM Carcinoembryonic antigen cell adhesion molecules 
CH Constant domain of the heavy chain 
CIMP CpG island methylator phenotype 
CIN Chromosomal instability 
CL Constant domain of the light chain 
CLSM Confocal laser scanning microscopy 
c-MET Tyrosine kinase receptor Met  
c-Myc c-Myc protooncogene 
COSD Chitosan oligosaccharides conjugated with deoxycholic acid 
CpG Dinucleotide cytosine-guanine 
CPP Cell penetrating peptide 
CQ Chloroquine 
CRC Colorectal cancer 
CRISPR Clustered regularly interspaced short palindromic repeat 
Cy5 Cyanine 5 dye 
Cy 7.5 Cyanine 7.5 dye 
  
D  
DCAMKL-1 Doublecortin like kinase 1 
DL Drug loading 
 viii 
 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOTAP 1,2-dioleoyl-3-trimethylammoniumpropane 
DR-5 Death receptor 5 
dsRNA Double-stranded RNA 
DTT D,L-1,4-Dithiothreitol 
  
E  
EDC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
eGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EPR Enhanced permeation and retention effect 
  
F  
Fab Fragment antigen binding 
Fab’ Fab’ antibody fragment 
F(ab)’2 F(ab)’2 antibody fragment 
FACS Fluorescence-activated cell sorter 
FAP Familial adenomatous polyposis 
FBS Foetal bovine serum 
Fc Fragment crystallisable region 
FcR Fragment crystallisable receptor 
FcRn Neonatal Fc receptor 
FDA  Food and drug administration 
FITC Fluorescein isothiocyanate 
FRα Folate receptor-alpha 
FTIR Fourier-transform infrared spectroscopy 
Fv Fragment variable region 
  
G  
GFP Green fluorescent protein 
GPI Glycosylphosphatidylinositol 
  
H  
HA Hyaluronic acid 
hAb Half-antibody fragment 
HER2 Human epidermal growth factor receptor 2 
HER3 Human epidermal growth factor receptor 3 
HGF Hepatocyte growth factor 
His Histidine 
hMLH1 hMLH1 tumour suppressor gene 
hMLH3 hMLH3 tumour suppressor gene 
hMSH2 hMSH2 tumour suppressor gene 
hMSH3 hMSH3 tumour suppressor gene 
HNPCC Hereditary non-polyposis colorectal cancer 
hPMS2 hPMS2 tumour suppressor gene 
ix 
hPMS1 hPMS1 tumour suppressor gene 
  
I  
Igs Immunoglobulins 
IP-10 Interferon gamma-induced protein 10 
iRGD 9-amino acid cyclic cell penetrating peptide 
IS Internalization score 
  
K  
Ka Acid dissociation constant in equilibrium 
KC Keratinocide-derived cytokine 
KD Equilibrium dissociation constant 
Ke Internalization rate constant 
KRAS KRAS protooncogene 
  
L  
LDH Lactate dehydrogenase 
LHRH Luteinizing hormone-releasing hormone 
LOH Loss of heterozygosity 
  
M  
mAb Monoclonal antibody 
MACC1 Metastasis-associated in colon cancer 1 
mAp Modified Ap cell penetrating peptide 
mCRC Metastatic colorectal cancer 
MDR1 Multidrug resistance protein 1 
MFI Mean fluorescence intensity 
MGMT O6-methylguanine DNA methyltransferase 
mHph1 Modified HpH1 cell penetrating peptide 
miRNAs  Micro-RNA 
MMR Mismatch repair genes 
MMP9 Matrix metallopeptidase 9 
MPs Microparticles 
MPS Mononuclear phagocytic system 
mRNA Messenger RNA 
MSI Microsatellite instability 
MTT 3-(4,5,-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
  
N  
NCI National cancer institute 
NHS N-hydroxysulfosuccinimide 
NIH National institutes of health 
NMCD Non-malignant colorectal disease 
NPs Nanoparticles 
N/P ratio Ratio of amine groups from the polyamine to the phosphate groups of 
the siRNA 
NRAS NRAS protooncogene 
NMR Nuclear magnetic resonance 
 x 
 
P  
PAGE Polyacrylamide gel electrophoresis 
PAMAM Polyamidoamine dendrimers 
PBMC Peripheral blood mononuclear cell 
PC Pancreatic cancer 
PdI Polydispersity index 
PEG Poly(ethylene glycol) 
PEI Polyethylenimine 
PFA Paraformaldehyde 
P-gp P-glycoprotein 
PIC Protease inhibitors cocktail 
PIK3CA Phosphatidylinositol 3-kinase, catalytic, alpha gene 
PI3K Phosphoinositide 3-kinase 
PLGA Poly(lactic-co-glycolic acid) 
PLK1 Polo-like kinase 1 
PLL Poly-L-lysine 
p-53 p-53 tumour suppressor gene 
  
Q  
QC Quinacrine 
QDs Quantum dots 
  
R  
RES Reticuloendothelial system 
RISC RNA-induced silencing complex 
RME Receptor-mediated endocytosis 
RNA Ribonucleic acid 
RNAi RNA interference 
RPMI Roswell park memorial institute 
RT Room temperature 
  
S  
scFv Single-chain variable fragment 
sdAb Single-domain antibody fragment 
SWCN Single-walled carbon nanotube 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SMCC Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
SM[PEG]4 Succinimidyl-[(N-maleimidopropionamido)-tetraethyleneglycol] ester 
SPIONs Superparamagnetic iron oxide nanoparticles 
SS-Fc SS-Fc bispecific antibody fragment 
  
T  
TAG-72 Tumour-associated glycoprotein-72 
TCEP Tris(2-carboxyethyl)phosphine hydrochloride 
TEM Transmission electron microscopy 
TfR1 Transferrin receptor protein 1 
TGF-α Transforming growth factor alpha 
xi 
TGF-β Transforming growth factor beta 
TGF-βRII Transforming growth factor beta receptor II 
TLR Toll-like receptor 
TNF-α Tumour necrosis factor alpha 
TNM TNM classification of malignant tumours 
TP53 TP53 tumour suppressor gene 
  
U  
UICC Union for international cancer control 
  
V  
VEGFR Vascular endothelial growth factor receptor 
VH Variable domain of the heavy chain 
VL Variable domain of the light chain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
Abstract 
Colorectal cancer (CRC) is one of the most common cause of cancer-related death in the 
world, mainly due to distant metastases events. The therapeutic regimens as platinum-
based standard chemotherapy recommended for metastatic stages of the disease are still 
far from satisfactory. Developing targeted strategies to treat those cases is needed. The 
carcinoembryonic antigen (CEA) is a cell surface-overexpressed glycoprotein in most CRC 
patients and the evaluation of its serum levels is recommended in the clinics. On the other 
hand, metastasis-associated in colon cancer 1 (MACC1) protein is a transcription factor 
recently known to trigger metastatic phenotype in CRC patients. Here, it was developed an 
innovative nanocarrier, made with well-known poly(lactic-co-glycolic acid) PLGA and 
poly(ethylene glycol) PEG polymers, one is a low toxicity material and the other was used 
to increase particles’ circulation time in body fluids, respectively. What makes this carrier a 
novelty is that it is CEA-targeted and loaded with MACC1 siRNA. The nanoparticles were 
surface-functionalized with an anti-CEA single-chain variable fragment (scFv), 
shMFELL2Cys. The internalization of CEA-linked nanosystems is expected to occur by the 
natural recycling of the CEA itself, enabling its longer retention and sustained release of the 
cargo. In the present dissertation it was demonstrated that: i) SW480 and HCT-116 
colorectal cancer cells are the ones that express at the same time significative levels of 
MACC1 and CEA; ii) MACC1 protein is efficiently silenced in SW480 cells, by the 
SMARTpool ON-TARGETplus siRNA MACC1; iii) CEA protein seems to be expressed at 
the surface of SW480 cells; iv) Nanoparticles were loaded with siRNA and functionalized 
with the shMFELL2Cys. Functionalized nanoparticles were close to 400 nm in size, 
negatively charged (~ - 25 mV) and the association efficiency of the MACC1 siRNA was 
5%. Nanoparticles functionalized with the shMFELL2Cys at 1:2.5 scFv ratio were able to be 
internalized better by the CEA-expressing SW480 cells, compared to lower ratios. To 
evaluate the specificity of the anti-CEA nanoparticles for the SW480 cells, a negative control 
antibody fragment was also used for nanoparticles functionalization. The efficiency of 
internalization was lower for the negative control antibody-decorated nanoparticles than the 
observed when particles were functionalized with the antibody fragment anti-CEA, probably 
contributing to demonstrate the specificity of the positive-targeted system to the CEA-
expressing cells. Moreover, the confocal microscopy indicated that intracellular vesicles 
formed by nanoparticles internalization had a significant higher size from the ones formed 
when smaller entities were uptake. This probably indicates that nanoparticles were 
internalized by phagosomes (pH ~ 5), instead of the vast-described endosome-mediated 
uptake. Nevertheless, the novel targeted therapy proposed is expected to be systemically 
administered in CRC patients with tumours harbouring CEA and MACC1 expression. It is 
xiii 
intended, in the future, to demonstrate the MACC1 silencing ability of the therapy developed 
on colorectal cancer CEA-expressing cells. 
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Resumo 
O cancro colorretal (CRC) é uma das maiores causas de morte relacionada com cancro no 
mundo, devido nomeadamente à ocorrência de eventos metastáticos distantes. Os regimes 
terapêuticos como quimioterapia standard baseada em platina que são recomendados em 
estadios metastáticos da doença continuam longe de ser satisfatórios. O desenvolvimento 
de estratégias dirigidas para tratar estes casos é necessário. O antigénio 
carcinoembriónico (CEA) é uma glicoproteína sobreexpressa em muitos doentes de CRC 
e a avaliação dos seus níveis séricos é recomendada na clínica. Por outro lado, a proteína 
associada à metastização em cancro do cólon 1 (MACC 1) é um fator de transcrição que 
se sabe recentemente desencadear o desenvolvimento de fenótipos metastáticos em 
doentes de CRC. Aqui, foi desenvolvido um transportador inovador, feito com polímeros 
bem conhecidos como o poli(ácido lático-co-glicólico) PLGA e o polietilenoglicol (PEG), um 
dos quais é um material de baixa toxicidade e o outro foi utilizado para aumentar o tempo 
de circulação das partículas nos fluídos corporais, respetivamente. O que torna este 
transportador uma novidade é o facto de ser dirigido para o CEA e transportar o siRNA 
MACC1. A superfície das nanopartículas foi funcionalizada com um fragmento variável de 
cadeia única anti-CEA (scFv), shMFELL2Cys. Na presente dissertação foi demonstrado 
que: i) As células de cancro colorretal SW480 e HCT-116 expressam ao mesmo tempo 
níveis significativos das proteínas MACC1 e CEA; ii) A proteína MACC1 foi eficientemente 
silenciada em células SW480, pela SMARTpool ON-TARGETplus siRNA MACC1; iii) A 
proteína CEA aparenta ser expressa à superfície de células SW480; iv) As nanopartículas 
foram carregadas com o siRNA e funcionalizadas com o shMFELL2Cys. As nanopartículas 
funcionalizadas obtiveram aproximadamente um tamanho de 400 nm, uma carga negativa 
(~ - 25 mV) e uma eficiência de associação do siRNA MACC1 de 5%. As nanopartículas 
funcionalizadas com o shMFELL2Cys ao rácio de scFv de 1:2.5 conseguiram ser melhor 
internalizadas em células SW480 que expressam o CEA, relativamente aos rácios 
menores. De forma a avaliar a especificidade das nanopartículas anti-CEA para as células 
SW480, um fragmento de anticorpo de controlo negativo foi também utilizado para a 
funcionalização das nanopartículas. A eficiência de internalização foi menor para as 
nanopartículas funcionalizadas com o anticorpo de controlo negativo do que a observada 
para partículas funcionalizadas com o fragmento de anticorpo anti-CEA, provavelmente 
contribuindo para demonstrar a especificidade do sistema dirigido positivamente para 
células que expressem CEA. Além disso, a microscopia de confocal indicou que as 
vesículas intracelulares formadas pela internalização de nanopartículas tiveram um 
tamanho significativamente maior que aquelas formadas quando entidades menores 
sofreram internalização. Isto provavelmente indica que as nanopartículas foram 
xv 
internalizadas por fagossomas (pH ~5), em vez de pela internalização mediada por 
endossomas já vastamente descrita.  Mesmo assim, pretende-se que a nova terapia 
dirigida proposta seja administrada sistemicamente em doentes de CRC que apresentem 
tumores que expressem CEA e MACC1. No futuro, é nossa intenção demonstrar a aptidão 
da terapia desenvolvida para silenciar a MACC1 em células de cancro colorretal que 
expressem CEA.   
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Tumorigenesis of CRC  
Colorectal cancer (CRC) is the 3rd more incident, the fourth most common cause of cancer-
related death and the third with the highest 5-year prevalence (post treatment) in the world 
[1]. This type of malignant neoplasm arises from the mucosa of the colon or the rectum and 
has the tendency of growing towards the lumen and/or spreading to neighbouring organs. 
It starts by the accumulation of genetic alterations that could change the normal epithelia to 
aberrant crypt foci, adenoma, carcinoma and ultimately, metastatic disease [2].The 
neoplasm could follow one of tree mechanisms of tumorigenesis (or a combination of all) 
that are categorized by: i) chromosomal instability (CIN), ii) microsatellite instability (MSI); 
and iii) CpG island methylator phenotype (CIMP) [3].  
 
Chromosomal Instability Pathway (CIN)  
The chromosomal instability pathway represents 65-70% of sporadic colorectal cancers. It 
first requires the acquisition of mutations in the adenomatous polyposis coli (APC) gene. 
The inactivation of tumour suppressor genes is genetically recessive, and so it is necessary 
the bi-allelic inactivation of this type of genes, which can arise by deletion, point mutation 
and methylation mechanisms. The next step of CIN is the activation of KRAS, a 
protooncogene, which can be made with a point mutation, chromosomal translocation or an 
amplification mechanism. Because of the dominant nature of mutations in this type of 
genes, it is only necessary a single allele mutational event. The major events in CIN tumours 
are the aneuploidy, which is characterized by an imbalance in the chromosomes number, 
and loss of heterozygosity (LOH). These events are referred to the majority of sporadic 
tumours (85%) and are also related with germline mutations in APC gene, a condition of 
familial adenomatous polyposis (FAP) cases. The last step of CIN is the additional mutation 
of TP53, TGF-β and PIK3CA specific pathways [4, 5].  
 
Microsatellite Instability Pathway (MSI)  
The microsatellite instability pathway is responsible for introducing inactivating mutations in 
the DNA mismatch repair genes (DNA MMR genes), such as hMSH2, hMSH3, hMLH1, 
hPMS2, hPMS1 and hMLH3, which are tumour suppressor genes that repair DNA 
replication errors. When the main role played by these DNA MMR genes is affected, occurs 
the accumulation of hundreds of somatic mutations in short repeated sequences or 
microsatellites, driving spontaneous errors of replication in the cell, that leads to mutational 
activation and inactivation of genes related to cancer, that could potentiate or inhibit the cell 
survival and cell growth. This pathway is followed by almost 15% of sporadic colorectal 
malignant neoplasms [3, 6, 7]. 
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If mutations in this kind of genes occur in germline cells, that represent 3% of the cases of 
MSI colorectal cancers, it possibly results in the production of dysfunctional DNA mismatch 
repair proteins. This is the main cause for people with Lynch Syndrome predisposed to 
hereditary non-polyposis colorectal cancer (HNPCC) [7]. 
CpG Island Methylator Phenotype (CIMP)  
The CpG island methylator phenotype pathway promotes the hypermethylation of tumour 
suppressor genes like MGMT and hMLH1. Most sporadic colorectal cancers (almost 80 %) 
that are considered to belong to mismatch repair (MMR) deficiency, are related to 
methylation of hMLH1 which is associated to the CIMP positive tumours. The 
hypermethylation of CpG island in promoter gene region of certain tumour suppressive 
genes inhibits their transcriptional activity. Almost all cases of tumours with mutation in the 
BRAF gene follow this tumorigenesis pathway [8, 9]. Figure 1 outline the major pathways 
of CRC tumorigenesis. 
 
 
 
 
 
 
Staging in colorectal cancer  
According to the American Joint Cancer Committee (AJCC)/Union for International Cancer 
Control (UICC) TNM classification, 7th edition (Table 1 and 2), a correct assessment of the 
pathological stage of the malignant neoplasm should consider several features. These are 
the extension of tumour into the bowel wall and adjacent organs (T stage), site and number 
of removed regional lymph nodes and their possible infiltration by cancer cells (N stage) 
and the involvement of other organs if submitted for removal or biopsy (M stage) [10, 11]. 
Figure 1. Schematic representation of two major pathways followed by colorectal cancer. The microsatellite 
instability pathway (MSI) includes the inativation of DNA mismatch repair genes, which can occour in the 
germline cells triggering the Lynch syndrome (~ 3-5% of MSI cases) or  in sporadic events (~ 12-15% of MSI 
ases). The chromosomal instability pathway (CIN)  triggers inativating mutations on tumour supressor genes 
and activating mutation in oncogenes, representing ~ 85% of the sporadic CRC events. Once those mutations 
occour  in the adenomatous polyposis coli (APC) gene from in germiline cells, it can trigger the Familial 
adenomatous polyposis (< 0.5%). 
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Table 1. Evaluation of the pathological stage of the colorectal cancer. Adapted from [10]. 
Primary tumour (T)  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T4a Tumour penetrates the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph nodes (N)  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in one to three regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in two to three regional lymph nodes 
N1c Tumour satellite deposits in subserose or in non peritonealised tissues 
N2 Metastases in ≥4 regional lymph nodes (a: 4–6, b: ≥7) 
Distant metastases (M)  
M0 No distant metastases 
M1 Distant metastases 
M1a Metastases confined to one organ or site  
M1b Metastases in more than one organ/site or the peritoneum 
 
Table 2. Prognostic groups according to AJCC/UICC 7th edition. Adapted from [10]. 
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
 T2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-T2 N1/N1c M0 
 T1 N2a M0 
IIIB T3-T4a N1/N1c M0 
 T2-T3 N2a M0 
 T1-T2 N2b M0 
IIIC T4a N2a M0 
 T3-T4a N2b M0 
 T4b N1-N2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
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Therapeutic strategies in colorectal cancer 
If the morphological structure of the polyp allows, the complete endoscopic polypectomy 
should be carried out. If identified a carcinoma in a polyp, it is necessary to study which 
histological features are associated and, in function of them, establish a possible prognosis, 
and then evaluate the better treatment strategy [10]. Table 3 represents several treatment 
options recommended, according to the stage of colorectal cancer. 
Table 3. Treatment options sorted by colorectal cancer stage. Adapted from [10, 12]. 
Stage 0 (Tis N0 M0) Treatment options 
 i) Local excision or simple polypectomy. 
ii) Segmentary in-bloc resection for lesions not suitable to local excision. 
Stage I (T1-2 N0 M0)  
 i) Wide surgical resection and anastomosis. No adjuvant chemotherapy is 
indicated. 
Stage II (T3 N0 M0,T4a-b N0 M0)  
 i) Wide surgical and anastomosis. 
ii) Following surgery, adjuvant therapy should not be recommended for 
unselected patients. High-risk patients who present at least one of the clinical 
characteristics: lymph nodes sampling <12; poorly differentiated tumour; 
vascular or lymphatic or perineural invasion; tumour presentation with 
obstruction or tumour perforation and pT4 stage, adjuvant therapy could be 
applied. 
Stage III (any T, N1-N2, M0)  
 i) Wide surgical resection and anastomosis. 
ii) Following surgery, the standard therapeutic scheme is oxaliplatin and 
fluoropyrimidine. FOLFOX4 or XELOX should be preferred to FLOX and have 
superior performance than 5-FU/FA alone [I, A]. When oxaliplatin is 
contraindicated, monotherapy with infusional or oral fluoropyrimidines should 
be preferred to bolus 5-FU FU/LV. 
Stage IV (any T, any N, M1)  
 i) Resectable liver and/or lung: Surgery and possible preoperative FOLFOX, with 
curative purpose. 
ii) Potentially resectable after cytoreduction therapy: Most active combination 
scheme to induce tumour shrinkage. 
iii) Multiple metastases:  Most active combination scheme for tumour shrinkage 
and control of disease. 
iv) Asymptomatic with multiples metastases: Intensive therapy not applied 
(FOLFOX as an exception), the major goal is the tolerability and ensure patient 
quality of life. 
FA: 5-fluorouracil and actinomycin D; FLOX: bolus of 5-fluorouracil and leucovorin, with oxaliplatin; FOLFOX: 5-fluorouracil, leucovorin and 
oxaliplatin; FOLFOX4: FOLFOX regimen; LV: leucovorin; XELOX: oxaliplatin and capecitabine; 5-FU: 5-fluorouracil. 
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Prognosis evaluation 
The biomarker carcinoembryonic antigen (CEA) is considered to have a prognostic value in 
preoperative setting (<5 ng/dL could mean poor prognosis). If it is observed an increased 
preoperative value, not normalised after 1 month of surgical resection it is probably an 
evidence of persistent disease.  CEA is also useful for postoperative follow-up of CRC 
patients and can be either used in the evaluation of treatment of metastatic disease, 
although it has a low predictive value for diagnosis in asymptomatic patients [10, 12]. Higher 
pre-therapy serum levels of CEA and carbohydrate antigen (CA 19-9) have a negative 
prognostic significance. There are specific entities and features that are under assessment 
for their alone or combined value for prognosis, under high-risk conditions: the KRAS proto-
oncogene, the apoptosis regulator BCL-2, the tumour suppressor p-53, the growth factors 
EGFR and TGF-alpha, the aneuploidy and proliferation index [10]. 
 
Cell surface molecules highly expressed on CRC 
Targeted technologies to diagnose, to evaluate the prognostic or the predictive response to 
a treatment, and even to treat tumours rely on identifying molecular entities characteristic, 
or at least, highly expressed in neoplastic rather than normal tissues. The histological 
features and genetic signature of certain tumours permit the stratification into distinct 
subtypes, providing in some cases a reliable prediction of response to a targeted therapy 
[13, 14].    
One of the most consensual definitions of tumour marker is given by the National Cancer 
Institute (NCI), from the National Institutes of Health (NIH), as entities, most of them proteins 
that are produced by cancerous or noncancerous cells in response to malign or benign 
events. When referring to a malignancy, they exist in higher levels and can be found in 
tissues or body fluids of some cancer patients [15].  
 One factor that cannot be discard is that the presence of a certain tumour marker in a 
patient is not always correspondent to a predicted clinical state or response to a treatment, 
and sometimes the variation between measurements into a population could be high, which 
invalidates its usage [16].  
The nanosystems made to specifically deliver a diagnostic probe or a therapeutic agent to 
the inside of a cancerous cell, require to be firstly highly targeted to a cell-surface molecule, 
and ideally, specifically expressed in the malign phenotype of study. For this reason, it is 
necessary to understand which are the molecular options that remain available for the 
targeting of colorectal cancer cells. The most common overexpressed cell surface 
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molecules in colorectal cancer are the cell-adhesion protein carcinoembryonic antigen 
(CEA), the tumour-associated glycoprotein-72 (TAG-72), the folate receptor – α (FRα) and 
the epithelial growth factor receptor (EGFR), that are present at 98.8 %, 79.0 %, 37.1 % 
and 32.8 % of cases, respectively, when compared with matched health tissues [14]. 
Another study suggests that CD44v6 overexpression, a hyaluronic acid (HA) receptor, 
represents a poor prognostic factor for colorectal adenocarcinoma patients [17]. Other 
authors confirmed the existence of a higher level of serum carbohydrate antigen 19-9 (CA 
19-9) and of alpha fetoprotein (AFP) in colorectal cancer patients, rather than in patients 
with non-malignant colorectal disease (NMCD) [18]. In addition, the vascular endothelial 
growth factor receptor (VEGFR) and the transferrin receptor protein 1 (TfR1) are also 
upregulated in CRC [19, 20]. Other relevant cell surface molecule is tyrosine kinase receptor 
c-MET, that is highly expressed in colorectal cancer and in liver metastases of this malignant 
neoplasm [21]. Lastly, the death receptor 5 (DR-5) is a cell-surface receptor with pro-
apoptotic characteristics that is overexpressed in stage II and III colorectal cancer patients 
[22]. Table 4 represent some of nanoparticle-based targeting systems to current most 
promising cell-surface molecules for gastrointestinal cancer treatment and monitorization.  
In clinics, the tumour biomarkers that are also cell-surface molecules, currently used either 
for disease monitoring, diagnostic, prognostic and predictive response in colorectal cancer 
are few. The CEA is indicated for several situations: i) stage II patients’ prognosis, ii) 
preoperative evaluation of newly diagnosed cases, iii) postoperative surveillance and iv) in 
advanced disease monitorization. The CA 19-9 (a cell-surface carbohydrate antigen) has 
emerged, although not yet FDA-recommended, as a postoperative surveillance marker, in 
cases of metastatic disease, when CEA is not upregulated [23]. The overexpression of MET 
and of human epidermal growth factor receptor 2 (HER2) configures de novo resistance to 
anti-EGFR immunotherapy (HER3 and EGFR mutations were not clearly associated). 
Despite of this, the overexpression evaluation of EGFR, HER2, MET or HER3 are not 
recommended for CRC patients [24]. In ultimate analysis, CEA is an overexpressed protein 
in the most CRC cases, and the only cell-surface molecule recommended for colorectal 
cancer patients’ management. These reasons motivate the selection of CEA as a promising 
molecule for nanoparticle-targeting systems in colorectal cancer. 
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Table 4. Nanoparticle-based targeting systems to promising cell surface molecules for gastrointestinal cancer 
treatment and monitorization. 
 
 
 
Receptor Cell lines  Ligand Formulation Drug delivered Remarks Ref. 
CEA LS174T 
HCT-116 
Monoclonal 
antibody (mAb) 
Magnetic NPs ----- Maghemite NPs conjugated to anti-CEA 
(~550 nm) had greater uptake by CEA+ 
CRC cells. The biocompatibility of the 
system was confirmed. 
[25] 
CEA and 
TAG-72 
LS174T 
HT29 
Anti-TAG-72 
mAb and Anti-
CEA mAb 
Human serum albumin 
NPs 
 In vivo studies performed with LS174T 
and HT29 xenografts. 
NPs with ~120 nm had specific binding 
for mice CRC tissues. 
[26] 
EGFR HCT-116 
SW-480 
HT-29 
SW-620 
Cetuximab-Fab’ 
fragment 
Liposomes Oxaliplatin Liposomes had ~120 nm, efficiency of 
encapsulation of ~32% and a loading 
capacity of ~65 µg/mg. 
Fab’-Liposomes induced cell-specific 
uptake, and cytotoxicity to EGFR+ CRC 
cells. 
[27] 
VEGFR CT26 Polyclonal 
antibody 
Dextran-coated iron 
oxide NPs 
---- In vivo studies performed with CT26 
xenograft. 
Anti-VEGF-NPs had 65 nm, 
demonstrated in vivo tumour targeting 
and efficient accumulation in tumour 
tissues. 
[28] 
CD44 Colon-26 Hyaluronic acid 
(HA) 
PLGA NPs Camptothecin 
(CPT) / 
Curcumin 
(CUR) 
HA-functionalized PLGA NPs with ~300 
nm, co-delivered Camptothecin (CPT) 
and Curcumin (CUR) (1:1) for CRC-
targeted combination chemotherapy 
evidenced enhanced toxicity. 
[29] 
CD44v6 MKN74 
(gastric 
cancer cell 
line) 
Fab (fragment 
antigen binding) 
PLGA-PEG NPs --- NPs of ~300 nm and tagged with the 
Fab had specific cellular binding. NPs 
coated with Fab(CD44v6+) showed 
negligible binding to negative cells, as 
the Fab(CD44v6-)-decorated NPs on 
the positive cells. 
[30] 
CD44v6 PANC-1 
(pancreatic 
cancer 
cells) 
Single-chain 
variable 
fragment (scFv) 
Amphiphilic deblock 
copolymer of poly 
(ethylene glycol) and 
poly (D, L-lactide) [mal-
PEG-PDLLA] 
Arsenic trioxide 
(As2O3) 
In vivo studies performed with PANC-1 
xenografts. 
mal-PEG-PDLLA vesicles had ~200 nm 
and encapsulation efficiency of 65.8%. 
scFv-loaded-NPs (drug concentration of 
8 mM), induced more apoptosis than the 
free drug or non-functionalized-loaded 
NPs. 
[31] 
Folate 
Receptor 
HT-29 Folic Acid (FA) PLGA NPs 5-FU Nanoparticles had ~200 nm, 
encapsulation efficiency of ~30% and 
drug loading of ~6%. FA conjugation of 
~47% was obtained using 1, 3-
diaminopropane as linker. 5-FU loaded 
FA-PLGA NPs showed cell toxicity at 
50µg/mL. 
[32] 
CA 19-9 Pancreatic 
cell lines:   
AsPC-1, 
BxPC-3-
Luc, KP4, 
PK-59 
L-fucose Liposomes Cisplatin In vivo studies performed with AsPC-1 
and BxPC-3-Luc xenografts. 
L-fucose-Liposome cisplatin-loaded 
had ~200 nm. The greatest cytotoxicity 
was observed when using 50µg/mL 
Fuc-Liposomes. Being these ultimate 
ones more cytotoxic than the free drug. 
[33] 
TfR Caco-2 mAb Liposomes ----- Anti-Trf-NPs with ~100 nm, had 4.5-fold 
greater binding than the ones non-
functionalized or coated with negative 
mAb. 
[34] 
DR-5 HCT-116 mAb PLGA-PEG NPs Camptothecin In vivo studies performed with HCT-116 
xenografts. 
Nanoparticles had ~200 nm, and 
association efficiency of ~18%. In mice 
treated with DR5-NPs, the malignant 
mass reduced ~35% over both PBS 
and control-IgG conjugated NPs. 
[22] 
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Carcinoembryonic antigen as a target for CRC-directed 
therapies 
CEA features  
Carcinoembryonic antigen (CEA) is a glycoprotein that belongs to the 12 members-family 
of carcinoembryonic antigen cell adhesion molecules (CEACAM), as Figure 2 suggests. On 
its turn, CEACAMs belong to the superfamily of immunoglobulins (Igs) and are generally 
characterized by harbouring one variable (IgV-like) N-terminal domain, homologous to the 
Ig variable domain, responsible for the binding to homophilic and heterophilic cell adhesion 
molecules. This terminal N-domain is generally linked to none or a maximum of 6 constant 
domains (IgC2-like), also homologous to immunoglobulins non-variable domains. In the 
specific case of the CEA protein, also known as CEACAM5 or CD66e, once produced it is 
covalently bound to glycosylphosphatidylinositol (GPI), and this post-translational 
modification leads to the anchorage of CEA at the external surface of the phospholipidic 
bilayer. This GPI-anchorage to the membrane does not allow CEA to perform by itself any 
transduction of signal since it lacks intracellular domains, requiring transactivation through 
other intracellular partners  [35, 36]. 
Carcinoembryonic antigen (CEA) is produced in human gastrointestinal tract during early 
stages of embryonic and fetal development (from 9 to 14 weeks), and before birth its serum 
levels decrease, remaining very low in the adult life [37]. Nevertheless, there are some 
structures that still produce CEA afterwards. Its expression is mainly observed in goblet and 
columnar epithelial cells of the colon, namely in the free luminal surface and at the upper 
third of the crypt. It is also present in prostate, cervix, tongue, esophagus, stomach and 
sweet glands [38]. An healthy adult produce about 50-70 mg/day of CEA from the apical 
surface of mature enterocytes and release it extracellularly into the gut lumen, which will 
get to the exterior environment with the defecation process [38, 39].  
When referring to glycoproteins, the linkage between the polypeptide backbone and the 
glycans typically occurs through two chemical strategies: i) the binding of the nitrogen atom 
of an asparagine residue to a glycan chain (N-glycans), as the case of CEACAM5; ii) or the 
binding of an oxygen atom of a serine or threonine residue to a glycan chain (O-glycans), 
like mucins. Glycoproteins as CEA, either in normal or neoplastic forms, are highly N-linked 
to oligosaccharides [40]. Namely, colorectal neoplasms produce high levels of CEA 
glycosylated forms that can reach the blood vessels, and at this point, can be detected into 
circulation. Indeed, in practice, the molecular mass of CEA is 180-200 kDa, and about 60% 
of this value is due to N-glycosylation. However, the theoretical molecular weight of the full-
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length protein, after deglycosylation treatment, decreases approximately to 80 kDa. 
Notably, the glycosylated patterns of CEA differ amongst tissues and cells. There are 
described isoforms, being the most abundant the splice variant derived from isoform 5D 
that has 60 kDa; and the splice variant derived from isoform 3D with estimated 40 kDa [41].  
Importantly, CEA protein expression is associated with melanoma, lung adenocarcinoma, 
mucinous ovarian carcinoma, and it is mostly seen in digestive tract cancers as pancreatic, 
gastric and namely, colorectal carcinomas [35, 38]. In opposition to an healthy context, in 
which colon cells express CEA only through the apical side, once the tumorigenic process 
occurs, there is no more defined basal lamina in the tissue, cells lose polarity and CEA is 
expressed in the entire surface [38]. 
 
 
 
 
 
 
 
 
 
 
Figure 2. The carcinoembryonic antigen cell adhesion molecules (CEACAM) family. Each molecule harbours one 
variable (IgV-like) N-terminal domain (rose ball), homologous to the Ig variable domain. The terminal N-domain is 
generally linked to constant domains (IgC2-like), that are represented here as the blue balls with the letters A and B. 
CEACAMs 5-8 are covalently bound to the membrane by a GPI linkage (blue arrows), whereas CEACAMs 1,3,4 and 
19-21 use transmembrane domains. CEACAM16 is the only fully secreted protein. CEACAMs are generally highly 
N-glycosylated (green shapes). 
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Recycling of the CEA protein 
This oncofoetal molecule is more often referred as a non-internalizing antigen. Besides, 
Jeffrey Bryan et al. studied the internalization and biodistribution of CEA at several time 
points. To achieve this, they used two antibodies, an anti-CEA mAb and a known rapid 
internalized monoclonal antibody, both labelled with a radionucleotide (cooper-64). They 
tested labelled mAbs in mouse xenografts from LS174T colorectal cancer cells. The results 
revealed that CEA had a fast blood clearance, an increased liver uptake and enhanced 
tumour vascular accumulation when compared with the supposed fast internalized antibody. 
These events suggested that CEA is continuously secreted by the tumour to the 
bloodstream and right after is cleared by receptor-mediated endocytosis in the hepatic cells. 
The secreted CEA, as the authors suggested, is probably immediately coupled to the CEA 
targeted mAb, establishing CEA-antibody complexes that could explain the fast appearance 
of radioactivity in the liver. Besides, the own affinity of the antibody influences its cellular 
penetration, being the high affinity ones more susceptible of binding firstly to the soluble 
CEA, leaving only a few to bind to the membrane-linked CEA, decreasing in this way the 
antibody penetration within tumours [42].  
Once inside the body, an antibody is immediately exposed to the bloodstream and 
clearance, extravasation from capillary vessels, tumour diffusion, internalization and finally, 
catabolic degradation in cancer cells [43]. Another recent line of thinking is suggested by K. 
Dane Wittrup et al. that compared the CEA detection using different antibodies and namely 
the internalization rate constant (Ke) of an mAb anti-CEA and two single-chain variable 
fragments (scFvs) anti-CEA, the Sm3E [44] and shMFE [45], latter referred in this 
dissertation, in several CRC cell lines [46]. The team interest on evaluating different 
antibodies is also due to their potential to transport pharma, either only using an antibody 
associated-drug or an antibody tagged-nanosystem carrying the drug. One factor that is 
certainly delaying the success of antibody technologies for drug deliver is precisely its lack 
of penetration in cancer cells [47]. The cellular internalization followed by antibody-ligand 
binding, and consequent catabolism that occurs inside the cell, decrease the penetration 
ability of the antibody, and by its turn, the penetration of the drug associated [46]. The 
monoclonal antibody tested, independently of its own affinity, exhibited a similar slow uptake 
by CRC cells (10-16h), compatible with the metabolic turnover of the CEA protein (~15 h). 
The uptake was enough to guarantee its distribution and retention in the cells. Importantly, 
none of the antibodies tested triggered changes in CEA expression. The hypothesis that is 
given by K. Dane Wittrup’s team, infers that the uptake of the antibodies into CRC cells 
results from a non-specific signalling mechanism and from the natural recycling of the CEA 
itself. In this way, it often underlines the role of CEA as a GPI-linked protein, with no known 
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ability to trigger signalling transduction pathways. Antibodies with slower internalization 
rates, as surface molecules with slow turnovers, are more likely to enhance the penetration 
and retention in the tumour cells [46]. Once the internalization into a CRC cell occurs by 
non-specific mechanisms, the usage of less affinity ligands for CEA recognition is probably 
the best choice when the main objective is the sustained intravenous release of drugs, 
avoiding thereby its binding to soluble CEA.  
 
Nanoparticles: An opportunity for safe drug delivery 
Drug delivery systems have been developed to improve the transport of therapeutic entities 
through the biological fluids of the body, enhancing their half-life time in circulation, and 
decreasing their side effects, namely toxicity [48]. The major role of drug delivery strategies 
not only comprises the overcoming of poor solubility and stability of standard therapies, 
giving the opportunity to test known drugs that otherwise would be ignored; but could even 
be applied to novel therapeutic entities, giving them the ability of overcoming biological 
barriers and making them more specific for tumour cells [49, 50]. 
The promising contributions of such technologies has attracted the attention of cancer 
researchers and physicians around the world. The chemotherapy, radiotherapy and surgery 
resection remain as the three “gold standards” anti-cancer therapies. Nevertheless, the 
majority of the standard chemotherapies approved for the clinical usage have no ability to 
distinguish normal from cancer cells. This leads to severe side effects, namely in fast-
growing cells, once those drugs act generally in impairing mitosis. Those cells include hair 
follicles, cells from bone marrow and gastrointestinal system, leading to hair loss, immune 
system failure and infections, respectively [10, 51, 52].  
Drug nanocarriers are solid and colloidal particles that emerge as safe drug vehicles, 
designed to generate much fewer toxic side effects and deliver high quantities of cargo to 
a very specific site of interest [53]. Nanoparticles allow 1 – 1000 nm diameter [54], however 
being the < 200 nm ones the most suited for intravenous administrations, considering the 
width of body microcapillaries. Their advantages over microparticles (with a diameter > 1 
µm) are notable, once the diameter of the body capillaries are 5-6 µm and particles over 5 
µm could aggregate and drive an embolism [55].  
The novel therapies produced so far that are currently used for colorectal cancer, include 
targeted agents, as monoclonal antibodies anti-VEGF like Bevacizumab [56], or anti-EGFR 
as Cetuximab [57] and Panitumumab, the anti-VEGF recombinant fusion protein 
Aflibercept, and the multikinase inhibitor Regorafenib [58]. For early colorectal cancer, no 
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biological targeted drugs are actually recommended [10]. Additionally, for metastatic CRC 
conditions, the majority of these therapies, namely the monoclonal antibodies, only 
evidence clinical benefit when combined with standard chemotherapeutics [24, 58]. Most of 
the work that have been done on encapsulating those novel targeted molecules, like 
monoclonal antibodies, only intended the encapsulation of a single drug. Nevertheless, as 
most of them are only useful when combined with standard therapies, it is perhaps more 
interesting to encapsulate the whole combinatorial therapeutic scheme into the particles, 
instead of just an entity of it.  
When developing a new formulation for therapeutic purposes, there are main objectives to 
accomplish. Firstly, to guarantee that the system is biocompatible and stable in body fluids, 
which can be ensured by properly coating the particle surface with materials, as 
poly(ethylene glycol) PEG, that avoid the adhesion of opsonins, permitting to escape to the 
immune system surveillance. Secondly, to increase the concentration of drug into the 
tumour tissue, by using materials that increase the tumour enhanced permeation and 
retention (EPR) effect, or simply by targeting the whole system to a molecule highly 
expressed in the tumour but not in healthy tissues. Finally, to reduce the toxic side effects 
of the drug, either by simply encapsulation, or encapsulating the drug within a targeted 
system [59].  
In the field of targeted drug delivery, strategies can be sorted through passive or active 
targeting. The targeted system, as other non-targeted vehicles, will be into the bloodstream. 
The difference is that the term ‘passive targeting’ is used as a synonymous of “blood 
circulation and extravasation”, meaning the passive accumulation of drugs in the 
vasculature surrounding the tumour, followed by an extravasation to tumour tissues, where 
it will be distributed [60]. The active targeting happens only after the “blood circulation and 
extravasation” where it occurs a specific interaction with a ligand from the drug/vehicle and 
a certain cancer cell molecule. The nanoparticles’ surface can also be functionalized with 
molecules that have affinity to a specific celular target of cancer cells as surface receptors 
and soluble proteins, to direct the whole system to a specific site [27].   
One characteristic that tumours have, although not exclusively, that might increase 
nanoparticles passive or active recruitment, is the enhanced permeation and retention 
effect, known as EPR effect. The EPR effect is a phenomenon observed for 
macromolecules such as certain proteins and polymers with a molecular weight higher than 
40-50 kDa. Such effect favours molecules and nanoparticles delivery systems preferential 
accumulation in the neoplastic tissue rather than in healthy tissue, increasing the local 
concentration of a given drug [61]. The main reason for this behaviour is the defective 
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hypervascularization with lacking of lymphatic drainage of the damaged tissues, so these 
molecules can invade the tumour tissue without being cleared for long time [62]. The 
inherent properties associated to these specific materials make them suitable to use in 
pharmaceutical formulations to enhance the accumulation of a drug into a solid neoplasm.  
Nanocarriers can be sorted into organic (liposomes, polymeric micelles, polymeric 
nanoparticles and dendrimers), inorganic (iron oxide nanoparticles, gold nanoparticles, 
mesoporous silica nanoparticles, carbon nanoparticles and quantum dots), and hybrid 
organic-inorganic particles [53]. One polymer that has become a success regarding 
polymeric nanoparticles is the poly(lactic-co-glycolic acid) (PLGA), mainly due to its 
biodegradability and low cellular toxicity [63]. Some PLGA polymers are FDA-approved 
materials and until nowadays several formulations of PLGA nanoparticles were clinically 
introduced, namely for advanced prostate cancer, ELIGARD®, that delivers leuprolide, the 
luteinizing hormone-releasing hormone (LHRH) that inhibits testosterone expression [64]. 
Importantly, PLGA nanoparticles are versatile systems, once depending on the production 
method, can deliver hydrophobic [65] or hydrophilic drugs [66]. The functionalization of this 
polymer with poly(ethylene glycol) (PEG) turns the system less immunogenic, difficult its 
internalization and subsequent degradation by cancer cells, enhances its stability in the 
body and its accumulation on solid tumours, profiting from the described EPR effect  [59, 
67]. For the reasons above mentioned, PLGA polymeric nanoparticles will be privileged 
here. 
 
CEA-targeting nanotechnologies 
To create a targeted nanoparticle, is necessary to tag at its surface a molecule that will 
specifically bind to a cell-surface receptor characteristic of a pathology, or at least 
overexpressed in comparison to normal tissues, or even any extracellular molecule of 
interest. The functionalization of nanoparticles with specific ligands is currently a field of 
development, and several types of molecules can be used, considering the desired 
application. The ligands explored until nowadays include vitamins [68], proteins [69], 
peptides [70], aptamers [71], monoclonal antibodies [72], and antibody fragments [73]. The 
last one covers a variety of entities as: i) F(ab)’2, Fab’, Fab and half-antibodies - hAb 
(∼67kDa), native antibody fragments (Figure 2B), which can be produced by introducing 
specific enzymes or chemicals to cleave strategic points of a total immunoglobulin [74]; and 
ii) single-chain variable fragments - scFv (~27 kDa), single-domain antibody fragments - 
sdAb (~13 kDa) and SS-Fc bispecific fragments (~80 kDa), genetically-engineered antibody 
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fragments (Figure 2C), generally produced by recombinant technologies like phage display 
techniques [74].    
The high affinity properties found in antibodies led to multiple applications in medicine, as 
the emerging immunotherapy. Nowadays, antibody fragments are arising as a new and 
improved technology that relies on full-antibody features with more advantages for 
conjugation to nanovehicles and tissue penetration [53]. 
Most of the applications of anti-CEA nanomaterials are used for detection of the secreted 
CEA protein itself, or even in the detection of CEA-overexpressing cells such as colorectal 
or pancreatic cancer cells [44, 75]. Despite of the huge potential of new tools to detect CEA 
as monitoring purposes, only a few are working in CEA-targeting systems to enhance the 
efficiency of cancer therapy in more developed stages [72, 73]. The Table 5 focus on the 
CEA-targeted nanotechnologies that can be applied to colorectal cancer therapy and 
monitorization. From now on, this dissertation will preferentially refer the contributions of 
antibodies, more specifically antibody fragments as promising molecules to nanoparticles 
driven therapies. 
 
Active targeting moieties 
Aptamers 
Aptamers are usually non-immunogenic, single-stranded, synthetic oligonucleotides from 
RNA or DNA that can bind specifically to cell surface molecules. The small size of aptamers 
(from 20 to 50 nucleotides) allow them to work as deliver vehicles into the intracellular 
space. Although not able to passively permeate through biological membranes, these 
molecules overcome the phospholipidic bilayer through specific binding to cellular receptors 
that have turnover metabolisms compatible with the degradation time of the aptamer. 
Ultimately, they exhibit nano to picomolar affinities for their targets [71, 76, 77]. 
 
Monoclonal antibodies 
The soluble form of antibodies is produced by professional B lymphocytes (plasmocytes), 
and there exist several manners of artificially fabricate antibodies against a desired protein 
epitope of an antigen. Each B lymphocyte clone produces antibodies that are specific for 
only a single epitope. A monoclonal antibody is in this way, an antibody produced by a 
single clone of B cells. To produce monoclonal antibodies of interest, host animals are first 
immunized with a specific immunogenic sequence of a given antigen, the epitope. Once 
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immature B cells, non-reactive to host-antigens, migrate to the host spleen, they follow the 
maturation step where they are presented to the foreign antigen previously introduced. Still 
in the spleen, mature B lymphocytes, expressing at their surface the Ig receptors 
recognizing specifically the desired epitope, are selected and isolated. Those B cells are 
then fused with immortal B cancer cells, the myeloma cells, to constitute a highly proliferative 
hybridoma, immortal producers of that monoclonal antibody [78]. 
As exposed in Figure 3A, each full length-immunoglobulin (~150 kDa) is composed by two 
Heavy chains (H, in blue) and two Light chains (L, in green). Within each chain there are 
two separated regions, the amino-terminal Variable region (V), containing VH and VL 
domains, and the carboxyl-terminal Constant region (C), containing CH1, CH2 and CH3 
domains. Disulphide bridges are essential to link all chains and create the ‘Y’ shape 
characteristic of an Ig. In addition, each heavy (VH) or light variable (VL) region contains a 
hypervariable domain, composed by three protein loops, the Complementary-Determining 
Regions (CDRs). The CDRs have different amino acid sequences from antibody to 
antibody, which make them responsible for the variety of antigen epitopes that antibodies 
can specifically recognize [74]. 
Moreover, the full antibody has two fragment antigen binding (Fab) regions that integrate 
the sites for antigen binding (hypervariable regions) and the constant regions from heavy 
(CH1) and light (CL) chains. The Fragment crystallisable (Fc) region is the antibody portion 
that activates cells containing Fc receptors (FcR), namely phagocytic cells. Phagocytes 
have in this way the ability of trigger an immunological response through antibody-
dependent cell-mediated cytotoxicity (ADCC). Fc fragments also initiate complement 
activation through the classical pathway, which ends with cell lysis [79]. Interestingly, 
immunoglobulins and albumin are the most abundant proteins present in human serum. To 
not waste much energy by producing de novo these proteins, the body has specific 
mechanisms to prolong their half-life in circulation. Particularly, FcRn (neonatal Fc 
Receptor) appears as an intracellular Fc-receptor that recognizes antibodies Fc domains 
and albumin, avoiding their degradation by lysosomes, which is an advantage of using 
whole Ig for targeting proposes [80].   
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Antibody fragments 
Some drawbacks of whole antibodies are the immunogenicity and the clearance from 
bloodstream, both due to binding of Fc receptor-containing entities to antibody Fc region, 
[81]. In addition, antibody size (~150kDa) difficult cell penetration. Besides this, the bigger 
advantage of using a full-length mAb for targeting systems is the presence of two antigen 
binding regions (Fab), while some antibody fragments carry only one. 
Antibody fragments, excluding SS-Fc ones [82], have multiple advantages in comparison 
to mAb, regarding their use in intracellular drug delivery systems. Firstly, they are less 
immunogenic than a whole Ig due to the lack of the Fc region, retaining almost the affinity 
and specificity found in whole immunoglobulins, and secondly, they are able to couple in a 
more oriented manner to a nanoparticulate system [47, 81]. For nanoparticle-decorating 
purposes, the size of the ligands is also important, making antibody fragments a certainly 
very promising toll. 
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A) Conventional IgG structure 
B) Native antibody fragments C) Genetically-engineered antibody fragments 
Figure 3. Structure of conventional whole immunoglobulin and antibody fragments. A) Conventional IgG has one 
Fragment crystallizable region (Fc) and two fragment antigen binding (Fab) regions, each one containing one 
Fragment variable (Fv) region. The two heavy (H, on blue) and Light (L, on green) chains contain the amino-ended 
Variable region (VH or VL, respectively), and the carboxyl-ended Constant region (CH1, CH2, CH3 or CL, 
respectively). The sites for antigen binding are given by three Complementary-Determining Regions, CDRs (the green 
arches on the amine-ending). The Fc portion is also glycosylated (yellow hexagons). The disulphide bridges (S-S) 
stabilize the ‘Y’ format of the Ig. B) Native antibody fragments. F(ab)’2, Fab’, Fab and half-antibodies - hAb (∼67kDa). 
C) Genetically-engineered antibody fragments. Single-chain variable fragments - scFv (~27 kDa), single-domain 
antibody fragments - sdAb (~13 kDa) and SS-Fc bispecific fragments (~80 kDa). 
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Table 5. CEA-targeted nanosystems for monitorization and therapeutic applications. 
 
Ligand Formulation Linker Drug Features Ref. 
CEA aptamer Combination of 
Silver nanoclusters 
(AgNCs) and gold 
nanoparticles 
(AuNPs) 
Half-complementary 
DNA + CEA aptamer + 
half complementary 
DNA 
_ _ _ _ _ _ Detects CEA within a range of 0.01-1 ng/mL. The CEA detection 
limit was 3 pg/mL. DNA-Au NPs had 15.4 ± 0.7 nm and -37.3 ± 1.5 
mV. This method was validated by testing CEA in healthy human 
blood samples. 
[71] 
Amine 
modified CEA 
aptamer 
Upconverting 
nanoparticles 
(UCPs) 
CEA amine modified 
aptamer + hexanedioic 
acid (HAD) 
_ _ _ _ _ _ The CEA detection occurred within a range of 4-100 pg/mL. The 
CEA detection limit was 1.7 pg/mL. The HSA-UCPs had 10-20 nm. 
The CEA aptamer was conjugated through carbodiimide 
chemistry. 
[77] 
mAb anti-
CEA 
Silica nanoparticles SMCC 
SM[PEG]4 
EDC/sulfo-NHS 
PAMAM dendrimers 
_ _ _ _ _ _ In vivo studies performed with LS174T xenografts. 
PAMAM dendrimer-conjugated particles had 71 nm. The CRC cell 
lines used for in vitro studies were LS174T, LoVo and HCT116. 
CEA-targeted PAMAM dendrimer-conjugated NPs had the highest 
binding to CEA comparing with the negative control. 
[83] 
mAb anti-
CEA 
Carbon nanotubes BSA-fluorescein Doxorubicin A single SWCN had ~1 nm, AE of 87.5% (indirect method) and 
theoretical DL of 11.6 %. The weight ratio of Doxorubicin to 
oxidised SWCNs is 20:1. The carbodiimide chemistry was applied. 
CRC cell lines for in vitro studies: WiDr. 
[72] 
mAb anti-
CEA 
PLGA 
nanoparticles 
PEG-COOH Paclitaxel NPs had ~ 200 nm and -10.4 mV with a low PdI. They had also a 
practical DL of 16.6% and AE of 99.4 %. Carbodiimide chemistry 
was applied and the NPs showed a sustained release up to 48h 
and had no cytotoxicity in the CRC cells.  CCR cell line CEA+ was 
Caco-2 and CEA- was SW480. 
[84] 
Sm3E (scFv) Superparamagnetic 
iron oxide 
nanoparticles 
(SPIONs) 
Dextran-OH 
Dextran-PEG-COOH 
_ _ _ _ _ _ Sm3E was engineered with a C-terminal (6x His) tag and 
produced in yeast. The scFv KD was 30 pM. Carbodiimide 
conjugation strategy was applied. CRC cell line CEA+ was LS174T 
and Melanoma cell line CEA- was A375M. 
[44, 46] 
shMFE (scFv) PEG chain (5 kDa) 
Fluorescein 
Biotin 
Nitroxide spin label 
Dibromomaleimide 
Dithiophenolmaleimide 
_ _ _ _ _ _ shMFE has tropism to the same CEA epitope as Sm3E does and 
was also produced in yeast. The KD of shMFE to CEA was 8.5 nM 
and the KD of spin-labeled scFv in PBS was 1.91 ± 0.78 µM, while 
in plasma was 4.35 ± 1.27 µM and in whole blood was 6.46 ± 1.7 
µM. The CEA detection limit was 100nM (spin labelled-scFv). 
Maleimide chemistry was applied. The PC cell line CEA+ was 
CAPAN-1 and the melanoma cell line CEA- was A375. 
[45, 46] 
MFE-23 
(scFv) 
Carbon nanotube 1-pyrene-NHS ester 
Hexahistidine tag 
_ _ _ _ _ _ Ni-NPs had 20-60 nm and are linked to nanotubes through an 
electrochemical technique. The scFvs have an hexahistidine tag 
in its C-terminal. The fragment was produced in bacteria. 
[85] 
SS-Fc Anti-Flag-FITC Histag 
Flagtag 
_ _ _ _ _ _ In vivo studies performed with LS174T xenografts. 
SS-Fc was produced in bacteria. The Histag (6x His) and Flagtag 
(polypeptide chain) motifs were added to the C-terminal of anti-
CEA-Fc and anti-CD16-Fc domain. The KD was 0.195 nM (for 
CEA) and of 5.75 nM (for CD16). The SS-Fc had potent toxicity 
against CEA+ cells HT29 and LS174T. The ovarian cancer cell line 
CEA- was SKOV3. 
[82] 
hAb anti-CEA Lipid-polymer 
hybrid NPs 
PEG-Maleimide Paclitaxel hAb-NPs had 95 nm and -55 mV. The hAb-NPs had an IC50 of 
251 nM and non-functionalized particles had an IC50 of 526 nM. 
The theoretical DL was 3.8 %. The maleimide chemistry was 
applied and NPs functionalized with hAb had more than 2-fold 
increase in toxicity comparing to naked NPs. The PC cell line 
CEA+ was BxPC-3 and CEA- was XPA-3. 
[73] 
sdAb-CEA Quantum Dots 
(QDs) 
Sulfo-SMCC 
PMPI 
_ _ _ _ _ _ The KD was 8.3 nM and sdAb-QDs had 11.9 ± 2.9 nm. sdAb was 
enginnered with a 6-Histidine tag chain in its C-terminal (sdAb-
C17 his6Cys). Produced in bacteria. The CRC cell line CEA+ was 
MC38CEA and CEA-was MC38. 
[75, 86] 
 AE: Association Efficiency; CRC: colorectal cancer; DL: Drug Loading;  His: Histidine;  KD: Equilibrium Dissociation Constant;  NPs: nanoparticles; PC: pancreatic cancer;  
PdI: polydispersity index;  scFv: single-chain variable fragment; SWCN: single-walled carbon nanotube;  
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Antibody conjugation strategies 
To covalently link two compounds, it is first necessary to understand the reactive groups 
that are present in each of them. Next, it is required to choose the most appropriate 
crosslinker to participate in the selected conjugation reaction. When referring to antibody 
conjugation systems, there are two main chemistries that might be applied: the carbodiimide 
and the maleimide one. Importantly, the conjugation chemistry that is selected to bind a 
antibody to a nanoparticle can influence the specific binding to a desired epitope [83]. As 
explored below, the linker chosen for ligand-nanoparticle coupling is essential to modulate 
the nanosystem characteristics. 
     
Carboxyl-to-Amine conjugation reaction 
This strategy is many times applied to covalently link the amine-containing residues (lysine, 
histidine and arginine) to a carboxylated structure or carboxyl-containing residues, as 
aspartic acid and glutamic acid, to a primary amine structure.  
The first of a two-step reaction of carbodiimide chemical conjugation, where 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), a carbodiimide linker, reacts with 
the carboxylated structure is represented in Figure 4A.The production of a relatively more 
stable and water-soluble ester complex is achieved through the addition of sulfo-NHS, N-
hydroxysulfosuccinimide, representing the second step of the reaction. Thereby, the 
carboxyl-activated groups of the structure react with the primary amine groups of the 
antibody fragment (scFv), producing ultimately a stable amide between both. More 
importantly, the carbodiimide is known as a “zero-length” linker, meaning that the unstable 
intermediate o-Acylisourea will not participate in the final product of the reaction. The same 
happens when carbodiimide is used in combination with NHS or sulfo-NHS (NHS linked to 
a sulfonate group – SO3-) [87]. Interestingly, James P Tiernan and collaborators tested two 
different linkers to conjugate a monoclonal antibody to nanoparticles by the carbodiimide 
chemistry: the EDC/NHS and the polyamidoamine (PAMAM) dendrimers. These 
dendrimers have primary amine groups at their surface that could either bound to the 
carboxylated silica nanoparticles or to the antibody. Authors studied the specificity of the 
conjugated systems, by conjugating separately with a negative control monoclonal 
antibody. Overall, they demonstrated that the EDC/NHS linkers provided 1.7-fold more 
binding comparing with the negative control, although not sufficient to guarantee specific 
binding. Moreover, the PAMAM dendrimers linked via carbodiimide chemistry showed a 
maximum binding of 12.3-fold comparing with negative control. These results could be 
explained due to the amplification of the conjugation when using crosslinkers that bind to 
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multiple molecules. In this case, each PAMAM dendrimer binds a single nanoparticle to 
several antibodies, amplifying the number of ligands that exist in the system, and therefore, 
increasing the available ligand epitopes for CEA receptor targeting. The article also alerts 
for the importance of using negative control antibodies to confirm that the binding of an 
antibody-functionalized nanoparticle is only due to the affinity of the antibody to its target 
epitope, and not due to nonspecific interactions that may occur [83].  
 
Maleimide-to-sulfhydryl conjugation reaction 
This chemical reaction is mostly applied to conjugate antibodies containing cysteine 
residues, that is the only amino acid containing a terminal thiol group. Such ligands can 
have just one sulfhydryl group (-SH) or multiple cysteines, which originates disulphide 
bridges (-S-S). The free cysteine amino acid is known as a relative rare constituent of 
proteins, and this feature is used as an advantage to artificially modify antibodies and 
another proteins of interest to produce the chemical conjugations desired through sulfhydryl 
binding reagents [88]. A structure containing the maleimide group (crosslinker) could then 
react with the previously reduced thiol groups of the scFv antibody fragment, as exposed in 
Figure 3B. The final product would be a stable thioether linkage between both compounds. 
Regarding the maleimide molecule, the ‘X’ groups on it (Figure 4B) will not participate in the 
final product of the reaction. Such groups are generally any hydrogen atom (-H), and 
preferably any good-leaving group as the bromine atom (-Br) and other halogens, for 
instance. Once the maleimide reaction is known as an irreversible one, it could change the 
conformation of the antibodies, which could affect its affinity to the target. Baker and 
colleagues used halogen-substituted maleimides as dibromomaleimides, that have the 
ability to create a rigid two-carbon bridge between two cysteines (not represented). This 
strategy confers a reversible linkage and maintains the stability of the antibody [45, 89]. 
Moreover, James P Tiernan and co-workers tested two different crosslinkers: succinimidyl-
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and (succinimidyl-[(N-
maleimidopropionamido)-tetraethyleneglycol] ester), (SM[PEG]4), with the main goal of 
linking the amine groups previously added to the silica nanoparticles to the thiol groups of 
a monoclonal antibody [83]. First the linkers reacted with the amine-coated silica particles 
and after this, the antibodies were added. Both crosslinkers have a NHS and a maleimide 
terminal group, one at each side, that will trigger, respectively, the binding of the amine 
groups of silica particles to the carboxyl-activated linker, and the binding of the antibody 
thiol groups to the maleimide molecule. Both linkers did not show any specific binding to the 
neoplastic cells. 
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A) Crosslinking carboxyl-to-amine functional groups by using EDC (1) and sulfo-NHS ester (2) reaction scheme  
B) Crosslinking maleimide-to-sulfhydryl functional groups by using maleimide reaction scheme  
Figure 4. Most common reaction chemistries to conjugate antibodies to other structures. A) The linkage between 
a carboxylated structure and the primary amines of scFv (antibody fragment) could occur by adding two 
crosslinkers: EDC and NHS, (or its more water-soluble form, sulfo-NHS). Generally, when applying EDC (step 1) 
is also added sulfo-NHS (step 2) to increase the efficiency of the reaction. There are also circumstances where 
the carboxylated structure is already activated by sulfo-NHS, forming a sulfo-NHS ester structure, and in this 
situation (starting on step 2) there is no need to add any crosslinker. B) In the linkage between a maleimide-
ended structure and a thiolated scFv, maleimide works as the crosslinker and the X groups on it could be, most 
commonly, a simple hydrogen or preferably, any good-leaving group as a halogen. The thiol (-SH) and 
disulphide(S-S) groups on scFv should be previously reduced to guarantee that they are ready for conjugation. 
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Small interfering RNA as an oncological therapy  
Gene therapy emerged as a new tool for treating, in a very specific and targeted way, 
genetic disorders that can trigger malignant neoplasms and other genetic-based diseases. 
There are several methods to perform gene therapy. The first is gene replacement, more 
suitable for diseases where a single-gene is affected. The second, is genetic addition, 
recommended for infectious disorders. The third method consists in the modification of gene 
expression at the RNA level, possibly in two ways: i) one just before splicing, recommended 
for diseases that originate problematic messenger RNAs due to incorrect alternative splicing 
events; and ii) the targeting of the mRNA to silence its posterior translation into a protein, 
suitable to any genetic disorder where the overexpression of a gene triggers tumorigenesis, 
for instance. The last method implicates gene editing and works at DNA level. It is either 
able to introduce specific alterations or silence genes, for instance, into the host nucleus 
with highly targeted machinery [90, 91]. The present work is going to approach the third 
point.  
 
Gene specific silencing tools 
Cancer is one of the best examples where many times a gene overexpression is 
pathological and suitable to be treated with targeted drugs to silence its function. Strategies 
to silence genes include the clustered regularly interspaced short palindromic repeat 
(CRISPR), which can efficiently silence genes at nuclear level and implicate the highly 
specific gene editing machinery previously enounced [92]. Other silencing strategy is the 
most recent TRIM-Away technology that enables, for the first time, the direct silencing of a 
given protein by protein degradation. Through this strategy, gene silencing occurs in the 
cytosol and can be applied to the silencing of proteins with extended half-lives [93].  
 
When designing a therapeutic system to silence genes, it is required to avoid as much 
cellular barriers as possible. Silence of genes at cytoplasmic level rather than in the nucleus, 
avoids the necessity to overcome the nucleus envelope. Although silencing technologies 
are potent drugs and include highly specific biological machinery, they are also very 
expensive and require time-consuming processes of fabrication. This limitation difficults 
many times its usage in nanotechnology, once significant amounts of pharma are 
necessary. A well-known and much more optimized option to silence genes at cytoplasmic 
level is the RNA interference (RNAi) machinery. It performs the post-transcriptional 
inhibition of a gene and is being improved, to present better features to trigger a highly 
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targeted silencing of any gene of interest with minimum side-effects [94]. This promising 
technique and is under the scope of this dissertation.    
   
Technologies of RNAi as a post-transcriptional silencing tool 
Mammalians and plants exhibit mechanisms to specifically recognize and inhibit at post-
transcriptional level the translation of targeted messenger RNAs (mRNAs) into proteins [95]. 
This system, termed RNA interference, is composed by several small RNAs that initiate 
different cellular pathways and lead to the inhibition of protein translation. The most 
important ones are the micro-RNAs (miRNAs) [96], the short hairpin RNAs (shRNAs) [97] 
and the small interfering RNA (siRNAs) [98]. To optimize siRNA characteristics, avoiding 
off-target effects, the SMARTpool ON-TARGETplus siRNA [99] was also created. The 
major differences between these four options are appointed forward in Table 6. 
Small interfering RNA (siRNA)  
The small interfering RNA can be artificially inserted into the cellular cytoplasm via external 
vectors or could simply result from the previous cleavage of the double-stranded RNA 
(dsRNA) naturally expressed by the cell. The cleavage of the dsRNA is performed by a 
Dicer ribonuclease, producing siRNAs, smaller double-stranded molecules, from 21 to 23 
base pairs that have two-nucleotide overhangs at each 3’ terminal (step 1 of Figure 6). 
siRNA molecules are in this way composed by a sense or passenger strand and an 
antisense or guide strand (the green and the blue strands, respectively, at Figure 5). The 
siRNA is now ready to react with the RNA-induced silencing complex (RISC) that is 
composed by several proteins, namely the endonuclease Argonaute-2 (AGO2). On its turn, 
AGO2 will first trigger the cleavage of the sense or passenger strand (step 2 of Figure 6), 
and the antisense or guide strand that exists in the recent activated RISC will full 
complementary bind to the target messenger RNA (mRNA). The AGO2 enzyme will finally 
trigger the cleavage of the recognized mRNA (step 4 of Figure 6), which leads to inhibition 
of protein formation, resulting in post-transcriptional gene silencing. Once AGO2 reaches 
the space between the 10th to the11th nucleotides relative to the siRNA antisense strand 5’ 
terminal, it triggers the cleavage of the mRNA phosphodiester linkage. The cleavage 
products are then degraded by several exonucleases in the cytoplasm. The activated RISC 
(complex formed by RISC and the antisense strand) has the opportunity to be recycled, and 
so one single siRNA molecule can silence several target mRNA molecules (step 5 Figure 
6), turning siRNA in a highly potent biological regulator [94, 100, 101].  
siRNA therapeutics could be applied through two different strategies. One of them consists 
on introducing a viral vector or plasmid to a cell, which delivers specific DNA sequences 
that will integrate the host cell genome and produce, at the nucleus level, the shRNA that 
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acts as a siRNA precursor. ShRNA will then migrate to the cytoplasm and suffer cleavage 
by the Dicer enzyme, originating the siRNA molecule. As shRNA is a naturally substrate of 
Dicer, the entire pathway downstream occurs in a more efficient and stable way [102]. 
Nevertheless, one big disadvantage is that the delivery of shRNA coding vectors generally 
is made through viral vectors, which could drive undesired toxicity problems. The other 
option of making siRNA therapeutics is the delivery of synthetically-produced siRNAs to the 
cells. These molecules will not pass through the Dicer-cleavage step, but will trigger the 
siRNA mechanism as well, despite with less efficiency and in a more transient manner [95]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Small interfering RNA (siRNA) structure. The siRNAs have two-nucleotide overhangs at each 3’ 
terminal and a sense and antisense strands (the green and the blue strands, respectively). Green and blue 
strand are the sense or passenger and antisense or guide strand, respectively. Red, grey, yellow and blue 
hexagons represent adenine, uracil, guanine and cytosine nitrogenous bases, respectively. There exist 
hydrogen bridges linking the nitrogenous bases (black tracery). 
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Table 6. Differences between several RNA interference tools for silencing purposes in cancer. 
Small RNAs Structure Complementarity 
to mRNA 
mRNA silencing 
mechanism 
Silencing 
duration 
Off-target effects Ref. 
micro-RNA Double-stranded 
RNA with 18-25 
bps and two 3’ 
overhangs 
 
Partial Each miRNA can bind up 
to 100 mRNAs at once 
and induce degradation, 
cleavage or translational 
inhibition 
 
Silencing up to 3 
days* 
Partial complementary 
binding of the guide strand 
and the release of the 
sense strand without its 
degradation 
 
[96, 101] 
shRNA Single stranded-
hairpin structure 
with 50-70 nts 
and a short 
3´overhang 
 
Full Similar to those of siRNA Long silencing 
up to 7 days** 
Similar to those of siRNA 
but its viral vectors  can 
trigger immunotoxicity 
[97, 103, 104] 
siRNA Double-stranded 
RNA with 21-23 
bps and two 3’ 
overhangs 
 
Full Binds to a single target 
mRNA at a time and 
cleave multiple mRNAs 
due to recycling 
Silencing up to 3 
days*** 
 
Can occur partial 
complementary binding 
with undesired mRNAs 
[98, 101] 
SMARTpool 
ON-
TARGETplus 
siRNA 
Generally 4 
siRNAs 
Full 4 different regions of the 
same target mRNA suffer 
siRNA silencing 
Silencing up to 3 
days**** 
Off-target effects are 
significantly reduced due 
to: 
Lower concentration of 
each siRNA 
Each siRNA is specific for 
a different region of the 
same mRNA 
Undesired sequences are 
removed to avoid non-
specific silencing 
 
[99, 101] 
The silencing duration depend of the delivery vector and other factors. *miRNA silencing in colorectal cancer cell lines using Lipofectamine™ 2000 (Invitrogen) 
[96]. **shRNA silencing was performed once a week by a lentivector in non-small-cell lung cancer xenografts and conferred silencing up to 21 days [97]. 
***siRNA silencing in colorectal cancer cell lines using Lipofectamine® RNAiMax (Invitrogen) [98]. ****SMARTpool ON-TARGETplus siRNA silencing in 
glioblastoma cell lines using Lipofectamine® RNAiMax (Invitrogen) [99]. 
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siRNA 
dsRNA 
Cytoplasm 
Sense strand cleavage 
Target mRNA 
Full complementary binding of 
siRNA to the target mRNA 
Cleavage of the target mRNA 
 
Recycling of the activated RISC 
complex ensures that one 
single siRNA can silence 
multiple mRNA targets 
 
Activated RISC complex 
1 
2 
3 
4 5 
Figure 6. siRNA post-transcriptional silencing mechanism. (Step 1) Dicer cleaves the dsRNA and gives raise to 
siRNAs. (Step 2) The siRNA migrates to the RNA-induced silencing complex (RISC) and the endonuclease 
Argonaute-2 (AGO2) cleaves the sense strand. (Step 3) The guide strand of the activated RISC will full 
complementary bind to the target messenger RNA (mRNA). (Step 4) The AGO2 enzyme will cleave the 
recognized mRNA, which leads to inhibition of the protein translation. (Step 5) The activated RISC can be 
recycled, so one single siRNA molecule can silence several target mRNA molecules turning siRNA in a highly 
potent biological drug. 
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Pharmacokinetics of siRNA and in vivo challenges 
The naked siRNA has an average molecular weight (Mw) of 13,3 kDa and a half-life range 
from few minutes to ~ 0.5h in human bloodstream [105]. In the context of cancer therapy, it 
is necessary to first understand how siRNA behaves in vivo to further design strategies to 
modulate its’ usage. 
The siRNA biodistribution studies are still very poor. Zicai Liang’s team purposed to study 
the naked siRNA distribution once administered intravenously in mice. They used two 
different siRNA sequences that were previously chemically modified to increase its stability 
in the serum and were both labelled with Cy5, a fluorescent probe. After parenteral delivery 
of the siRNA solution, they have sacrificed the animals at different time points, isolated their 
organs and collected the image signal. It was concluded that the siRNAs exhibited the same 
behaviour, indicating that this is probably a general process, independent of the siRNA 
sequences [105]. 
They observed that once intravenously administered, both siRNAs had a fast-huge 
accumulation in kidneys and bladder. Half an hour after, it was possible to see the coverage 
of all body, and some accumulation in the liver, due to the blood stream. Nine days after 
injection, it was still possible to detect a strong signal in pancreas, submandibular and 
bulbourethral glands. The authors suggested that siRNAs mostly accumulate for long 
periods in gland tissues due to the anatomic characteristics of their endothelium. The lung 
and heart, for instance, have a continuous endothelium with no fenestrations; instead the 
glands, the glomerular filtration barrier in the kidney, and the gut exhibit a fenestrated 
continuous endothelium (fenestrae are spaces in the cells that reach 80 - 100 nm); 
ultimately, the sinusoidal endothelium from the liver and the tumour associated vasculature 
have big intercellular spaces (from 30 to 40 µm). After the 9 days, very low siRNA levels 
were found in the bloodstream, although visible accumulation of siRNA in the kidney, 
meaning that siRNA is still somewhere in the body and being cleared. Lastly, siRNA did not 
trigger any gene silencing in glandular tissues. Taking this into account, these glands can 
represent probably a site for siRNA reservoir and can enable the long-lasting slow release 
of it. Parenteral-administered siRNA (naked or complexed) is first eliminated in the kidneys 
and bladder, metabolized in the liver, and secreted into the gut (via bile ducts) where it is 
finally eliminated via defecation process [105, 106].  
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Strategies to overcome extracellular barriers  
To perform a siRNA therapy to a metastatic cancer, the intravenous route is privileged 
because of its enhanced facility to reach the dispersed malignant cells. These cells can be 
in any part of the body, despite of the a priori tropism for reaching preferentially certain types 
of organs. Regarding metastatic colorectal cancer (mCRC), the liver is the organ that 
generally accommodates more metastases [24]. It is important to define the route of 
administration, to study the barriers to overcome in the siRNA treatment. 
Naked siRNA systemically introduced can suffer degradation by blood stream RNAses, and 
when in high levels can trigger the activation of Toll-like receptors (TLRs), present at 
immune cells’ surface, and which recognize specific sequences of siRNA, inducing the 
production of inflammatory cytokines and recruiting professional phagocytic cells. These 
two features can be avoided by adding certain chemical modifications to the siRNA, as 2’-
O-methyl modifications, where the ribose 2’ -OH group is replaced by a -O-methyl group. 
Importantly, the immunogenic sequences of siRNA should be also removed during siRNA 
design. Other chemical modification strategy to overcome naked siRNA limitations is to 
conjugate small molecules, as some peptides and polymers, to the siRNA passenger 
strand, as cell-penetrating peptides capable of penetrating cellular membranes, or 
poly(ethylene glycol), the PEG polymer, capable of increasing the complex half-life in 
circulation. Liver cells are a good example of the application of siRNA conjugates, being the 
cholesterol-siRNA complex a well-known delivery system. For the cellular types that are not 
receptive to the uptake of siRNA-conjugates, the encapsulation of siRNA into nanoparticles 
is the ideal strategy to be used [94, 107]. 
Technologies to deliver drugs and other substances have generally a size > 20 nm to avoid 
renal filtration. Moreover, the negative charge associated to the glomerular basement 
membrane of the glomerulus serves to repel negatively-charged blood proteins and 
interferes with the electrostatic interactions that may exist in much nanoparticulate systems 
that carry siRNA. Namely, siRNA carriers made with positively-charged materials can be 
attracted to the negatively-charged glomerular basement membrane. This results firstly in 
the escape of the siRNA from the vehicle, once the electrostatic interactions used to 
associate the negative siRNA to the positive material were affected, and subsequently, with 
carrier excretion [107]. Probably, the usage of neutral or negatively charged materials to 
encapsulate the siRNA would be the best strategy to avoid this charge selection. 
Small interfering RNA can also be detected by the reticuloendothelial system (RES) that is 
composed by phagocytic cells. The particles < 100 nm usually accumulate in the Kupffer 
cells, liver resident tissue-macrophages, tissue macrophages that exist in the liver) but also 
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in their homologous in the spleen; the ones > 100 nm generally are covered by serum 
proteins as antibodies to signalize foreign antigens, a process known by opsonization,  for 
further destruction by cells from the mononuclear phagocytic system (MPS), also part of the 
RES. The shielding of the nanoparticles’ surface with PEG polymer also avoids the 
adsorption of plasma proteins as opsonins. It is therefore important to establish an 
equilibrium between the size of particles ideal to get advantage from the enhanced 
permeability and retention (EPR) effect, and the maximum size that a particle could have, 
without trigger RES immune responses [100, 107].  
As an anionic and hydrophilic molecule, siRNA must be encapsulated to translocate target 
cellular membranes [101]. Nevertheless, the toxicity of the siRNA vehicle is important to 
permit optimal silencing with minimal toxicity. The usage of viral vectors can trigger severe 
immunological responses, so the formulation of nanoparticles made with non-viral 
materials, such as lipids or polymers is of vital importance. Once high molecular weight 
molecules are required to encapsulate the siRNA, they should be biodegradable. In this 
way, after safely deliver the drug inside the cell, the vehicle should be degraded right there, 
avoiding posterior cytotoxic effects [108]. Moreover, the nanoparticles with positive zeta 
potential are better suited for cellular uptake, being more often used in in vitro experiments. 
Examples like the cationic liposomes Lipofectamine™ 2000 or Lipofectamine® RNAiMax 
have at the same time more non-specific interactions with healthy cells, and with plasmatic 
negatively charged proteins in vivo, being more cytotoxic [95]. Nanoparticles with high 
positive zeta potential have also tendency to aggregate [107]. The targeting of the particle 
to a cell-surface molecule or other entity characteristic of the neoplasm and almost 
exclusively present on it, is other way to overcome cytotoxicity, once the therapy is more 
likely to reach neoplastic cells than the healthy ones [44].    
 
Strategies to overcome intracellular barriers 
If the nanoparticles’ design were able to overcome all the extracellular barriers and filed the 
non-toxicity requirements, they will eventually reach the cells of interest. After migrating 
through fenestrated blood vessels, the nanoparticles reach the tissue extracellular matrix. 
If from one hand that environment can potentiate the EPR effect, on the other hand, when 
being constituted with an excess of high density molecules as polysaccharides, it can 
difficult the movement of the carriers to their target cells [94]. Once they have reached a 
target cell, the nanoparticles are mostly internalized by cellular endocytosis, namely when 
they are not targeted to a cell-surface molecule characteristic of a given cell. Once targeted, 
the nanoparticle carrier specifically binds to the target cell-surface molecule, and this 
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receptor-ligand complex is internalized by receptor-mediated endocytosis (RME). Most of 
the RME phenomena’s follow clathrin-dependent endocytosis, and once in a endosome, 
the receptor-nanoparticle complex could: 1) be degraded though a lysosomal pathway; 2) 
suffer separation, that allows the recycling of the receptor that migrates to the cell surface 
again; 3) suffer separation, and also cause the endosomal escape of the nanoparticle, 
resulting in the release of its cargo to the cytoplasm [54, 109, 110]. A good example of RME 
is triggered by nanoparticles coated with antibody fragments that specifically target a 
desired receptor [107]. 
The early endosome is the first place that the particles meet, inside the cell. An endosome 
is a structure that results from the invagination of portions of the cytoplasmic membrane. 
Then the early endosome maturates into a late endosome, where the pH is around 5-6. It 
will then fuse with the lysosome, enriched in enzymes as nucleases, which will, at a pH 
around 4.5,  degrade the siRNA [95]. The cytosol, by its turn, has pH ~7.4 [108]. The 
endosomal escape is in this way a necessity to complete the siRNA delivery to the 
cytoplasm, where it is available to interact with the RISC machinery. It is however very 
important that the nanoparticle has the ability to escape before the fusion of the late 
endosome with the lysosome. There are strategies to escape from the endosome, such as 
the introduction of cationic polymers with linear or branched structures, as PEI 
(polyethylenimine) and cyclodextrin polymers, or secondary/tertiary amines and histidines, 
though proton-sponge mechanisms. These cationic molecules can efficiently associate to 
the anionic siRNA by electrostatic interactions, neutralizing the complex charge. They also 
stimulate non-specific endocytosis and endosomal escape [94, 100]. 
Nanosystems for siRNA delivery in metastatic CRC 
The success of a siRNA therapy strongly depends on the vector used, the administration 
route, the specific target and its abundance in the body and the efficient in vivo delivery [94]. 
Currently, there is only one clinical trial testing the potential of siRNA administration in 
metastatic colorectal cancer patients that cannot be submitted to resectable surgery [111]. 
This siRNA strategy targets the Casitas-B-lineage lymphoma protein-b (Cbl-b), which is a 
regulator of lymphocyte activation. The siRNA was first introduced into the autologous 
peripheral blood mononuclear cells (PBMCs) and then the infusions were systemically 
injected during 30 minutes, at each 28th day, for 3 times. So far, the injections were well 
tolerated and classified as safe to proceed for Phase II clinical trials [112]. 
When designing siRNA carriers for metastatic colorectal cancer treatment, the specific 
target to select, its role in the tumorigenic progression and its abundance in the body (if it is 
exclusive from the disease or if is present in healthy tissues) is an important factor to take 
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into consideration. There are promising genes involved in mCRC pathogenesis, the most 
common ones are oncogenes like KRAS, BRAF, NRAS, EGFR or MET, for instance [24].  
Lipid-based materials as liposomes, and cationic polymers are the two most used materials 
for in vivo siRNA delivery [94]. There are clinical trials on-going using Lipid-based carriers 
[113] that perform an efficient silencing, but that can  induce toxicity, in particular when 
considering intravenous delivery. One of the recent clinical trials testing siRNA delivery by 
this materials was finished due to this kind of limitations [114]. The siRNA complexes made 
though electrostatic interactions with cationic polymers, like cyclodextrin and the anionic 
siRNA, were also studied in clinical trials [115]. Even carrying PEG (Figure 7B) as stabilizing 
agent and being targeted to the transferrin receptor present in cancer cells, the complexes 
seemed to exhibit kidney toxicity [116]. These siRNA-complexing strategies do not allow 
the sustained release of the siRNA, which is a crucial step for long-lasting activity of the 
therapeutics. Moreover, its stability in circulation and during storage is not clear yet [117].  
 
PLGA nanoparticles: a suitable siRNA carrier for mCRC 
The polymeric nanoparticles made of poly(lactic-co-glycolic acid) (PLGA), have low toxicity, 
sustained release profiles and biodegradable characteristics. Moreover, some of the PLGA 
polymers are Food and Drug Administration approved materials [118, 119]. PLGA is a 
biocompatible polymer that results from the junction of lactic and glycolic acid (Figure 7A). 
Once in the cytosol, it can be degraded into these two constituents, naturally metabolized 
by eukaryotic cells [120]. Those advantages make PLGA nanoparticles a more suitable 
carrier for gene delivery. As being solid nanoparticles, they allow stability in long-term 
storage and in circulation [121]. There are evidences that PLGA nanoparticles can be 
internalized by the cell through endocytosis and when targeted, to receptor-mediated 
endocytosis [109]. PLGA particles were found to escape to the lysosomal degradation 
through the reverse of the surface charge from anionic to cationic, when exposed to the 
acidic pH of the lysosome. The pKa of the PLGA polymer is influenced by the individual 
pKas of its monomers and their abundance (Lactic : Glycolic acid ratio) in the system, being 
the pKa of glycolic acid and lactic acid 3.82 and 3.86, respectively [122]. Considering the 
PLGA acid terminated, modified to contain a carboxyl at the chain terminus, at pH 7.4, it will 
exhibit a negative charged carboxyl’s (-COO-) [123], characteristic of the cytosol [108]. This 
contributes to its stability, once it has a low surface potential and it is less hydrophobic as 
well [123]. The negative potential is also seen at the nanoparticles’ surface made with this 
polymer [84]. Once inside the lysosome, the carboxyl groups will be protonated, the pH of 
the compartment will decrease, and when it reaches the pH 4-5, the PLGA will show its 
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buffer capacity and induce the translocation of protons to the inside, disrupting that 
compartment and migrating to the cytosol to trigger mRNA silencing [118]. After this step, 
the particle gains the ability to stay in the cytoplasm for a maximum of two weeks, where it 
will perform the sustained release of its cargo [124]. 
In addition, PLGA is a hydrophobic material, so the encapsulation of the hydrophilic, highly 
anionic siRNA is difficult. Several studies have showed that the encapsulation of naked 
siRNA in PLGA nanoparticles is not efficient, due to the high hydrophilicity of the anionic 
siRNA. That features allow that during the particles production, the siRNA tends to get out 
of the hydrophobic particle matrix to the exterior hydrophilic phase. siRNA as other 
hydrophilic small molecules share this low encapsulation problem [125]. Therefore, in this 
dissertation it is intended to develop a strategy to overcome this hard encapsulation issue. 
The challenges related to PLGA nanoparticles usage in vivo are associated to the difficult 
delivery of siRNA in therapeutic amounts. The strategies to contradict this major point are 
summarized in: 1) increase the encapsulation of siRNAs within the particles; 2) increase 
their cellular targeting and uptake; 3) enhance the endosomal escape of the particle; and 
4) promote the free-siRNA release to the cytosol without toxicity issues related to co-
encapsulants. Some strategies to overcome them are the focus of this work. 
The cellular targeting and uptake can be achieved by the functionalization of the particle 
with cell penetrating peptides (CPP) [126], as the ones used by J. Zhou et al., the iRGD, 
mAp or mHph1 [117]; or even high affinity ligands that will specifically target a cell surface 
molecule of interest [44, 84]. The enhancing of the endosomal escape can be achieved by 
co-encapsulating siRNA with molecules that have buffer capacity at the endosomal pH, 
increasing the osmotic pressure inside the endosome, which deals to its burst and release 
of the formulation to the cytosol. Those molecules as chloroquine (CQ) and its analogue 
quinacrine (QC) were used once more by J. Zhou and co-workers, to promote escape from 
the endosome [117, 127]. Is very important that this nanocarrier release from the endosome 
occurs as fast as possible, once only 3h of exposure to the acidic pH of this vesicles is 
enough for complete siRNA escape from the PLGA matrix [128]. 
When used in combination with other excipients or polymers, PLGA nanoparticles represent 
a huge opportunity to overcome problems that the most used siRNA nanocarriers have. To 
solve the not efficient siRNA encapsulation, seen in this colloidal system, scientists have 
studied the use of co-encapsulants to increase the association efficiency of the siRNA in 
PLGA nanoparticles. These co-encapsulants are reviewed in the Table 7 and will be 
mentioned over the text.  
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The cationic molecules appear as an opportunity to neutralize the charge of the anionic 
siRNA, turning it less hydrophilic and more likely to be encapsulated into hydrophobic 
matrices. W. Mark Saltzman and colleagues have found that the encapsulation of the 
hydrophilic naked siRNA into polymeric hydrophobic PLGA nanoparticles have a very low 
association efficiency (< 5%), and once complexing the siRNA with cationic polymers, 
turning it more hydrophobic, the association efficiency increases over 40-fold [129]. Their 
team first complexed siRNA with small and natural polyamines [130] such as spermidine 
(Figure 7C) and putrescine at N/P ratios of 3:1, 8:1 and 15:1 (ratio of amine groups from 
the polyamine to the phosphate groups of the siRNA), to optimize the association efficiency 
and loading of siRNA. They found out that the siRNA functionality did not change after its 
encapsulation, being the formulation with spermidine at 3:1 N/P ratio the one with better 
characteristics. Curiously, the siRNA-spermidine complexes were not able to internalize the 
cells without the PLGA vehicle [129]. The natural polyamines, as their metabolic products, 
have roles in the cellular function and are generally present at millimolar range inside the 
cells. They have, in this way, the advantage of being degraded into small molecules that 
are fully metabolized by the body. When its utilization is applied in the proper amounts, this 
co-encapsulant is non-toxic [131]. Moreover, the usage of natural, lower molecular weight 
polyamines is already described as an in vivo stabiliser of nucleotides [129].  
Polyethylenimine (PEI) is a branched cationic polymer that demonstrate wide success on 
transfecting DNA in cells, but its efficacy on siRNA delivery is not such pronounced. The 
modulation of its characteristics, namely the usage of low molecular weight PEI or 
encapsulating it in less toxic polymers can also help to dilute toxicity issues [132, 133]. Poly-
L-lysine (PLL) is a cationic polypeptide that emerges as an alternative to PEI, minimizing 
the toxicity many times associated to PEI/siRNA complexes and keeping the cationic 
characteristics that enable siRNA complexation [134]. The positively charged 
polysaccharides, such as chitosan are many times associated with toxicity issues [135].  
J.Y. Lee et al. purposed the usage of its oligomeric form grafted with deoxycholic acids, 
which gave rise to an amphiphilic copolymer, the chitosan oligosaccharides conjugated with 
deoxycholic acid (COSD). It represents higher hydrophilic properties with fewer toxicity 
associated. The authors defend that complexes of siRNA made with COSD provide a more 
stabilized structure, due to the deoxycholate groups that stay at the complexes’ surface 
[136]. Other strategies include siRNA complexation with 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP) or calcium phosphate [137, 138].   
The complexation of siRNA with cationic molecules is not the only strategy to enhance the 
siRNA encapsulation into PLGA matrices. D. Cun and colleagues have studied other 
approaches, such as the use of acetylated bovine serum albumin (Ac-BSA), not as a 
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complexation agent but rather as a simple co-encapsulant. The surface of BSA works as a 
surfactant, stabilizing the emulsion and decreasing the coalescence of the particles, which 
avoids the siRNA migration to the aqueous phase [139, 140].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
Figure 7. Chemical structures of important polymers. (A) The junction of lactic acid and glycolic acid gives rise 
to the poly(lactic-co-glycolic acid) (PLGA) polymer. (B) The poly(ethylene glycol) (PEG) is many times used to 
confer shield properties to the particles, increasing the carriers half-life in circulation. (C) Spermidine is a natural 
polyamine that enable siRNA complexation without toxic effects many times associated to co-encapsulants. 
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Table 7. Co-encapsulants to improve the encapsulation of siRNA in PLGA nanoparticles suitable for oncological 
therapy. 
Co-encapsulants 
 
Carrier Target 
gene 
Delivery 
route and 
disease 
Targeted ligand 
and linker 
Silencing 
efficiency 
Features Ref. 
Spermidine PLGA 
NPs 
Survinin Intratumoral 
in bladder 
cancer 
Palmitate-Avidin-
Biotin-Chitosan 
 
Palmitate-Avidin-
Biotin-Penetratin 
In vivo 
silencing up to 
~75% 
The NPs had ~150 nm and AE of 70%. The 
functionalization occurred with chitosan of 
2.5 (CH2.5) or 20 kDa (CH20), or even the 
CPP Penetratin (2.3 kDa). CH2.5-NPs (N/P 
ratio 8:1) had 10-fold more sustained 
release than CH20-Nps, during 13 days.  
[141] 
PEI 
 
 
PLGA 
NPs 
 
DCAMKL-1 Intratumoral 
in CRC 
 
--------- In vivo 
relevant 
silencing 
The particles had ~ 200 nm and a practical 
DL of 7.45 µg/mg. 
[133] 
Arginine 
PEI 
PLGA 
MPs 
 
VEGF Intratumoral 
in sarcoma 
--------- Effective in 
vivo silencing 
with 
PEI/siRNA 
MPs 
 
The MPs had ~ 45 µm and were made with 
PEI/siRNA (N/P ratio 1:30). The Mw(PEI) ~ 
25 000 Da and Mw(Arginine) ~ 211 Da. The 
AE of MPs loaded with PEI/siRNA and 
arginine/siRNA was ~ 80% and ~ 64%.  The 
sustained release was seen for 1 month in 
both MPs. 
[142] 
PLL PLGA 
NPs 
MDR1 
BCL2 
Ovarian 
cancer 
--------- In vitro 
silencing of 
~78% 
The NPs had ~ 200 nm and ~ -3 mV. The 
N/P ratio of PLL/siRNA was 1:1. The AE was 
~ 72 %. The sustained release of ~ 50% of 
the loaded siRNA over 10 days. At 2 mg/mL 
loaded nanoparticles were not cytotoxic 
(48h). 
[134] 
PLL PLGA 
NPs 
 
PLK1 Intravenous 
in lung 
carcinoma 
PLGA-palmitate-
avidin-mHph1 
 
PLGA-PLL-PEG-
Mal-mAP 
 
PLGA-PLL-PEG-
iRGD 
In vivo 
silencing up to 
~47% 
 
The NPs had ~ 150 nm, AE of ~ 24 % and 
practical DL of 240 pmol/mg. The Mw of PLL 
was ~1-4 kDa. Sustained release of ~55% of 
the loaded siRNA over 7 days. CQ and QC 
were added to enhance endosomal escape. 
[117] 
COSD PLGA 
NPs 
GFP Breast 
cancer 
--------- In vitro 
silencing of 
37% 
The particles had ~ 230 nm and the 
Mw(COS) was ~ 3-5 kDa. The COSD/siRNA 
complexes were efficiently encapsulated. 
[136] 
Glycol chitosan 
 
PLGA 
NPs 
 
AQP1 Cervix 
cancer 
--------- In vitro 
silencing of 
70% 
The NPs had ~160 nm, ~ -25 mV and a 
practical DL of 24 pmol/mg, at N/P ratio 8:1. 
The sustained release of ~50% of the loaded 
siRNA over 2 days. At 4 mg/mL loaded 
nanoparticles were not cytotoxic (72h). 
 
[128] 
Calcium phosphate PLGA 
NPs 
TNF-α 
KC 
IP-10 
 
 
Intrarectal in 
inflamma-
tory bowel 
disease 
--------- In vivo 
silencing of 
~40% for TNF-
α and ~50% 
for KC and IP-
10 
The NPs had ~150 nm, ~ 22 mV and a 
practical DL of 10 µg/mg. At 0.1 µg/mL 
siRNA, the loaded NPs were almost not 
cytotoxic (24h). 
[137] 
Ac-BSA 
 
 
 
PLGA-
PEI NPs 
P-gp Intravenous 
in breast 
adenocarci-
noma 
PLGA-PEG-
Biotin 
Effective in 
vivo silencing 
The NPs had ~237 nm, ~ -12 mV, AE of ~ 80 
% and practical DL of ~ 6.5 µg/mg. The 
Mw(PEI) was ~25 000 Da. In vitro, 80% 
siRNA release was seen for 10 days. At 100 
nM loaded NPs were cytotoxic. 
[140] 
Ac-BSA PLGA 
NPs 
 
 
 
 
eGFP Lung cancer --------- Effective in 
vitro silencing 
with siRNA 
extracted from 
NPs 
The NPs had ~ 200 nm, ~ -40 mV and a 
practical DL of ~ 2.2 µg/mg. Sustained 
release of ~ 60% of the loaded siRNA over 
54 days. 
[139] 
Ac-BSA: Acetylated bovine serum albumin;  AE: Association Efficiency; AQP1: aquaporin 1; BCL2: apoptosis regulator B-cell lymphoma 2; CPP: cell penetrating 
peptide; CQ: chloroquine; CRC: colorrectal cancer; DCAMKL-1: doublecortin like kinase 1; DL: drug loading; eGFP: enhanced green fluorescent protein; GFP: 
green fluorescent protein; IP-10: interferon gamma-induced protein 10; iRGD: 9-amino acid cyclic peptide; KC: keratinocide-derived cytokine; mAp: Modified Ap 
peptide; MPs: microparticles; MDR1: multidrug resistance protein 1; N/P ratio: ratio of amine groups from the polyamine to the phosphate groups of the siRNA; 
P-gp: p-glycoprotein; PLGA: poly(lactic-co-glycolic acid); PLK1: polo-like kinase 1; PLL: Poly-L-lysine; QC: quinacrine; TNF-α: tumour necrosis factor alpha; 
VEGF: vascular endothelial growth factor. 
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MACC1 contribution for metastasis in colorectal cancer 
Colorectal malignancies of early-stage have very good responses to treatment, generally 
through surgery resection, presenting a 5-year survival rate of almost 90%. Once 
metastasis occurs, this reduce closer to 10 % [143]. Importantly, about half of the colorectal 
cancer patients will develop distant metastases. The majority of them (30-70%) will migrate 
to the liver, 20-40% to the lung, 5-10% to the bones, and can still be found vestigial levels 
in the ovary, brain and adrenal gland [11]. Liver metastases are the cause of death of most 
colorectal carcinomas. At the time of diagnosis, 25% of the patients have liver metastases, 
and in the first 3 years of follow-up, after primary tumour resection, it grows to approximately  
50 % [144]. 
Colorectal cancer tumorigenesis involves the disease progression from the colon normal 
epithelia to metastatic neoplasms (Figure 6). It involves the gradual accumulation of 
modifications on important genes, such as the activating mutations of oncogenes like β-
catenin and K-RAS [145], the inactivating mutations of tumour suppressor genes like APC, 
p53, Smad 2, Smad 4 and TGF-βRII [146], and even at epigenetic level like the 
hypermethylation of DNA mismatch repair genes [6].  
These events can trigger the detachment of potential metastatic cells from the primary 
colorectal tumour that will migrate to the bloodstream and/or lymph nodes. The selection of 
the recipient organ can be restricted by anatomical reasons, or even due to the propitious 
tumour microenvironment founded in that specific metastatic site to initiate tumour 
development [147]. The metastatic profile includes the initiation of neo-angiogenesis, 
proliferation, and the tumour microenvironment modulation to escape immune surveillance 
and facilitate the invasion of the surrounding tissues [148]. 
The therapeutic options for metastatic CRC are still not satisfactory, once the average 
survival of the patients is about two years. Standard chemotherapies remain the most used 
options to treat those phenotypes, and therapeutic schemes based on irinotecan, 
capecitabin, oxaliplatin are used in combination with fluoropyrimidine [11].  
The current knowledge about tumorigenesis progression and the study of histopathological 
features of the tumour has led to the production of personalized therapies, tailor made, to 
increase patient survival time. In fact, nowadays the therapeutic strategy is no longer to 
cure people from cancer at all cost, as it could bring intolerable morbidity levels that are 
harmful to guarantee quality of life. The experience has shown that the best strategy is to 
treat people ensuring at the same time that the morbidity imposed does not significantly 
affect the patient’s quality of life. So, many times the strategy is rather to turn cancer a 
chronic disease, treating the patients with combination therapies that include drugs with 
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known predictive response. Such drugs are generally specifically made to react against a 
pathological molecule that is characteristic of the patient tumour phenotype. Hence, 
targeted therapies are made to treat populations with specific subtypes of cancer.  
The targeted therapies that have been so far applied are mostly used in combination with 
the standard ones and include anti-EGFR and anti-VEGF monoclonal antibodies as 
panitumumab and bevacizumab, respectively. Other molecules in development include 
tyrosine kinase inhibitors and the potent small interfering RNA [11]. 
MACC1: a transcription factor inducing metastatic behaviour  
One of the current most promising CRC metastatic biomarkers is the metastasis-associated 
in colon cancer 1 protein (MACC1). The MACC1 gene is located on human chromosome 7 
(7p21.1) and represents a key regulator of HGF-MET pathway, as Figure 7 indicates. Once 
the hepatocyte growth factor (HGF) recognizes the MET tyrosine kinase receptor, it will 
induce motility, cell proliferation, HGF-triggered scattering in cell cultures, tumour growth 
and metastasis in xenograft models. Moreover, MACC1 was never found to trigger in vitro 
apoptosis [11, 149, 150].  
Intracellular signals emitted by MET, via the mitogen-activated protein kinase (MAPK) and 
the phosphoinositide 3-kinase (PI3K)-Akt pathways, will drive survival, invasion, migration, 
wound healing and inhibit apoptosis [151].  
MACC1 has been considered as a potential prognostic biomarker for metastatic disease in 
primary colorectal cancer [152], hepatocellular carcinoma [153], endometrial carcinoma 
[154], lung adenocarcinoma [155], gastric carcinoma [156], breast cancer [157] and 
esophageal cancer [158]. Note that in all referred malignancies, MACC1 was highly 
expressed in more developed stages of the malignant tumours but not in the respective 
normal tissues.  
According to Stein et al., MACC1 mRNA is highly expressed in malignant tissues, including 
liver and lung metastases and primary CRC with metastatic potential, rather than in colon 
and liver normal tissues or adenomas. In the CRC tumorigenesis progression, the MACC1 
is first produced in the transition from adenoma to carcinoma (Figure 6). The MACC1 works 
as a transcription factor and migrate to the nucleus to trigger the activation of the MET gene. 
Metastatic stages of CRC contain high levels of nuclear MACC1 and it was also found their 
significant levels on in situ colorectal tumours that will latter develop metastases (Figure 8 
and 9). On the other hand, primary tumours with cytoplasmic MACC1 generally do not 
develop distant metastases [11].   
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These authors also tested two cell lines, human colon carcinoma SW480 cells and SW620 
cells (derived from metastatic site) and conclude that SW620 cells had higher mRNA and 
protein MACC1 expression than SW480 cells [149]. 
Next, they evaluate the effect of HGF on MACC1 highly expressing cell line and conclude 
that HGF induced cell scattering. The HGF-induced phenotype was inhibited by addition of 
small interfering RNA for MACC1 and MET (MACC1 siRNA and MET siRNA). Moreover, 
the MACC1 siRNA silenced efficiently the MACC1 and MET expression, while MET siRNA 
did not affected the MACC1 expression [149].  
More recent studies have evidenced that MACC1 upregulation increases the expression of 
β-catenin, c-Myc, cyclin D1, MMP9, and the phospho-glycogen synthase kinase 3β [159]. 
Still, very little is reported about other target genes of MACC1, and their respective signalling 
pathways that may contribute to CRC metastatic dissemination. The potential of producing 
therapies to target a transcription factor involves very likely the inhibition of multiple 
signalling pathways that may exist along the tumorigenesis process. For all these reasons, 
MACC1 is a promising target for novel therapeutic applications intending to treat mCRC 
patient subgroups. 
 
 
 
 
 
 
 
 
Figure 8. MACC1 impact on the tumorigenesis progression of colorectal cancer. MACC1 first appears in the 
benign to malign transition and its nuclear levels arise in more advanced stages of the disease. 
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Figure 9. MACC1 as a key regulator of HGF-MET pathway in CRC. In more advanced stages (mCRC) MACC1 protein 
migrates to the nucleus where it will activate the expression of MET gene. The hepatocyte growth factor (HGF) is the 
ligand of the tyrosine kinase receptor MET and triggers the signalling pathway that induces proliferation, migration, 
invasion, tumour growth and metastasis in CRC. 
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II. Aims of the Dissertation 
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The innovative therapy herein proposed intends to produce CEA-targeted nanoparticles 
with tropism to colon cancer cells expressing the carcinoembryonic antigen, and carrying a 
siRNA directed to the MACC1 protein. These nanoparticles are intended to be intravenously 
delivered to patients with metastatic CRC, expressing both CEA and MACC1 proteins. The 
ultimate goal of this therapeutic strategy is to silence the expression of the intracellular 
metastasis-associated in colon cancer 1 protein, specifically on colon cancer cells that 
express the CEA antigen at their surface.  PLGA-PEG nanoparticles were loaded with 
MACC1 siRNA and functionalized with anti-CEA single-chain variable fragment (scFv). 
These particles were further characterized and their internalization into CRC cell line was 
evaluated. The specific objectives of this dissertation were:  
1. Selection CEA and MACC1 most expressing CRC cell lines; 
2. Demonstrate the effective MACC1 silencing through MACC1 siRNA delivery in the 
selected CRC cell line; 
3. Produce and characterize PLGA-PEG NPs functionalized with anti-CEA scFv and 
loaded with MACC1 siRNA; 
4. Demonstrate the cell uptake of anti-CEA scFv-functionalized nanoparticles. 
 
 
 
 
 
 
43 
 
 
 
 
 
 
 
III. Materials and Methods 
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Materials 
Acid terminated end-capped PLGA with 50:50 D,L-lactide:glycolide ratio and 0.4 dL/g 
viscosity (PLGA 5004A, 44 kDa) was kindly offered from Corbion, Netherlands. The 
Poly(lactic-co-glycolic)-b-Poly(ethylene glycol)-Maleimide (PLGA-PEG-Maleimide, Mw 
~30,000-5,000Da) and the PLGA-FL(FITC) (Mw ~ 20,000 - 40,000 Da) were purchased 
from PolySciTech, USA and spermidine from Sigma, USA. Dichloromethane was 
purchased from Thermo Fisher Scientific, USA. The surfactant Poloxamer 407 (Kolliphor® 
P407) was provided by BASF, USA. The Amicon® centrifuge filters (100 kDa MWCO) were 
from Merck, USA. The 5(6)-Carboxy-X-rhodamine N-succinimidyl ester (NHS-Rhodamine) 
was purchased from Santa Cruz Biotechnology, USA. UltraPure Distilled Water 
DNase/RNase Free was from Gibco, USA. Every experiment where proteins or antibodies 
are used were performed in protein LoBind eppendorfs and the ones where siRNA was 
used were performed in RNase free eppendorfs, both from VWR, USA. The DMSO were 
from Sigma, USA. DTT (D,L-1,4-Dithiothreitol) and Versene were from Thermo Fisher 
Scientific, USA. The foetal bovine serum (FBS) and penicillin-streptomycin were from Merck 
Millipore, USA. Dulbecco’s modified Eagle medium (DMEM) was purchased from Lonza, 
Switzerland, and Roswell Park Memorial Institute (RPMI) medium from Gibco, USA. 
SMARTpool ON-TARGETplus siRNA MACC1 was provided by Dharmacon (USA) and the 
CCR5 siRNA was purchased at Thermo Fisher Scientific, USA. Non-silencing siRNA was 
provided by Qiagen (Germany), the Lipofectamine® RNAiMax and SYBR gold probe by 
Invitrogen (USA), and Dharmafect reagent by Dharmacon, USA. The SMARTpool ON-
TARGETplus siRNA MACC1 contains the guide strands: AGCAACAAAUGGAGGCAUA; 
UGGAAAUCAUGUUAGGCAA; GCUGUAUGGUUUAGUGAGA; 
ACUAGAAUGUAUUGCGUUU. 
The human modified single-chain variable fragment anti-CEA, shMFELL2Cys, was kindly 
provided by Professor Kerry Chester at the University College London (UCL). As negative 
control, nanoparticles were also functionalized with a human negative Fab, that is known 
not to recognize the CD44v6, and was also chemically modify to express three cysteines at 
its’ carboxyl terminus (Bio-Rad, USA).  The primary antibodies used include the polyclonal 
Rabbit anti-MACC1 (Thermo Fisher Scientific, USA) and the monoclonals Rabbit anti-β-
actin and Mouse anti-CEA (CEA31) from Abcam (UK) and Mouse anti-Histidine tag (Bio-
Rad, USA). The secondary antibodies include Mouse anti-rabbit HRP (Santa Cruz 
Biotechnology, USA), Goat Anti-Rabbit (HRP) (Abcam, UK) and Goat anti-Mouse HRP 
(Merck, USA) were used. 
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Western Blot analysis 
To prepare whole cell lysates, the cells were incubated on ice during 15 min with lysis buffer 
containing protease inhibitors cocktail PIC (Merck Millipore, USA), phosphatase inhibitors 
as sodium orthovanadate, sodium pyrophosphate tetrabasic (both from Sigma, USA) and 
sodium fluoride (Merck, USA), RIPPA Buffer (1% NP-40, 1% Triton X-100, 20 mM Tris-HCl 
(from Sigma, USA) and 150 mM NaCl (from BDH Prolabo, USA). The resulting lysates were 
scrapped and centrifuged at 14 000 rpm, at 4ºC, for 10 min. To perform lysates protein 
quantification, the Protein Assay Kit from Bio-Rad (USA) was used according to supplier 
instructions and bovine serum albumin, BSA (VWR, USA) was selected to perform the 
calibration curve. The 7.5 % SDS-polyacrylamide gel was loaded with sample buffer 
containing β-mercaptoethanol (Bio-Rad, USA) and 35 µg of total protein. The samples were 
further separated by electrophoresis and transferred to a Hybond-nitrocellulose membrane 
(GE Healthcare, UK). The membranes were subsequently blocked for 1h at room 
temperature with 4% non-fat dry milk (Molico, Switzerland) in PBST (PBS(1x) with 0.5% of 
Tween 20, both from Sigma, USA). After the blocking procedures, they were incubated with 
antibody solutions made in 4% non-fat dry milk in PBST. The incubation with the primary 
antibody occurred overnight at 4°C (Rabbit anti-MACC1 at 1µg/mL, Mouse anti-CEA at 0.25 
µg/mL or Rabbit anti-β-actin at 1:5000 dilution). After, the membranes were further 
incubated with the solution of secondary antibody (Goat-anti-Mouse HRP at 1:4000 or 
Mouse-anti-Rabbit HRP at 1:5000 dilution) for 1h at room temperature. Therefore, they were 
finally exposed to the chemiluminescent substrate KIT Amersham ECL-Western Blotting 
(GE Healthcare, UK).   
Small interference RNA (siRNA) delivery and evaluation 
SW480 cells were seeded in 6-well plates, both for silencing with Lipofectamine® RNAiMax 
and Dharmafect vectors. Non-silencing siRNA was used as negative control. Thirty to forty 
percent confluent monolayers were washed and incubated in serum- and antibiotic-free 
DMEM medium and silenced according to supplier’s instructions, with 25 nM and 100 nM 
of SMARTpool ON-TARGETplus MACC1 siRNA. The silencing efficiency was posteriorly 
evaluated at 24h, 48h and 72h by Western blot technique as reported previously, this time 
using the secondary antibody Goat-anti-Rabbit HRP at 1:10 000 dilution. 
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Production of the PLGA-PEG nanoparticles and physicochemical 
characterization 
The polymeric PLGA-PEG nanoparticles were produced through the water-in-oil-in-water 
(w/o/w) double emulsion technique, based in a modified solvent emulsification evaporation 
method [66]. To produce the oil phase, 19 mg of PLGA 5004A and 1 mg of PLGA-PEG-
Maleimide (95:5 ratio) were solubilized in dichloromethane (500 µL) for 1h at RT. After, 1.33 
µg of SMARTpool ON-TARGETplus MACC1 siRNA were added at a final volume of 100 
µL. Importantly, the siRNA was previously complexed with spermidine at N/P ratio (ratio of 
amine groups from the polyamine to the phosphate groups of the siRNA) of 3:1 or 8:1, as 
described further in this section. This aqueous phase was promptly added to the oil phase 
and the mixture was vortexed vigorously for 90s, producing the first emulsion (w/o). To not 
waste polymer, 4 mL of surfactant solution (Poloxamer 407 at 0.5 % in ultrapure water), 
were added directly to the first emulsion and immediately sonicated for 60s in an ice bath, 
using a Vibra-Cell™ultrasonic processor at 70% of amplitude. The produced second 
emulsion (w/o/w) was added to 8 mL of the surfactant solution and left stirring for 3h at 300 
rpm to evaporate the organic solvent. The PLGA nanoparticles that were functionalized with 
the negative Fab are composed by a ratio of 85 PLGA5004A : 5 PLGA-PEG-Maleimide : 10 
PLGA-FL(FITC).  
To purify the formulations, nanoparticles were washed three times in ultrapure water using 
Amicon® centrifuge filters (100 kDa MWCO) at 600xg and concentrated to a final volume 
of 2 mL. A schematic representation of the nanoparticles production can be seen on Figure 
10. The functionalization of the nanoparticles as the siRNA/spermidine complexation will be 
posteriorly described. 
To characterize the nanoparticles’ properties, as the hydrodynamic diameter and 
polydispersity index (PdI), the dynamic light scattering method was used. For zeta potential 
measurements, the electrophoretic light scattering was used. Both methods were performed 
by the Malvern Zetasizer Nano ZS instrument (Malvern Instruments, UK). For these 
measurements, samples were diluted 1000-fold in NaCl 10 mM solution at pH 7.4.  
 
The morphology of non-functionalized and functionalized particles (with siRNA complex at 
3:1 N/P ratio) were characterized by transmission electron microscopy (TEM) with different 
amounts of particles (100 µg and 20 µg, respectively). Functionalized nanoparticles were 
made at a 1 PLGA-PEG-Maleimide to 0.4 scFv mol ratio. All samples were mounted in a 
copper grill and treated with 2% uranyl acetate (negative staining). The particles were 
observed through a JEOL JEM-1400 electron microscope (JEOL, USA). 
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Complexation of siRNA with spermidine 
For the siRNA complexation procedure, the siRNA solution in HEPES buffer at pH 7.4 
(Sigma Aldrich, USA) was added to the spermidine solution also in HEPES buffer at a 1:1 
(v/v) ratio. The mixture was vortexed during 5sec and left resting at RT for 20 min [160]. 
The calculations of spermidine mass for siRNA/spermidine complexation are given in 
Equation (1), where ‘A’ is the mass of siRNA to be complexed and ‘R’ is the N/P ratio. Is 
necessary to consider that one molecule of siRNA contains 21 base pairs, and as it is a 
duplex, the final number of nucleotides per siRNA molecule are 42. Each nucleotide 
contains one phosphate group. 
Considering: 
𝑀𝑤(21 𝑚𝑒𝑟 𝑠𝑖𝑅𝑁𝐴) = 13 300 𝑔/𝑚𝑜𝑙 
𝑀𝑤(𝑠𝑝𝑒𝑟𝑚𝑖𝑑𝑖𝑛𝑒) = 145.25 𝑔/𝑚𝑜𝑙 
1 𝑚𝑜𝑙 (𝑠𝑖𝑅𝑁𝐴) = 42 𝑚𝑜𝑙 −𝑃𝑂4
2−   
1 𝑚𝑜𝑙 𝑆𝑝𝑒𝑟𝑚𝑖𝑑𝑖𝑛𝑒 = 3 𝑚𝑜𝑙 −𝑁𝐻3
+ (𝑎𝑡 𝑝𝐻 7.4) 
Figure 10. General scheme of nanoparticles production and functionalization carrying the siRNA/spermidine 
complex. After the complexation of siRNA with spermidine (at N/P ratio of 3:1 or 8:1), the siRNA complex 
(aqueous phase) was added to the dichloromethane- solubilized polymers (oil phase) and a vigorous vortex 
was applied to perform the 1st emulsion (w/o). After, it was immediately added the surfactant solution (aqueous 
phase) to help stabilizing the formulation and a sonication step was done to guarantee that the 2nd emulsion 
occur (w/o/w). The evaporation of the organic solvent triggered the nanoparticles formation. The purification of 
the colloidal dispersion gave rise to the PLGA-PEG nanoparticles loaded with the siRNA complex. The ultimate 
step was the functionalization of the particle surface with the anti-CEA single-chain variable fragment 
(shMFELL2Cys). 
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𝑀𝑎𝑠𝑠 𝑠𝑝𝑒𝑟𝑚𝑖𝑑𝑖𝑛𝑒 (𝑔) = 145.25 × 𝑅 ×  
42 × 𝐴
39900
                (1) 
Extraction of encapsulated siRNA and quantification using SYBR gold probe 
The Association Efficiency (AE) of the siRNA into the nanoparticles was assessed by direct 
method (Equation 2) as the Practical Drug Loading (Equation 3). After nanoparticles 
production and purification, the 2 mL of the final formulation were freeze-dried in the Freeze 
Dryer equipment (Labconco, USA). Once in powder, the nanoparticles were solubilized in 
5 mL of dichloromethane for 24h, at 150 rpm in the orbital shaker. The 5 mL of destroyed 
nanoparticles (oil phase) were sorted into smaller portions of 500uL for several RNase free 
eppendorfs. Once sorted in those eppendorfs, the aqueous phase for siRNA extraction, 500 
µL of TE buffer (10 mM Tris-HCl and 1mM EDTA (from VWR, USA) at pH 7.4) was added 
and the content was vortexed during 60s. The mixture was left resting and once the 
complete separation of phases was seen, the aqueous phase was collected and freeze-
dried again, to concentrate the samples. After, 100 µL of TE buffer were added to the freeze-
dried siRNA. In a 96-well black plate, the samples were treated with 2 µL of 100-fold dilution 
of SYBR gold (Invitrogen, USA) in TE buffer (final 10,000-fold dilution). After incubation, 
fluorescence was measured (λexcitation 485 nm; λemission 540 nm) using a micro-plate reader 
(Biotek, USA) [161]. 
 
                                  𝐴𝐸 (%) =  
𝑃𝑟𝑎𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑠𝑖𝑅𝑁𝐴
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑠𝑖𝑅𝑁𝐴
 × 100           (2) 
 
 
𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑎𝑙 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (%) =  
𝑃𝑟𝑎𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑠𝑖𝑅𝑁𝐴
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟
 × 100            (3) 
 
Evaluation of the complexation siRNA/spermidine and siRNA precipitation 
To evaluate the complexation efficiency of the siRNA with spermidine, a 10% 
polyacrylamide gel (1.5 mm) in TBE (1x) buffer was loaded with 400 ng of siRNA containing 
six µL of glycerol per 30 µL of sample. The samples were further separated by 
electrophoresis during 1h and SYBR gold at 1:10 000 in TBE (1x) buffer was added directly 
to the gel (~20 minutes at RT, protected from light). The gel was then analysed by the 
equipment Molecular Imager® Gel Doc™ XR+ (Bio-Rad, USA). 
There were selected several siRNA samples reflecting different production steps: i) before 
encapsulation, where the siRNA was just complexed with spermidine as previously 
mentioned; and ii) after being submitted to the nanoparticle production and purification 
procedures. For the first class of samples, 400 ng of siRNA were complexed at several 
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ratios (at N/P ratio 3:1, 8:1, 20:1, 50:1) to evaluate the influence of the spermidine amount 
in the complexation efficiency. It was also used a different siRNA with other sequence (a 
single siRNA targeting the CCR5) as positive control of naked-siRNA, to confirm that the 
SMARTpool ON-TARGETplus MACC1 siRNA itself is not degraded. Regarding the siRNA 
complex integrity once encapsulated, to simplify the procedure, the siRNA complex-loaded 
nanoparticles were not destroyed, and only the non-encapsulated complexes were 
evaluated.  For this, three several siRNA samples were selected: i) the formulation before 
being washed (Before washing), that resulted from the 10 mL of final formulation obtained 
before the purification steps; ii) the first supernatant of the Amicon® filter (Supernatant), 
that resulted from the 10 mL of supernatant obtained after the first washing step; and iii) the 
concentrated formulation after all the washing steps (After washing), that corresponded to 
the 2 mL of final formulation. 
As one of the problems of quantifying siRNA in nanoparticles is the contamination of the 
samples with surfactant and other reagents, before evaluating the samples, they were 
previously purified, by performing siRNA ethanol precipitation. Nevertheless, as this 
procedure requires the addiction of 100% ethanol, this could somehow destroy the 
nanoparticles present in the total formulation. Those nanoparticles include the ones 
obtained before washing steps (Before washing) and after being purified (After washing). 
For this reason, after collecting the (Before washing) and (After washing) samples, they 
were first submitted to a centrifugation step of 10 000xg, 20 min, 4ºC. Moreover, the 
supernatant obtained during the purification steps that contained free siRNA and surfactant 
(Supernatant), was collected and submitted to the siRNA precipitation assay.  
The siRNA precipitation assay was in this way performed to isolate the siRNA present in 
the formulations of complex-loaded nanoparticles. This isolation allowed a more reliable 
subsequent evaluation of the siRNA, once contaminant agents were theoretically removed. 
This assay starts by adding to the siRNA samples 1:0.1 (v/v) of 3M sodium acetate and 1:3 
(v/v) of ice cold 100% ethanol (Valente e Ribeiro, Portugal), followed by vigorous vortexing. 
Then, the siRNA was left precipitating overnight at -80ºC. After, samples were centrifuged 
at 13 000 rpm at 4ºC for 30 min and the pellets were washed twice with 500 µL of ice cold 
75% ethanol (Valente e Ribeiro, Portugal), and centrifuged at 13 000 rpm, 4ºC, for 10 min 
at each time. To remove ethanol remnants, samples were left drying at RT. Once the drying 
process was complete, the precipitated siRNA was solubilized in 30 µL of UltraPure Distilled 
Water DNase/RNase Free. Importantly, all the samples were manipulated in RNase free 
eppendorfs and the siRNA complexation efficiency was evaluated as mentioned in the 
beginning of this section.   
 50 
 
Functionalization of nanoparticles with shMFELL2Cys and negative Fab 
The maleimide chemistry was applied to perform the conjugation reaction between the thiol 
group (-SH) of the cysteine’ single-chain antibody fragment (shMFELL2Cys) or the cysteine’ 
negative Fab, with the maleimide end-groups of PEG chains in the PLGA-PEG 
nanoparticles. The shMFELL2Cys was engineered with two cysteines on its long linker, and 
the negative Fab contains 3 terminal cysteines. Briefly, the scFv and the negative Fab were 
first reduced with DTT (D,L-1,4-Dithiothreitol, Mw 154.25 g/mol) at 1:20 mol ratio in PBS(1x), 
90 µL final volume, for 1h at RT, (separated reactions) as described by Schumacher  [45]. 
After reducing the disulphide bridges, the excess of DTT was removed not to interfere with 
the posterior conjugation with the nanoparticles, by passing through a Bio-Spin® 6 (SEC 
column, MWCO 6 kDa) from Bio-Rad, USA. The Bio-Spin® 6 was first activated, the excess 
of buffer was physically removed, and the reminiscent buffer was removed by centrifugation 
at 1 000xg for 2 min, 4ºC. The reduced antibody fragment solution was then applied and 
centrifuged for 4 min, 4ºC at 1 000xg. To perform the maleimide conjugation reaction, 200 
µg of nanoparticles reacted overnight, in PBS (1x) at 4ºC with several mol ratios of 
maleimide group to shMFELL2Cys (1:2.5; 1:1; 1:0.4; 1:0), and at 1 mol PLGA-PEG-
Maleimide to 0.4 mol of shMFELL2Cys for the negative Fab (100 µL final volume of 
reaction). The conjugates were after purified, by performing 3 centrifugation steps at 
10 000xg, during 20 min at 4ºC with 300 µL ultrapure water. The last pellet was 
resuspended in 300 µL of PBS(1x). A scheme of the functionalization process is 
represented in Figure 11. 
 
 
 
Figure 11. Representation of the functionalization protocol through maleimide chemistry. The disulphide bridge 
that existed in the long linker of the anti-CEA scFv (shMFELL2Cys) was broken due to the reduction made by 
the DTT, which can separate the two domains (the heavy and light variable domains). This separation will not, 
theoretically, influence the binding once each domain has its own specificity to CEA protein. The further 
functionalization of the PLGA-PEG nanoparticles occurred through maleimide reaction of the thiol group (-SH) 
of the cysteine’ single-chain antibody fragment (shMFELL2Cys) with the maleimide end-groups of PEG chains 
in the PLGA-PEG nanoparticles.   
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NHS-Rhodamine conjugation to shMFELL2Cys 
The 5(6)-Carboxy-X-rhodamine N-succinimidyl ester (NHS-Rhodamine, Mw 631.37 g/mol) 
was solubilized in DMSO (VWR, USA) and immediately added (1:10 mol ratio) to the 200 
µg of shMFELL2Cys solution in PBS(1x) at pH 7.2 (90 µL final volume of reaction). The 
conjugation reaction occurred during 1h at RT. To purify the antibody fragment, it was used 
the Bio-Spin® 6 (SEC column), as previously described.  
 
Cell culture 
The colorectal cancer cell lines SW620, HCT-116, HT-29, RKO, HCT-15 and C2BBe1 
Clone of Caco-2, available at our Institute, were previously purchased from American Type 
Culture Collection (ATCC, USA). SW480 colorectal cancer cells were kindly provided by the 
University of Göttingen. The SW480 and Caco-2 cell lines were cultured in DMEM medium, 
while all the others in RPMI medium, all supplemented with 1%(v/v) penicillin-streptomycin 
and 10%(v/v) FBS (complete medium). Cells were maintained at 37 °C in a 5 % CO2 water 
saturated atmosphere in an incubator (ESCO, USA). 
 
In vitro cell uptake studies  
To perform the in vitro internalization studies of the formulations produced, 2.0 x 105 cells 
(SW480 cells) were seeded in a 24-well plate and left growing in DMEM complete medium 
overnight in the incubator. To assess the impact of the nanoparticles functionalization in the 
cellular uptake, 20 µg of functionalized nanoparticles tagged with increasing ratios of scFv, 
as NPs 1:0.4, NPs 1:1 and NPs 1:2.5 were added for 1h at 37ºC to the SW480 cells. To 
note, the single-chain variable fragment was previously stained with the rhodamine probe, 
as described already in this section, before being used for nanoparticles functionalization. 
As controls, the SW480 cells were either maintained in medium (Untreated) or incubated 
with 20 µg of non-functionalized nanoparticles (NPs 1:0) for 1h at 37ºC. Cells were also 
incubated with ~5 µg of rhodamine alone (Only Rhodamine) or with 10 µg of rhodamine-
stained scFv (scFv-Rhodamine) for 2h at 37ºC. To assess the uptake behaviour of 
functionalized nanoparticles when exposed to colorectal cancer cells not expressing the 
cell-surface CEA, the SW480 was firstly incubated with 10 µg of scFv alone for 1h at 37ºC, 
to saturate all the CEA antigen-binding sites, and was followed by 1h incubation at 37ºC 
with functionalized-nanoparticles at 1:1 ratio (scFv + NPs 1:1). One last control was 
performed, where the cells were incubated for 1h at 37ºC with 20 µg of nanoparticles tagged 
with a negative control antibody fragment at 1:0.4 ratio (NPs 1:0.4 Fab (-)). The negative-
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control functionalized nanoparticles were exceptionally made with a PLGA-FITC polymer. 
The samples’ features are also summarized in Table 8. All the mixtures were added in 
DMEM supplemented with 1%(v/v) penicillin-streptomycin.  
After incubation, the cells were washed three times with PBS (1x) and further detached 
using versene, to impair CEA protein degradation. Then, the cells were removed with 500 
µL of PBS(1x) to a protein Lobind eppendorf and centrifuged at 300xg for 7 min at 4ºC. The 
supernatant was discarded, the cells were resuspended in 2% PFA (300 µL) and incubated 
at RT for 30 minutes. After this fixation step, the suspension was centrifuged once more, to 
remove the PFA. The supernatant was discarded, and the fixed cells were resuspended in 
60 µL of PBS(1x). Therefore, cells were posteriorly stored at 4ºC, protected from light, and 
analysed as soon as possible by the confocal laser scanning microscopy (Leica 
Microsystems, Germany) and the imaging flow cytometer ImageStream®X (Amnis 
Corporation, Germany). 
Table 8. Scheme of samples analysed in the cell uptake experiments. 
 
 
Confocal laser scanning microscopy (CLSM) 
Cells were analysed through a CLSM (TCS-SP5 AOBS, Leica Microsystems, Germany). 
The control of untreated cells was used to remove autofluorescence seen in the red and 
green channels. A Z-stack of all treated samples previously reported in this section was 
also performed. Images were treated though LAS X Core version 3.3.0 (Leica Microsystems 
software, Germany). 
 
 
 
Samples scFv-Rho Only Rho scFv NPs 1:0 NPs1:0.4 NPs 1:1 NPs 1:2.5 NPs 1:0.4 (-) Fab 
Untreated - - - - - - - - 
scFv-Rho + - - - - - - - 
Rhodamine - + - - - - - - 
scFv + NPs 1:1 - - + - - + - - 
NPs 1:0 - - - + - - - - 
NPs 1:0.4 - - - - + - - - 
NPs 1:1 - - - - - + - - 
NPs 1:2.5 - - - - - - + - 
NPs 1:0.4 Fab (-) - - - - - - - + 
Fab(-): negative control antibody fragment;  Rho: Rhodamine; scFv: anti-CEA single-chain variable fragment; The functionalization ratio corresponds to 
PLGA-PEG-Maleimide to scFv-Rhodamine (anti-CEA single-chain variable fragment) mol ratios; 
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ImageStream®X analysis 
All the samples passed through a 70 µm nylon filter before being analysed by the imaging 
flow cytometer ImageStream®X (Amnis, Germany). The rhodamine (λexcitation 575 nm; λ emission 
605 nm) and FITC (λexcitation 490 nm; λemission 525 nm) fluorescence was assessed using an 
excitation laser at 488 nm at 100 mW, and the images were acquired in channel Ch04 (595-
660 detection band) and Ch02 (480-560 detection band), respectively, using a 40x 
objective. The brightfield images were obtained using an excitation laser of 785 nm at 13.44 
mW (channel Ch01, 430-480 detection band). At least 1.0 x 104 events were detected in all 
samples. The software IDEAS® version 6.2 (Amnis, Germany) was used to perform the 
images analyses. The values of internalization score, IS, are expressed in median, 
maximum and minimum. The values of mean fluorescence intensity (MFI) are expressed in 
mean ± standard deviation. There were selected a minimum of 100 cells per sample. 
 
Statistical analysis 
Statistical analysis was performed by the GraphPad Prism Software version 7 (GraphPad 
Software), and differences were interpreted by Unpaired t-test or One-way ANOVA with 
Dunnett's multiple comparisons test. The statistical differences are considered significative 
at * p< 0.05; very significative at ** p < 0.01; highly significative at *** p < 0.001 and 
extremely significative at **** p < 0.0001.  
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IV. Results 
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1. Selection of CEA and MACC1 most expressing CRC cell 
lines 
 
The innovative therapy proposed herein intends to produce nanoparticles that can silence 
the intracellular metastasis-associated in colon cancer 1 (MACC1) protein and at the same 
time, to be directed to cells expressing at their surface the carcinoembryonic antigen, CEA. 
As the present therapy is expected to generate benefit only in CRC tumours presenting this 
dual positivity, it is important to first select a cellular model capable to mimic, as much as 
possible, such conditions. MACC1 protein must exist at such concentration to allow that its 
silencing can trigger a significant response in the cancer cell. In this way, seven colorectal 
cancer cell lines (HCT-15, HT-29, SW480, SW620, RKO, Caco-2, and HCT-116) were 
selected to evaluate CEA (76 kDa) and MACC1 (97 kDa) protein expression levels (Figure 
12A and 12B respectively). As loading control, β-actin (42 kDa) expression was also 
assessed. Other control tested involved the incubation with the secondary antibody alone, 
(Control 2nd Ab only, Figures 12A and 12B). Briefly, the membrane was exposed to the 
blocking step, that was prolonged overnight at 4ºC, followed by incubation with the 
secondary antibody solution. Both membranes seem not to show unspecific staining of the 
secondary antibody applied. Additionally, a last control was further applied to guarantee the 
detection of the MACC1 protein (+ Control, Figure 12B), being this a positive control 
composed by mouse liver tissue lysate recommended by the supplier. 
The cells that most expressed both proteins were the HCT-116 and the SW480 cancer cell 
lines. Please note that in the present project only the full-length CEA protein and not its 
isoforms are being studied. Curiously, the full-length CEA expression band for SW480 and 
HCT-116 cells is different (Figure 12A). Instead of just a single well-defined band (as seen 
for SW480), it is also seen a region of bands around the expected full-length molecular 
weight of the CEA (HCT-116). This is possibly related to the different expression of the core 
chain of the CEA protein in distinct CRC cells, being possible the existence of splicing-
related variants in this region. The MACC1 expression (Figure 12B), on the other hand, is 
restricted to one single band (indicated by the arrow). The other bands seen around, result 
very likely, from the unspecific staining inherent to the polyclonal primary antibody used, 
which had ability to recognize other similar proteins. Finally, the SW480 and HCT-116 cells 
were further selected for immunofluorescence assays (Figure 18, Appendices section) and 
only SW480 was selected for silencing experiments. 
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2. Silencing efficiency of MACC1 in SW480 cell line 
 
In the present work, a commercially available pool of four MACC1 siRNAs, the SMARTpool 
ON-TARGETplus MACC1 siRNA (from now on MACC1 siRNA), was selected to specifically 
silence the metastasis-associated 1 (MACC1) protein, instead of using just a single MACC1 
siRNA molecule. This class of siRNA pools are known to be carefully designed, not to trigger 
off-target effects, many times associated with general siRNA molecules [99]. It was in this 
way expected that this pool was able to trigger an efficient gene silencing of the MACC1 
protein, in a very specific way, without the collateral issues associated with most commercial 
siRNAs. To assess the silencing efficiency of the MACC1 siRNA, a silencing assay was 
conducted with commercially available vectors in the CEA-expressing SW480 colorectal 
cancer cell line. The silencing efficiency evaluation was performed through western blot 
analysis, selected at three time points (24h, 48h and 72h), and also at different 
concentrations of MACC1 siRNA (25 nM and 100nM). The Lipofectamine® RNAiMax was 
used as transfection agent, and as control, the Dharmafect (25nM Dharmafect) vector was 
also tested, to assess the influence of different siRNA vectors in MACC1 silencing. As 
controls, the SW480 cells were incubated with medium (Only cells) or silenced with 25 nM 
of a known non-silencing siRNA (25 nM non-silencing siRNA). The last control involved the 
incubation of the western blot membrane with the secondary antibody alone, to ensure that 
the bands seen do not result from unspecific staining. As revealed by the first western blot 
A B 
Figure 12. Evaluation of CEA and MACC1 expression in seven colorectal cancer cell lines through Western Blot 
analysis. (A) CEA and (B) MACC1 protein expression was assessed in the colorectal cancer cells (HCT-15, HT-
29, SW480, RKO, Caco-2 and HCT-116), and as loading control was also assessed the β-actin protein 
expression in both experiments. An additional control where membranes were only incubated with the secondary 
antibody was performed (Control 2nd Ab only) and ensured that the non-specific staining of the secondary 
antibody applied did not occur. Lastly, on (B) a positive control for MACC1 expression (+ Control) was also 
applied. The colorectal cancer cells that most expressed both proteins were SW480 and HCT-116. 
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image at Figure 13A, the MACC1 protein starts to be gently silenced in the first day after 
silencing (24h). In comparison with cells not treated (Only cells, 24h) there was in fact a 
gentle silencing at 25 nM and 100 nM. On the other hand, on Figure 13B, at the second day 
(48h), there was an efficient silencing of the MACC1 protein when using 100 nM of MACC1 
siRNA (red rectangle), while at 25 nM the silencing was not such evident. As the small 
interfering RNA technology is known to trigger a brief transient silencing, it is expected that 
at the third day (72h) the recovery of the MACC1 protein expression had occurred for both 
concentrations (25 nM and 100 nM), as seen in the figure.  
Curiously, once using the Dharmafect transfection reagent, the MACC1 silencing was not 
such evident in both figures, due to the presence of a tenuous signal on the Dharmafect 
respective band (25 nM Dharmafect at 24h and 48h), comparing to the Lipofectamine® 
RNAiMax. For this reason, probably the Lipofectamine® RNAiMax is a more suitable vector 
to perform the silencing of the MACC1 siRNA. Moreover, the non-silencing siRNA (25 nM 
non-silencing siRNA) did not trigger the silencing of MACC1 in both figures, as expected. 
Lastly, the samples chosen for control of secondary antibody also showed no unspecific 
staining of the secondary antibody applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 13. Western blot analysis of MACC1 silencing in SW480 colorectal cancer cells through silencing with 
MACC1 siRNA. The SW480 cells were incubated with two concentrations of MACC1 siRNA (25 nM and 100 
nM), and the MACC1 silencing efficiency was evaluated at different time points (24h, 48h and 72h). Moreover, 
the silencing was performed using Lipofectamine® RNAiMax, and as control it was also assessed the silencing 
efficiency of other vector, Dharmafect, with 25 nM MACC1 siRNA (25 nM Dharmafect). Additionally, cells were 
incubated in medium (Only cells) or with 25 nM of a non-silencing siRNA (25 nM non-silencing siRNA). As a final 
control, the western blot membrane was also incubated with the secondary antibody alone (Control 2nd Ab only). 
(A) At the time point of 24h, the MACC1 silencing was not very significant for both MACC1 siRNA concentrations 
(25 nM and 100 nM). (B) At 48h, the MACC1 silencing was effective for 100 nM MACC1 siRNA concentration 
(100 nM, red rectangle) and additionally, the recovery of the protein expression was seen at the third day (72h). 
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3. Physicochemical characterization of nanoparticles 
The PLGA-PEG nanoparticles were produced through the double emulsion solvent 
evaporation technique, as described in the Material and Methods section. Nevertheless, the 
surfactant pH at which PLGA nanoparticles were produced influenced their stability, and 
consequently, the siRNA encapsulation efficiency [30]. At pH 5-6 from the endosome, PLGA 
suffer hydrolysis which affects the nanoparticles features and trigger the fast release of the 
siRNA from the polymeric matrix [128]. To optimize such production, empty and siRNA-
loaded PLGA-PEG nanoparticles were prepared at different surfactant pHs (7.4, 6 and 5) 
and their impact on nanoparticles features was evaluated (Table 9). The results indicate 
that pH decrease enhances NPs hydrodynamic diameter and polydispersity index (PdI), 
which suggests that the stability of formulations was affected. Still, no alterations on 
nanoparticles zeta potential were observed. Moreover, no significant differences between 
the empty and siRNA loaded nanoparticles were detected. Since the nanoparticles 
produced at surfactant pH 7.4 exhibited smaller size (~200 nm) and PdI (~0.190), the higher 
surfactant pH (pH 7.4) was selected to prepare further formulations. 
 
Table 9. Nanoparticles characterization at different surfactant pH. 
 
 
As mentioned before, the encapsulation of siRNA in PLGA nanoparticles is not efficient. To 
increase the siRNA association efficiency, the siRNA is alternatively non-covalently 
associated to cationic materials such as spermidine. In fact, Mark Saltzman’s team 
demonstrated that this natural polyamine permits the encapsulation of siRNA in PLGA 
nanoparticles with ~40 % of association efficiency [129]. To assess if the complexation of 
siRNA with spermidine affects the association efficiency and/or modifies any nanoparticles 
features, a physical characterization was performed (Table 10). Those features were 
studied on PLGA nanoparticles loaded with free siRNA, or with siRNA associated with 
NPs 95 PLGA5004A : 5 PLGA-PEG-Maleimide Empty VS MACC1 siRNA loaded 
 
Hydrodynamic diameter (nm) Polydispersity Index Zeta Potential (mV) 
Empty NPs at pH~7.4 206 ± 2 0.190 ± 0.009 -9.6 ± 0.4 
Loaded NPs at pH ~7.4 204 ± 2 0.194 ± 0.013 -10.0 ± 0.4 
Empty NPs at pH ~6 279 ± 4 0.270 ± 0.017 -10.9 ± 0.7 
Loaded NPs at pH ~6 294 ± 5 0.329 ± 0.034 -10.0 ± 0.6 
Empty NPs at pH ~5 392 ± 25 0.437 ± 0.048 -9.1 ± 0.3 
Loaded NPs at pH ~5 383 ± 11 0.425 ± 0.028 -10.2 ± 0.5 
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spermidine (forming complexes), at 3:1 and 8:1 N/P ratios. The N/P ratios selected were 
previously studied by other authors [129]. The results demonstrated that the nanoparticles 
presented a size of ~200 nm, with a low PdI (~0.200) and a zeta potential near – 10 mV, 
independently of being empty, loaded with free siRNA or loaded with an siRNA complex. 
The particles that were siRNA complex-loaded and functionalized at 1 PLGA-PEG-
Maleimide to 0.4 scFv mol ratio (spermidine/siRNA NPs (3:1) scFv-functionalized (1:0.4)) 
exhibited a higher size (~350 nm) and PdI (~0.550), as well a more negative zeta potential 
of ~ -23mV. 
The direct quantification of the Association Efficiency (AE) revealed that nanoparticles 
loaded with the complex of siRNA with spermidine at 3:1 N/P ratio, or with the free-siRNA, 
showed a low value of < 5%. The complexation at 8:1 N/P ratio was not possible to be 
detected by SYBR gold method. This indicates that the N/P ratio used to perform the 
complexation of siRNA with spermidine does not influence its association efficiency, as it 
was not enough to significantly increase the siRNA entrapment efficiency when compared 
with naked siRNA.  
 
Table 10. Nanoparticles characterization and association efficiency evaluation. 
 
Moreover, Transmission Electron Microscopy (TEM) was used to evaluate the impact of 
distinct formulations on nanoparticles morphological (Figure 14). The samples evaluated 
included the ones functionalized or non-functionalized, empty or loaded with the spermidine/ 
siRNA complex at 3:1 N/P ratio. All samples seemed to present a spherical morphology.  
 
 
NPs 95 PLGA5004A : 5 PLGA-PEG-Maleimide at pH 7.4 with 1.33 µg MACC1 siRNA  
 
Hydrodynamic 
diameter (nm) 
Polydispersity 
Index 
Zeta Potential (mV) Association 
Efficiency (%) 
Empty NPs 220 ± 5 0.243 ± 0.018 -10.9 ± 0.4 --- 
siRNA NPs 200 ± 2 0.158 ± 0.009 -12.1 ± 0.7 4.8 ± 5.6 
Spermidine/siRNA NPs 3:1 (N/P ratio) 189 ± 2 0.200 ± 0.023 -11.1 ± 0.6 4.7 ± 1.6 
Spermidine/siRNA NPs 8:1 (N/P ratio) 195 ± 2 0.208 ± 0.010 -14.6 ± 0.6 nd 
Spermidine/siRNA NPs (3:1) scFv-tagged 
(1:0.4) 
345 ± 79 0.554 ± 0.091 -22.9 ± 2.1 --- 
AE: Association Efficiency; nd: not determined; N/P ratio: ratio of amine groups from the polyamine to the phosphate groups of the siRNA; The 
functionalization ratio 1:0.4 corresponds to 1 mol PLGA-PEG-Maleimide to 0.4 mol anti-CEA single-chain variable fragment (scFv). 
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4. Evaluation of siRNA complexation with spermidine 
Once encapsulating siRNA complexes, it is necessary to ensure that first, the complexation 
of the siRNA occurs, and second, the complexation is maintained after being exposed to 
the nanoparticle production and purification processes. To achieve this, several siRNA 
samples were selected: i) some before being encapsulated, where the siRNA was just 
complexed with spermidine as previously mentioned (Figure 15B); and others ii) after being 
submitted to the nanoparticle production and purification procedures (Figure 15A). Inside 
this last condition (after nanoparticles production, Figure 15B), three more samples were 
taken: i) the nanoformulation before being submitted to the washing steps (Before washing), 
ii) the first nanoformulation’ supernatant after the first washing step (Supernatant), and iii) 
the concentrated nanoformulation after purification (After washing). 
The siRNA complexation efficiency was evaluated by electrophoresis made in a 
polyacrylamide gel loaded with the previously mentioned siRNA samples. The 
electrophoresis triggers the separation of the of the samples’ constituents, in this way 
evaluating whether the complexation occurred or not.  
Figure 14. TEM images of the nanoformulations. The empty and siRNA complex loaded-nanoparticles, either 
functionalized (C, D) or not (A, B). The siRNA complex contained spermidine/siRNA at 3:1 N/P ratio and the 
nanoparticles were functionalized with anti-scFv at 1:0.4 ratio. Bar scale of 100 nm, with a 100 000x 
amplification. 
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Firstly, as exposed in Figure 15A, to evaluate the siRNA complexation after the 
nanoparticles production and purification, some wells of the polyacrylamide gel were also 
loaded with empty nanoparticles (Empty nanoparticles) as control and did not show any 
signal, meaning that no siRNA was present in there, as expected. Moreover, for the 
nanoparticles loaded with the siRNA/spermidine complex at 3:1 N/P ratio, the samples 
before and after washing presented signal for siRNA in the same position as naked-siRNA 
(siRNA) and complexed-siRNA (siRNA 3:1). Nevertheless, if the siRNA was truly 
complexed with the spermidine, the complex charge would be neutral, and it would not 
migrate through the gel, staying on the top of the well. It is in this way possible to conclude 
that the siRNA complexation was not completely efficient. Additionally, the siRNA signal 
was less strong in those nanoparticle batches (siRNA 3:1 NPs) when compared with the 
controls of the free siRNA (siRNA) and the spermidine/siRNA complex at 3:1 N/P ratio 
(siRNA 3:1), due to losses that possibly occurred during the pipetting steps. Moreover, the 
supernatant of loaded nanoparticles (Supernatant, siRNA 3:1 NPs) do not seem to have 
detectable siRNA.  
On the other side, to evaluate the impact of the N/P ratio of the spermidine/siRNA complex 
used on the complexation efficiency, in Figure 15B, there were tested different complexation 
ratios (3:1, 8:1, 20:1 and 50:1). To assess the siRNA integrity, a different siRNA was 
compared with the previous one, a single siRNA molecule anti-CCR5 (CCR5 siRNA). As it 
is exposed, is possible to identify a more intense smear under the siRNA MACC1 band, (as 
also seen in the first well of the Figure 15A), meaning that siRNA MACC1 is likely to be 
more degraded than siRNA CCR5. Moreover, even when increasing the complexation ratio, 
from 3:1, 8:1, 20:1 to 50:1 (N/P ratio), no significative differences were found in the 
complexation, meaning that very likely, the complexation, even at higher ratios is not 
complete.  
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5. Physicochemical characterization of functionalized 
nanoparticles 
To target the nanoparticles to the CEA cell-surface molecule present at metastatic 
colorectal cancer cell lines, it is necessary to functionalize the nanoparticles with specific 
ligands for this molecule. The ligand chosen was the shMFELL2Cys, a human disulphide-
stabilized single-chain variable fragment anti-CEA. To guarantee that the particles’ 
properties after the functionalization are still suitable for systemic delivery, their 
physicochemical characteristics were evaluated at several ratios of functionalization, as 
1:2.5, 1:1 and 1:0.4. Non-functionalized nanoparticles were also tested, as control (NP 1 
A 
 
B 
 
Figure 15. Polyacrylamide gel electrophoresis (PAGE) of siRNA complex-loaded nanoformulations and siRNA 
complexes. (A) To assess the siRNA complexation efficiency after the nanoparticles production, 
spermidine/siRNA complexes at 3:1 N/P ratio were loaded into the NPs, and there were evaluated different 
conditions: i) nanoformulation before being washed (Before washing), ii) the first nanoformulation’ supernatant 
(Supernatant), and iii) nanoformulation after purification (After washing). Moreover, as control, empty NPs 
(Empty NPs) were also submitted to the same procedure. Additionally, naked siRNA (siRNA) and 
spermidine/siRNA complexes at 3:1 N/P ratio were also loaded into the gel. As expected, the empty NPs did 
not evidence siRNA presence. On the other hand, the siRNA complexes submitted to NPs production exhibited 
similar signal from the one of the naked siRNA (siRNA) and complexed siRNA at 3:1 N/P ratio (siRNA 3:1). (B) 
To assess the value of the N/P ratio in the complexation efficiency, the spermidine/siRNA complexes were made 
at multiple N/P ratios (3:1, 8:1, 20:1 and 50:1). As controls, the naked MACC1 siRNA (siRNA) and a single 
siRNA molecule (CCR5 siRNA) were tested. The N/P ratio seemed not to interfere with the complexation 
efficiency and the MACC1 siRNA (siRNA) appeared to be more degraded than the single siRNA duplex (CCR5 
siRNA). 
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PLGA-PEG-Mal : 0 scFv). It was also selected a negative control antibody fragment, a 
human negative Fab, to functionalize the particles.  
As the results in Table 11 suggest, the nanoparticles functionalized at 1 mol PLGA-PEG-
Maleimide to 0.4 mol scFv (NP 1 PLGA-PEG-Mal : 0.4 scFv) obtained better characteristics 
than all the other functionalized formulations and were selected for further experiments. 
Those nanoparticles had 446 ± 560 nm, a polydispersity index of 0.542 ± 0.047 and an anti-
CEA scFv conjugation efficiency (CE) of ~33% (direct method). The direct method of 
conjugation efficiency was evaluated by previously staining the anti-CEA scFv with the 
rhodamine probe (already described) and evaluating the mean fluorescence intensity of the 
dispersion. However, the first strategy selected to evaluate the anti-CEA scFv conjugation 
efficiency that was not further developed, was the enzyme-linked immunosorbent assay 
(ELISA) as referred in Figure 21 and Table 13, on the Appendices section. Moreover, the 
nanoparticles functionalized with the positive antibody fragment (scFv) exhibited a higher 
size and PdI than the ones not exposed to the functionalization reagents (Naked NPs). This 
observation possibly indicates that the anti-CEA scFv was really at the surface of the 
nanoparticles. Although the zeta potential has shown to be more negative than the naked 
particles, there is no relationship between the zeta potential of the functionalized particles 
and the increase of scFv amount at their surface. Nevertheless, the conjugation efficiency 
was evaluated by direct and indirect method, and in fact, its values enhanced at lower ratios 
of nanoparticles functionalization.  
 
Table 11. Nanoparticles production and scFv-Rhodamine conjugation efficiency evaluation. 
NPs 95 PLGA5004A : 5 PLGA-PEG-Mal pH 7.4, DTT reduction (scFv-Rhodamine) 
 
Hydrodynamic 
diameter (nm) 
Polydispersity 
Index 
Zeta Potential 
(mV) 
Conjugation 
Efficiency (%) 
Direct method 
Conjugation 
Efficiency (%) 
Indirect method 
Naked NPs  209 ± 2 0.201 ± 0.017 -11.4 ± 0.4 ---- ---- 
NP 1 PLGA-PEG-Mal : 2.5 scFv 463 ± 118 0.653 ± 0.113 -23.9 ± 2.7 8.0 ± 0.5 32.3 ± 4.5 
NP 1 PLGA-PEG-Mal : 1 scFv 816 ± 453 0.895 ± 0.090 -27.9 ± 2.8 18.0 ± 1.4 51.7 ± 18.0 
NP 1 PLGA-PEG-Mal : 0.4 scFv 446 ± 56 0.542 ± 0.047 -25.4 ± 2.2 33.1 ± 3.2 51.0 ± 1.8 
NP 1 PLGA-PEG-Mal : 0 scFv 499 ± 47 0.585 ± 0.108 -20.3 ± 1.9 ---- ---- 
 
Additionally, the nanoparticles tagged with the negative Fab (Table 12) exhibited significant 
better characteristics (lower size and PdI) than the ones coated with the positive scFv.  
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Table 12. Nanoparticles production using FITC- PLGA polymer. 
 
6. Cell Uptake Studies  
6.1 Confocal microscopy results  
In this work, the nanoparticle’s functionalization with the single-chain variable fragment was 
performed to trigger the specific recognition of CEA cell-surface molecules expressed in 
CRC cell lines. Once targeting the nanocarrier to the carcinoembryonic antigen, it is 
expected that the nanoparticle’s uptake occurs through CEA-mediated internalization, only 
affecting the CRC cells expressing this protein. In order to evaluate the internalization 
potential of the functionalized nanoparticles in CEA-expressing colon cancer cells, SW480 
cells were incubated with formulations of functionalized nanoparticles at different ratios of 
anti-CEA scFv. Flow cytometry analysis was the first strategy followed to perform such 
evaluation, as exposed on Figure 20, in the Appendices section. Previously, the 
assessment of the CEA recognition by the anti-CEA scFv was also performed by FACS 
(Figure 19, Appendices). Both studies did not had success, and therefore other techniques 
were further developed.  
To note, the anti-CEA scFv was previously stained with the rhodamine probe before 
producing the functionalized nanoparticles. Several PLGA-PEG-Maleimide to scFv-
Rhodamine mol ratios were then selected to conjugate at the nanoparticles surface. The 
non-functionalized nanoparticles correspond to the (NPs 1:0), and in the further ratios the 
amount of scFv added was gradually increased (NPs 1:0.4, NPs 1:1 and NPs 1:2.5), to 
assess the influence of the scFv functionalization ratio in the nanoparticles uptake. As 
controls, SW480 cells were also incubated with the probe alone (Rhodamine Only), or with 
the rhodamine-stained single-chain variable fragment (scFv-Rhodamine). To mimic the use 
of negative CEA cells (CRC cells not expressing surface-CEA), another control was also 
applied, where SW480 was firstly incubated with scFv alone, intending to saturate all the 
CEA antigen-binding sites, to theoretically difficult the functionalized-nanoparticles at 1:1 
ratio uptake by those treated cells (scFv + NPs 1:1). A last negative control was performed, 
producing functionalized nanoparticles at 1:0.4 ratio with a negative control antibody (NPs 
NPs 85 PLGA5004A : 10 PLGA-FITC : 5 PLGA-PEG-Mal pH 7.4, DTT reduction 
 
Hydrodynamic diameter (nm) Polydispersity 
Index 
Zeta Potential (mV) 
Naked NPs 208 ± 4 0.210 ± 0.014 -10.9 ± 0.6 
NP 1 PLGA-PEG-Mal : 0.4 Fab (-) 273 ± 8 0.373 ± 0.05 -33.1 ± 1.4 
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1:0.4 Fab (-)). The negative-control functionalized nanoparticles were exceptionally made 
with a PLGA-FITC polymer and no rhodamine staining of the scFv was performed.  
Confocal microscopy was the first technique used to evaluate the cell uptake of the 
formulations. The functionalized nanoparticles at 1:2.5 mol ratio (NPs 1:2.5) seemed to 
have more spots of signal fluorescence, meaning probably a higher internalization than the 
other nanoparticles functionalized at lower ratios (Figure 16A). The signal observed is 
mostly distributed inside the cell, rather than associated to the cytoplasmic membrane 
(Figure 16B). Additionally, in the Figures 16C and 16D, the cells incubated with the 
rhodamine probe alone (Only Rhodamine) appeared to have a different behaviour of 
internalization, existing multiple little spots of signal, more dispersed and smaller than the 
ones observed in the cells incubated with the functionalized nanoparticles at higher ratio 
(NPs 1:2.5), or simply incubated with the rhodamine stained-scFv (scFv-Rhodamine). It is 
also likely that the latest two samples (NPs 1:2.5 and scFv-Rhodamine) were internalized 
as aggregates. Therefore, likely, as observed in Figures 16E and 16F, the cells incubated 
with the functionalized nanoparticles at 1:1 ratio (NPs 1:1) exhibited more spots of 
fluorescence signal and subsequently, internalized more fluorescence than the cells that 
were firstly saturated with the scFv and further exposed to the functionalized nanoparticles 
(scFv + NPs 1:1). Curiously, the spots of fluorescence found in the last referred cell sample 
(scFv + NPs 1:1) are likely to indicate that the functionalized nanoparticles were mostly 
concentrated at the cell surface, instead of being internalized. Lastly, the SW480 cells 
incubated with the functionalized nanoparticles at 1:0.4 ratio (NPs 1:0.4, red channel) 
appeared to exhibit, very likely, a higher internalization rather than the negative Fab 
functionalized particles (NPs 1:0.4 Fab (-), green channel), as exposed on Figures 16G and 
16H. Although the negative Fab functionalized particles were stained with a different probe 
(FITC) from all the other samples, the signal exhibited was almost negligible and can be 
compared to the other conditions. The scFv functionalization ratios seemed to influence the 
nanoparticles uptake behaviour in SW480 cells, suggesting that at higher ratios (NPs 1:2.5) 
the functionalized nanoparticles were more internalized by the CEA-expressing cells. 
Moreover, the uptake of smaller molecules as rhodamine alone (Only Rhodamine) was 
apparently done through a mechanism of internalization different from the one observed for 
the other samples, where bigger systems were implicated. Lastly, the specificity of the 
antibody fragment that existed at nanoparticles surface for the targeted antigen (CEA) 
seemed to influence the efficacy of its cellular internalization. It might possibly prove that 
the uptake of functionalized particles did not occurred due to the unspecific interactions 
between the antibody fragment domains and the cell.   
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Figure 16. Confocal microscopy evaluation of uptake studies performed. (A) SW480 cells untreated or incubated 
with non-functionalized nanoparticles (NPs 1:0), or even with functionalized nanoparticles (A, B) with increasing 
ratios of scFv, as NPs 1:0.4, NPs 1:1 and NPs 1:2.5. (C, D) Cells were also incubated with rhodamine alone (Only 
Rhodamine) or the rhodamine-stained scFv (scFv-Rhodamine) and compared with the functionalized NPs at 
higher scFv ratio. (E, F) The cells were first incubated with the scFv and then exposed to the functionalized 
nanoparticles at 1:1 scFv ratio (scFv + NPs 1:1), and further compared with the functionalized NPs at 1:1 ratio 
(NPs 1:1). (G, H) SW480 cells were treated with the negative control functionalized NPs at 1:0.4 negative Fab 
ratio (NPs 1:0.4 Fab (-)) and further compared with the functionalized NPs at 1:0.4 ratio (NPs 1:0.4). The images 
from z-stack were taken in several samples (B, D, F, H). 
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6.2 Imaging Flow Cytometry (ImageStream®X) Results 
Afterwards, the evaluation of functionalized nanoparticles cellular internalization was further 
complemented with imaging flow cytometry analysis, that is a technique that combines flow 
cytometry and microscopy together. In the Figure 17A it is exposed the microscopy images 
taken by the ImageStream®X equipment to each sample. On the unstained cells, no 
significant background was seen. The SW480 cells seemed to internalize easily the 
rhodamine probe (Rhodamine Only), being this sample the one that appeared to exhibit 
more intensity of internalized signal. Once increasing the scFv amount tagged at the 
nanoparticle surface, an enhanced signal of fluorescence intensity was observed inside the 
cell (NPs 1:0.4, NPs 1:1 and NPs 1:2.5). Curiously, as above suggested by the confocal 
microscopy results, the cells first saturated with the scFv and further incubated with the 
functionalized NPs (scFv + NPs 1:1) appeared to difficult the internalization of the 
nanoparticles added after the CEA binding-site saturation, once a high intense fluorescence 
signal seemed to be at the cellular surface instead of being internalized. Moreover, the cells 
incubated with the negative control functionalized NPs (NPs 1:0.4 Fab (-)) appeared to 
display a less intense fluorescence signal, suggesting the less facility of the negative control 
functionalized NPs to be internalized by the CEA-expressing cells, when compared with the 
nanoparticles functionalized with the anti-CEA scFv. 
The ImageStream®X equipment allows the evaluation of the mean fluorescence intensity 
(MFI) internalized by the cell and estimates the nanoparticles Internalization Score (IS). It 
was firstly evaluated the Internalization Score, (Equation 4), that is the ratio between the 
fluorescence intensity inside the cell and the total fluorescence intensity of the cell. 
 
𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑆𝑐𝑜𝑟𝑒 (𝐼𝑆) =
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝐼𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝐶𝑒𝑙𝑙
𝑇𝑜𝑡𝑎𝑙 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝐶𝑒𝑙𝑙 
                         (4) 
 
It is important to refer that the IS is calculated by the software equipment by applying firstly 
an automatic mask to each cell, by covering the expected area where the cytoplasm is. 
Importantly, as indicated in all the figures of this section that evaluate the IS, it increased 
with the enhance of the fluorescence signal expected to be internalized by the cells, and 
therefore, indicated that nanoparticles were mostly internalized by the cells. On the other 
way, once the IS started to decrease below zero (IS < 0), it meant the reduction of the 
fluorescence signal internalized, and consequently, indicated that the nanoparticles were 
mostly absorbed at the cell surface and not internalized.  In this way, it was selected in the 
Figure 17B the cells that had a positive internalization score (IS > 0). Those cells had higher 
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internalized fluorescence (in the cytoplasm) rather than in the membrane. Looking again to 
Figure 17B, there is exposed a graph of the Normalized Frequency (Normalized number of 
cells) VS Internalization Score for each sample, where it is possible to see that the 
distribution of the populations internalization score did not appeared to be symmetric. So, 
the analysis of this graph must include the median, the maximum and the minimum, and is 
reported on Figures 17C, 17D and 17E. Starting by analysing the data from Figure 17C, a 
significant statistical difference was found between the non-functionalized nanoparticles 
(NPs 1:0) and all the functionalized nanoparticles (NPs 1:0.4, NPs 1:1 and  NPs 1:2.5), with 
a p-value <0.05. This statistical test compared the difference between the means of IS from 
each sample. Although significative difference was found, it only reveals that the non-
functionalized nanoparticles (NPs 1:0) had a higher internalization score than all the others. 
Importantly, as indicated in Figure 17P, this last sample (NPs 1:0) was the less positive for 
the staining. This means, probably, that the low fluorescence signal exhibited by the cells 
treated with non-functionalized NPs (NPs 1:0) was mostly localized inside the cell, rather 
than at its surface. Additionally, in the Figure 17D, there were no significative differences 
between the internalization score of the functionalized nanoparticles at 1:1 scFv ratio (NPs 
1:1) and the IS from CEA-saturated cells that were further incubated with the functionalized 
NPs (scFv + NPs 1:1). Moreover, the Figure 17E revealed that the IS of the rhodamine-
stained single-chain variable fragment (scFv-Rhodamine) and from the probe alone 
(Rhodamine Only) were highly significant than the IS observed in functionalized NPs at 
higher scFv ratio (NPs 1:2.5).  
Other analysis performed by the ImageStream®X software follows the evaluation of the 
mean fluorescence intensity (MFI) that is expected to be internalized by the cell (MFI in cells 
with IS > 0). Therefore, the Figure 17F shows the cells, between the populations, that were 
positive for the rhodamine staining (Ch04+). To evaluate which cell populations internalized 
more fluorescence, it was necessary to select, inside of the positive-stained populations 
(Figure 17F, population Ch04+), the ones that had a positive internalization score (IS > 0), 
as showed in the Figure 17G by the population (Ch04+). These data were first analysed in 
Figure 17H, where the population of functionalized NPs at higher scFv ratio (NPs 1:2.5) 
exhibited more internalized fluorescence intensity than the non-functionalized ones (NPs 
1:0), with a p-value < 0.05. This might suggest the ability of the functionalized nanoparticles 
at high scFv ratio to internalize more easily than the non-functionalized ones (NPs 1:0). The 
functionalized NPs at other ratios (NPs 1:0.4 and NPs 1:1) also had a bigger internalized 
mean fluorescence intensity (MFI) than the non-functionalized nanoparticles (NPs 1:0), but 
it was not significant. Additionally, in the Figure 17I, the functionalized nanoparticles at 1:1 
scFv ratio (NPs 1:1) had a higher internalized MFI than the ones applied after the CEA-
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saturation binding-site (scFv + NPs 1:1), but it was also not significant. Finally, in the Figure 
17J, the functionalized nanoparticles at higher ratio (NPs 1:2.5) had a statistically 
significative higher internalized MFI than the rhodamine-stained scFv (scFv-rhodamine) and 
the probe alone (Rhodamine Only), with a p-value < 0.05. These results pointed that 
functionalizing the particles at 1:2.5 ratio (NPs 1:2.5) favours their internalization more than 
the use of the antibody fragment alone (scFv-Rhodamine) or the probe alone (Rhodamine 
Only). 
Lastly, the evaluation of the negative control functionalized nanoparticles (NPs 1:0.4 Fab (-
)), internalization profile was performed. To note, the negative Fab-functionalized 
nanoparticles were produced with PLGA-FITC polymer, instead of staining the antibody 
fragment with the rhodamine probe, as done in other functionalized nanoparticles (NPs 
1:0.4, NPs 1:1, NPs 1:2.5). Considering this limitation, a separated analysis had to be 
performed, once the probe (FITC) was different. Once more, the internalization score 
(Figure 17K) was evaluated, as the MFI internalized values (Figures 17M and 17N), where 
were shown the positive populations for the FITC staining and the ones that being positive 
for the staining, also internalized more fluorescence, respectively. Looking firstly to Figure 
17L, it is again compared the total internalization score among populations. Here, the 
negative control functionalized nanoparticles (NPS 1:0.4 Fab (-)) exhibited a higher 
internalization score than the one observed in functionalized NPs at all the scFv ratios (NPs 
1:2.5, NPs 1:1, and NPs 1:0.4), with a significant difference at a p-value < 0.05. Conversely, 
in the Figure 17O, which evaluates the MFI mostly internalized by the cells, the negative 
control functionalized nanoparticles (NPS 1:0.4 Fab (-)) exhibited a statistically significant 
lower internalized fluorescence intensity than the functionalized nanoparticles at higher and 
medium scFv ratios (NPs 1:2.5 and NPs 1:1), with a p-value <0.05. Negative control 
functionalized nanoparticles (NPS 1:0.4 Fab (-)) had also, although not significant, lower 
MFI than the functionalized nanoparticles at 1:0.4 scFv ratio (NPs 1:0.4). The higher IS 
observed for the negative control functionalized nanoparticles (NPS 1:0.4 Fab (-)) can mean 
that the reduced fluorescence signal seen in cells incubated with these nanoparticles, was 
almost internalized by them. Additionally, it was a relatively non-relevant signal when 
compared with the fluorescence obtained by other cells treated with functionalized 
nanoparticles (NPs 1:1 and NPs 1:2.5). Therefore, these results might probably contribute 
to prove that once functionalizing the nanoparticles with a negative control antibody 
fragment (NPs 1:0.4 Fab (-)), its efficiency of internalization was smaller than the observed 
when the particles were functionalized with a positive antibody fragment for the CEA at ratio 
1:2.5 and 1:1 (NPs 1:2.5 and NPs 1.1). It is necessary to highlight once more that the CEA-
specificity of the antibody fragment tagged at nanoparticles surface seemed to influence the 
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efficacy of the carrier cellular internalization. The last results presented in this section 
possibly contribute to prove again that the uptake of functionalized particles did not occurred 
due to the unspecific interactions between the antibody fragment domains and the cell. In 
ultimate analysis, the results obtained in the ImageStream®X analysis appeared to 
corroborate the observations of the confocal microscopy analysis.  
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Figure 17. ImageStream®X analysis of uptake studies performed. (A) ImageStream®X images taken in Ch01, 
Ch04 and Ch02 (brightfield, Rhodamine and FITC) channels, bar scale 10 µm. SW480 cells untreated or 
incubated with non-functionalized nanoparticles (NPs 1:0), or even with functionalized nanoparticles with 
increasing ratios of scFv, as NPs 1:0.4, NPs 1:1 and NPs 1:2.5. Cells were also incubated with rhodamine alone 
(Only Rhodamine) or the rhodamine-stained scFv (scFv-Rhodamine). In other negative control, the cells were 
first incubated with the scFv and followed with functionalized nanoparticles at 1:1 scFv ratio (scFv + NPs 1:1). 
Lastly, cells were also treated with the negative control functionalized NPs at 1:0.4 negative Fab ratio (NPs 1:0.4 
Fab (-)). (B, K) Total internalization score of stained populations. (C, D, E, L) Analysis of the differences in total 
internalization score among stained populations. (F, M) MFI in stained populations. (G, N) MFI in populations 
with positive internalization score. (H, I, J, O) Analysis of the differences in MFI among populations with mostly 
internalized fluorescence. (P) Percentage of positive cells for the staining. The data shown in Figure C, E, H, J, 
L and O were interpreted by One way ANOVA, Dunnett's multiple comparisons test. The data presented in 
Figures 9D and 9I were interpreted by Unpaired t-test. The statistical differences are given by * p< 0.05; ** p < 
0.01; *** p < 0.001 and **** p < 0.0001. 
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In the present dissertation, an innovative nanoparticulate system was designed to 
systemically target and treat colorectal cancer in more advanced stages. The nanoparticles 
were constructed with a low toxicity polymer, poly(lactic-co-glycolic acid) (PLGA), to deliver 
a pool of siRNAs to silence the oncogenic metastasis-associated in colon cancer 1 
(MACC1) protein. This system is also functionalized with a single-chain variable fragment 
(scFv) with high affinity to the carcinoembryonic antigen (CEA) cell-surface protein 
expressed in metastatic colorectal cancers (mCRC). The MACC1 is an intracellular protein 
proven to be upregulated in metastases of colorectal cancer [149]. On the other hand, CEA 
is the only cell-surface molecule present in mCRC that is used for disease monitorization in 
the clinics [23]. This promising dual targeting system has never been made before and 
intends to be administered in patients with MACC1 and CEA-expressing subtypes of 
colorectal cancer.  
The first step of this study intended to evaluate the colorectal cancer cell lines that best fit 
as a model to test this nanoparticulate system. From our knowledge, the percentage of CRC 
patients that present tumours with this dual positivity (CEA+ and MACC1+) has never been 
evaluated before. Considering that MACC1 expression is correlated with metastases events 
in colorectal cancer [162] and CEA is present in > 90% of the CRC patients [14], it is 
expectable that this subpopulation of individuals is significative. In the present work, SW480 
and HCT-116 were the colorectal cancer cells that most express both proteins. The CEA is 
known to be at the cell surface [35], and herein, despite of no incontestable proof had 
demonstrated the CEA protein presence at the cell surface of colorectal cancer cells, some 
preliminary experiments seemed to indicate that. 
Additionally, some authors defended the upregulated expression of MACC1 in metastatic 
colorectal cancer lines and already performed its efficient silencing using commercial 
vectors [149]. In this work, a SMARTpool of four different siRNA sequences targeting 
different sites on the MACC1 mRNA was used (SMARTpool ON-TARGETplus siRNA), 
instead of a single siRNA duplex. It is in this way expectable that such improved technology 
can dilute the off-target effects associated to the use of single siRNAs [99]. Nevertheless, it 
is important also that MACC1 protein exists in adequate amount inside the cells, so its 
silencing can trigger a significant response. In this dissertation, the effective silencing of 
MACC1 in SW480 cells occurred at the second day, with 100 nM of MACC1 siRNA. 
Regarding the strategy of nanoparticles production, once encapsulating a hydrophilic 
molecule in hydrophobic polymeric matrices, that entity will not stay dispersed in the matrix, 
it will rather be on the pores of the matrix. Moreover, the release of such molecules, as 
siRNA, from the particles is also expectable to occur due to its diffusion through the aqueous 
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channels, once the polymer starts to be degraded (due to acidic pH for instance) [140]. This 
reason motivated the evaluation of the optimal pH at which the nanoparticles should be 
produced, once it influences significantly the integrity of the system and the association 
efficiency of the siRNA. The nanoparticles produced at physiological pH presented a smaller 
size and PdI when compared to the others produced at higher pHs. With the pH decrease, 
both polydispersity index and size increased. A possible explanation for this is associated 
with the fast hydrolysis seen of the PLGA, PLGA-PEG-Maleimide and the surfactant at 
those pH values, which increases the porosity of the polymeric matrix, modifying its 
features, and possibly facilitating the release of siRNA from the carrier (not evaluated) [128]. 
Importantly, the surfactant solution was made in water, instead of other buffered solution. 
This detail implicates that the pH initially imposed was probably not maintained during the 
nanoparticles production and purification. Moreover, the fully protonated profile of 
polyamines (spermidine), at physiological pH, turn them more reactive with negative 
charges, and is other reason to support the usage of those conditions (pKa of spermidine 
10.9, 9.9, 8.4) [130]. It was also determined by Huiqing Cao et al. that encapsulating the 
siRNA in polymers with pKa ranging from 5.8 to 6.2 can trigger the endosomal escape and 
the sustained release of the siRNA, once siRNA is strongly released in the early endosome, 
if exposed to pH 5-6 [95, 163].  
The PLGA particles were found to escape the lysosomal degradation through the reverse 
of the surface charge from anionic to cationic, when exposed to the acidic pH of the 
lysosome. Considering the PLGA acid terminated has a pKa near 3.8 [122, 123], once 
inside the lysosome, the carboxyl groups will be protonated, the pH of the compartment will 
decrease, and when it reaches the pH 4-5, the PLGA will show its buffer capacity and induce 
the translocation of protons inside, disrupting that compartment and migrating to the cytosol 
to trigger mRNA silencing [118]. After this step, the particle has the ability to stay in the 
cytoplasm for a maximum of two weeks, where it will perform the sustained release of its 
cargo [124]. Once the PLGA particles only escape at lysosomal level and to avoid the 
migration of siRNA to the endosomal space, co-encapsulants with higher pKa can be added 
to the PLGA matrix. 
To optimize the method for siRNA extraction from the loaded nanoparticles, several 
strategies were tested. Once solubilizing 20 mg of polymeric nanoparticles in 5 mL of 
dichloromethane, to destroy the particles, the siRNA was the only hydrophilic entity and was 
surrounded by the hydrophobic phase, which causes siRNA precipitation. When adding 
directly 1 mL of TE buffer (aqueous phase), the siRNA can migrate to this hydrophilic phase, 
that is not miscible with the oil one, to further proceed with the extraction [129]. When 
working with co-polymers, that are a mixture of hydrophobic (PLGA) and hydrophilic (PEG) 
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polymers, like the PLGA-PEG-Maleimide, it is expectable that the PEG chain itself, exposed 
to a hydrophilic environment, tends to migrate to them [164]. This was exactly what seemed 
to happen once adding the 1 mL of TE buffer directly to the 5 mL of oil phase. After vortexing 
the mixture, so siRNA gets a chance to migrate for the hydrophilic one, and after leaving 
the mixture resting so the two phases could separate for siRNA extraction, the formation of 
an intermediate white phase was seen. This white phase seemed to involve all the 
hydrophilic phase and is very likely a result of the PEG chains (from PLGA-PEG-Maleimide) 
tendency to migrate to the aqueous phase. To minimize this white phase, 5 mL of destroyed 
nanoparticles in dichloromethane were sorted in 500 µL portions for RNase free eppendorfs. 
After that, 500 µL of TE buffer were added to each eppendorf, and the white phase present 
in each eppendorf was in this way almost fully reduced (from 1 mg/mL to 0.2 mg/mL of 
PLGA-PEG-Maleimide assuming the sorting for 10 eppendorfs).  
Moreover, the encapsulation of high molecular weight (> 3 000 Da) hydrophilic molecules 
such as proteins, peptides and antibodies in PLGA matrixes through double emulsion 
technique is feasible. The siRNA is also a hydrophilic high molecular weight molecule, but 
its encapsulation is not efficient in hydrophobic polymers. This phenomenon is also seen 
for small hydrophilic molecules (< 500 Da), which can translocate the membrane through 
passive diffusion [109, 125]. Ubrich and colleagues have found that the entrapment of such 
hard-to-encapsulate molecules can be enhanced by increasing the amount of drug (loading) 
to be encapsulated, the molecular weight of the polymer and its viscosity, as the viscosity 
of the inner aqueous phase, which can be a consequence of increasing the loading [125].   
Additionally, for nanoparticles loaded with naked siRNA, the siRNA quantification was 
performed without previously freeze-drying the aqueous siRNA-extracted from destroyed 
particles and was obtained without any sorting of the oil phase. These details can probably 
influence the results. Despite of this, it is expectable that the association efficiency remains 
lower than 5%, as already described by Woodrow and colleagues. They have found that 
the encapsulation of the naked siRNA into PLGA nanoparticles has a very low association 
efficiency (< 5%), and once complexing the siRNA with cationic materials, turning it more 
hydrophobic and increasing its bulk volume, the association efficiency increased over 40-
fold [129]. Their team first complexed siRNA with small and natural polyamines [130] to 
optimize the association efficiency and drug loading. They found out that the siRNA 
functionality did not change after its encapsulation, being the formulation with spermidine 
at 3:1 N/P ratio the one with better characteristics. In the present work, the siRNA 
complexation was made with spermidine (at 3:1 and 8:1 N/P ratio), due to the success of 
Saltzman’s team performing the encapsulation of siRNA in PLGA nanoparticles.   
 80 
 
In fact, the analysis of siRNA complexation by PAGE indicated that the complexation was 
not efficient. The SYBR gold probe used is a cationic fluorescent probe that non-covalently 
binds to the phosphate groups of siRNA, triggering the fluorescence increase. If 
complexation really occurred, it will difficult the role of SYBR gold on detecting it, since the 
phosphate groups will not be available [161]. And once running it in a gel, as the complex 
should partially or fully neutralize the charge of siRNA, it will not migrate during gel 
electrophoresis, and should stay arrested in the well, on the top of the gel. 
Nevertheless, several reasons are likely to justify the non-complexation of the siRNA with 
spermidine. The first is that the complexation efficiency with the cationic material is 
sequence-specific. As showed by Woodrow and co-workers, some siRNA sequences were 
likely to form complexes with spermidine, but others not [129]. Secondly, perhaps 
spermidine is not the best material to complex the SMARTpool ON-TARGETplus siRNA 
MACC1. Instead of using small linear polyamines, maybe branched polymers such as PEI 
[133], polysaccharides as chitosan [128], and other cationic polymers are an option, but 
there must always exist an equilibrium between the complexation efficiency and the toxicity 
that such co-encapsulants can impose in the cell. Another strategy to enhance the 
association efficiency is the acetylated bovine serum albumin (Ac-BSA), a recent alternative 
to potential toxic cationic materials. It works mostly by increasing the stability of the primary 
emulsion when used at low PLGA concentrations [139].  
Since complexation was fairly inefficient, more likely, as showed in Table 10, producing 
nanoparticles with naked siRNA or spermidine/siRNA complexes will obtain around < 5% 
of association efficiency. On Figure 15, the supernatant of the loaded nanoparticles does 
not seem to present detectable siRNA concentrations, suggesting that likely, the siRNA is 
being entrapped in the upper content of the Amicon® filter or on the filter itself. The siRNA 
(13.3 kDa) is theoretically able to pass through the Amicon® filter (100 kDa MWCO), but 
the cellulose membrane on it can possibly interfere. An assay evaluating if the free siRNA 
can pass through the Amicon® filter and be detected in its lower compartment can be 
necessary. 
Considering the functionalization steps, the conjugation efficiency was evaluated and 
although their values are different for nanoparticles functionalized at different ratios, the 
amount of scFv that exists at the particles’ surface is almost the same (Table 11). The 
conjugation efficiency did not increase with the raise of functionalization ratio. NPs 
functionalized at 1:2.5, 1:1 and 1:0.4 ratio had 1.54 µg, 1.39 µg and 1.02 µg of scFv at its 
surface, respectively. As these values are so close, it could be an explanation for the similar 
zeta potential seen. 
81 
After achieving functionalization, it was necessary to evaluate the interaction between the 
anti-CEA scFv and the cells, and additionally, the internalization potential of functionalized 
nanoparticles. The methodologies followed for such evaluation were the confocal 
microscope imaging and the ImageStream®X.  
Regarding the ImageStream®X analysis, to evaluate if the samples’ fluorescence is inside 
the cell, the Amnis software for data treatment applied an automatic cytoplasm mask. This 
mask only covered the expected area where the cytoplasm was. In this way, as it is drawn 
in the Figure 17B and 17K, a cell that has a positive internalization score, an ‘IS > 0’, is a 
cell that has mostly internalized fluorescence (in the cytoplasm) rather than in the 
membrane. On the other hand, a cell that has a negative internalization score, is a cell that 
has mostly fluorescence in the membrane rather than in its cytoplasm. Finally, a cell that 
has an internalization score around 0 is a cell that has almost the same fluorescence 
quantity associated to the membrane and in the cytoplasm, being the Internalization Score 
ranging from  (−∞; +∞) [165]. So, a positive internalization score does not mean 
necessarily that the fluorescence is all internalized by the cell, but rather that even being 
possible that any fluorescence is associated to the membrane, most of it is expected to be 
inside the cell. 
A good example to support that the analysis of the IS alone can generate fallacious 
conclusions is what happens with non-functionalized nanoparticles (NPs 1:0). On Figure 
17P, the percentage of positive cells for the staining was evaluated. Although the IS of non-
functionalized NPs (NPs 1:0) was higher than all the others (Figure 17C), this sample was 
exactly the one that seemed to be less positive for the staining. This might suggest that the 
reduced fluorescence intensity that was observed in this population was mostly internalized. 
This fact highlights the importance of understanding that the ImageStream®X gives an 
estimation of internalization in cells that are already positive for the staining, and does not 
consider the percentage of staining that exists in the total population. From now forward, 
the analysis of MFI values will be prioritised. 
In the confocal microscope imaging, nanoparticles functionalized with shMFELL2Cys (the 
positive antibody fragment) at 1:2.5 mol ratio seemed to obtain a higher internalization than 
the others functionalized at lower ratios (Figure 16A), as expectable. The MFI results 
(Figure 17H and 17J) pointed that functionalizing the particles (20 µg) at 1:2.5 ratio allow 
them to internalize more, when compared to non-functionalized particles. Also reveal that 
at that ratio, the particles were able to internalize more than the antibody fragment alone (at 
10 µg) or the probe alone (~ 5 µg). Similar conclusions were obtained by other researchers, 
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where the functionalization of the particles allowed a higher uptake by the cells, when 
compared with naked nanoparticles [73, 84]. 
In the Figure 16C and 16D, the SW480 cells that were only incubated with the rhodamine 
probe (Only Rhodamine) seem to have a different behaviour of internalization, existing 
several little spots of signal, smaller and more dispersed than the ones observed either in 
NPs 2:5 or scFv-Rhodamine. The NHS-Rhodamine (Mw = 631.37 g/mol) cannot passively 
diffuse into the cell (needed a < 500 Da) [109]. The molecules that can passively translocate 
membranes, perform a homogenous staining, because are not confined inside vesicles. 
The internalization of NHS-Rhodamine seems to be mediated by small vesicles and is very 
likely to result from a non-specific interaction with the cells. 
Many authors defend that the uptake of functionalized particles occurs through receptor-
mediated endocytosis, that is a very similar to the clathrin-dependent endocytosis 
mechanism of internalization. The particles are then supposed to be exposed to the 
endosome and/or lysosome environments, where they will trigger their own escape from 
such organelles through proton-sponge effect [54, 109, 118].  
In this work, the cells incubated with functionalized nanoparticles at higher scFv ratio (NPs 
2:5) and the ones incubated with the rhodamine-stained single-chain variable fragment 
(scFv-Rhodamine) seemed to have bigger spots of signal, when compared with the cells 
incubated with the rhodamine probe alone (Only Rhodamine). This possibly suggests that 
functionalized nanoparticles (NPs 2:5) and the stained antibody fragment (scFv-
Rhodamine) were internalized in vesicles with higher size than the ones observed for the 
rhodamine probe alone (Only Rhodamine). Several studies have found that particles with 
higher sizes can be internalized by larger vesicles, as phagosomes (diameter of 0.5 – 10 
µm, pH ~ 5) [166], and smaller particles can be internalized in smaller vesicles as 
endosomes (diameter of 0.06 - 0.7 µm, pH 5-6) [167, 168]. The phagocytic internalization 
is more often referred to phagocytes, like macrophages, but in fact, other eukaryotic cells 
have also ability to trigger this phenomenon. It is known that non-phagocytic cells can 
uptake particles up to 1 µm [169]. The size of a particle is influenced by the adsorption of 
serum proteins that generate the protein corona, in vivo [170]. In this work, the 
shMFELL2Cys-nanoparticles produced at lower (1:0.4) and higher (1:2.5) functionalization 
ratio had 446 ± 56 nm and 463 ± 118 nm, respectively, both with a high polydispersity index 
of ~ 0.5-0.6. The nanoparticles were incubated without FBS, but the influence of the 
surfactant [30], of the antibiotic and the ions from the medium are parameters that cannot 
be discarded. There is in this way, a small opportunity window to internalize particles of > 
500 nm in endosomes that can handle particles up to 700 nm. As phagosomes are more 
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suitable to internalize bigger particles, it is a possibility this is the pathway followed by the 
present nanoparticles. It would be also important to assess the stability of the formulations 
in such conditions, to determine if significant changes occur in terms of size or surface 
charge. 
The Figure 16E and 16F seem to indicate that the cells incubated with functionalized 
nanoparticles, at 1:1 scFv ratio (NPs 1:1), internalize more fluorescence than cells 
previously saturated with the scFv for CEA binding-site blocking, followed by incubation with 
functionalized nanoparticles (scFv + NPs 1:1). Since adding the anti-CEA scFv to occupy 
all the sites for the ligand recognition, the cell-surface CEA protein gets saturated. If the 
complex anti-CEA scFv-nanoparticle has few or no unspecific binding to the cell, there will 
be no signal, once the previously added anti-CEA scFv is competing with the anti-CEA scFv 
from the nanoparticle to bind to the carcinoembryonic antigen. 
The data presented so far suggests, although not proven, that the anti-CEA scFv-
nanoparticles are specific for the cell-surface CEA protein. 
Moreover, the FITC fluorescence seen in the negative fab functionalized particles is almost 
negligible, and from now on it will be compared with rhodamine-stained samples. Tiernan 
and co-workers defended that the binding of the antibody-functionalized nanoparticles is 
supposed to occur due to the affinity of the antibody itself to the target, and not due to its 
nonspecific interactions [83]. This reason motivated the use of a negative control antibody 
fragment (negative Fab), to confirm the specificity of the targeting system. Looking at Figure 
16G and 16H, it is very likely that a higher internalization occurred in the functionalized 
nanoparticles at 1:0.4 scFv ratio rather than in the negative Fab functionalized particles. In 
fact, the ImageStream®X results also contribute to prove that when functionalizing the 
nanoparticles with a negative control antibody fragment (NPs 1:0.4 Fab (-)), its efficiency of 
internalization is smaller than the observed when the particles are functionalized with a 
positive antibody fragment for the CEA at scFv ratio of 1:2.5 and 1:1 (NPs 1:1 and NPs 
1:2.5). Similar results were also obtained by other authors [75, 83].   
Finally, it was also the intention of the proposed dissertation to evaluate the toxicity of the 
proposed vehicles, once the siRNA itself should not trigger significant toxicity. The naked 
siRNA is very negatively charged, which difficult its interaction with the cellular membrane 
and is easily degraded by serum nucleases [94]. A metabolic activity assay (MTT) and LDH 
release assay (Figure 22, Appendices section), were in this way performed, without 
success, once all the values were highly variable in the samples tested, possibly due to the 
lack of homogeneity when seeding the cells in the plate, which invalidates the results 
achieved. Moreover, it is expected that the empty PLGA-PEG nanoparticles at relatively 
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higher concentrations (up to 270 µg/mL), even functionalized or not, will not trigger 
significant toxicity in SW480 cells, as shown previously by our group [84]. But since the 
practical Drug Loading of the present particles was very low ~ 0.007%, a higher number of 
particles is necessary to deliver the siRNA amount desired, which will eventually generate 
more toxicity. The solution for increasing the loading of siRNA passes through the usage of 
higher amounts of siRNA, its complexation with cationic polymers, or other strategies 
previously mentioned. 
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VI. Conclusions and 
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Colorectal cancer is one of the diseases that most kill worldwide, namely due to metastatic 
events. In those advanced stages of the disease the therapeutic recommended includes 
generally platinum-based regimens and other ‘blind’ combination schemes with standard 
chemotherapeutics. The targeted biomolecules that were developed so far include 
monoclonal antibodies and tyrosine kinase inhibitors that mostly benefit from the 
combination with the last referred standard therapies. The multidisciplinary evaluation and 
the study of the histopathological features of the host cancer microenvironment, stratify the 
individuals in specific cancer subtypes with known predictive response to a given 
therapeutic regimen. Even incorporating the targeted pharma, to reduce toxicity in healthy 
tissues, individuals with metastatic stages of CRC are still having very poor prognosis and 
very high mortality rates. There is, in this way, a wide window of opportunity to improve the 
metastatic colorectal cancer therapy. Importantly, the morbidity imposed to the patients by 
the therapeutic regimen cannot compromise their quality of life, so, developing new targeted 
strategies to treat individuals in more developed stages is needed. 
The therapeutic proposed here, emerges as a novel intravenous targeted therapy for 
metastatic colorectal cancer, namely to treat the subgroup of patients with tumours 
expressing CEA and MACC1 proteins. The metastasis-associated in colon cancer 1 
(MACC1) is an intracellular protein that works as a transcription factor of many genes, 
namely the tyrosine kinase receptor c-MET. It was already proven that CRC patients with 
in situ tumours that express this protein are more likely to develop distant metastasis in the 
future, as well that its upregulation is seen is metastases of colorectal cancer. Thus, the 
overexpression of this protein is related with CRC cancer metastases and have very low 
prognostic outcome. The potential of technologies to silence MACC1 in positive tumours is 
high. On the other hand, the only cell-surface molecule that is used in the clinics to monitor 
and make the post-operative evaluation of CRC is the carcinoembryonic antigen, CEA, that 
is also expressed in more advanced stages of the disease. 
Moreover, the design of a nanocarrier to deliver MACC1 siRNA to mCRC that is at the same 
time targeted to the CEA protein was developed using PLGA-PEG nanoparticles. 
Poly(lactic-co-glycolic acid), PLGA, exhibits low toxicity, biodegradable features and a 
sustained release profile whereas PEG increases circulation time in body fluids, which 
makes this carrier suitable for siRNA delivery. The system was surface functionalized with 
single-chain variable fragment with high affinity to the CEA protein (shMFELL2Cys). 
In the present project it was demonstrated that: 
i) Between the cell lines tested, SW480 and HCT-116 colorectal cancer cells 
expressed at the same time significative levels of MACC1 and CEA;  
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ii) MACC1 protein was efficiently silenced in SW480 cell line by the pool of 
MACC1 siRNAs used;  
iii) CEA protein seemed to be expressed at the cell-surface of SW480 cells;  
iv) Nanoparticles were loaded with the SMARTpool ON-TARGETplus siRNA 
MACC1 previously complexed with spermidine at 3:1 N/P ratio, followed by 
functionalization with anti-CEA scFv (shMFELL2Cys); 
v) The nanoparticles functionalized with the shMFELL2Cys appeared to be 
specifically internalized by SW480 cells. 
Firstly, the uptake of the nanoparticles by CEA-mediated endocytosis occurs due to the 
natural recycling of the CEA, that has a slow turnover half-life (~15h), which enables the 
longer retention of ligand-CEA complexes inside the cell. By its turn, this could enhance the 
sustaining release of the nanoencapsulated siRNA. Importantly, the linker and the chemical 
conjugation scheme chosen for ligand-nanoparticle coupling is essential to modulate the 
nanosystem characteristics. The functionalization of the particles with less affinity ligands 
for CEA recognition is maybe the best choice when an intravenous administration is wanted, 
to avoid the binding to the serum-available soluble CEA.  
Nevertheless, the functionalized and loaded nanoparticles present a size ~ 400 nm, with 
high polydispersity index, and negative zeta potential (~ - 25 mV). The association efficiency 
of the MACC1 siRNA was only of 5%, even when previously complexed with spermidine at 
3:1 N/P ratio. The practical drug loading was very low ~ 0.007%. Besides the cytotoxicity 
studies have been inconclusive, as a high number of particles is necessary to cellular 
delivery of the siRNA quantity desired, it will eventually generate more toxicity. The solution 
for increasing the loading of siRNA passes through the use of higher amounts of siRNA, its 
complexation with cationic polymers or other strategies to increase the inner aqueous phase 
viscosity of the double emulsion, previously mentioned along this dissertation. 
As seen in the present work, the nanoparticles functionalized with the shMFELL2Cys seem 
to be internalized by phagosomes (pH ~ 5), instead of the vast-described endosome-
mediated uptake. The knowledge of the pathways followed by the carrier after its uptake 
helps to improve therapies design. Moreover, higher internalization occurred in NPs 
functionalized with higher amount of the shMFELL2Cys (1:2.5 ratio), when compared with 
the lower ratios ones. Moreover, once applying the negative control, the efficiency of 
internalization is smaller than the observed when the particles are functionalized with the 
positive antibody fragment anti-CEA at ratio 1:2.5 and 1:1. This probably proves the 
specificity of the positive-targeted system to the CEA-expressing cells. 
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In ultimate analysis, it was showed the innovative potential of the developed CEA-targeted 
nanocarrier for siRNA delivery into metastatic colorectal cancer. The proposed intravenous 
therapy intends to benefit the mCRC patients’ subgroup that exhibit dual positivity for 
MACC1 and CEA. Considering the difficulty of the work, many important demonstrations 
were not accomplished. It is our intention, in the future, to study other relevant goals: i) 
prove that the CEA protein exists at the cell surface of the colorectal cancer cells; ii) prove 
that the anti-CEA scFv functionalized nanoparticles specifically target CEA-expressing 
cells; iii) being able to encapsulate MACC1 siRNA with higher association efficiency, either 
by complexation with other cationic polymers or other strategies; iv) prove by other 
methodologies (NMR, FTIR) that the anti-CEA scFv is covalently linked to the PLGA-PEG 
nanoparticles; v) prove that the nanoformulations functionalized and loaded with the 
MACC1 siRNA do not trigger significant toxicity and are able to specifically silence MACC1 
expression in CEA-expressing cells as SW480; vi) testing the effect of such formulations in 
vivo. 
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Immunofluorescence assay for evaluation of CEA localization 
in SW480 and HCT-116 cells 
 
 
 
 
 
 
 
Figure 18. Immunofluorescence assay for cell-surface CEA detection in HCT-116 and SW480 colorectal cancer 
cells. The cells were both fixed in methanol and 4% paraformaldehyde. On the first column is exposed the DAPI, 
followed by CEA staining. The cells exhibited a high autofluorescence in the green channel, namely, in the 
methanol-fixed SW480 cells, where the staining seems to be equivalent to the one observed for the CEA. The 
overlap of the DAPI, CEA and Autofluorescence images (Merge) and also the overlap of the DAPI and CEA images 
(DAPI + CEA) was not clear. The staining of the CEA protein was inconclusive due to technical issues related to 
the weak specificity of the anti-CEA monoclonal primary antibody applied. 
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Cell interaction studies with anti-CEA scFv by flow cytometry 
analysis (FACS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Preliminary FACS analysis to evaluate scFv interaction in SW480 (CEA expressing CRC cell line). 
The cells were not treated (unstained) or incubated with the anti-CEA single-chain antibody fragment followed 
by primary (Mouse anti-histidine tagged) and secondary (Goat anti-mouse) antibodies to assess the recognition 
of the CEA by the scFv (scFv + M-a-His + G-a-M). As controls the cells were incubated with the anti-scFv 
followed by the secondary antibody (scFv + G-a-M) or even with the secondary antibody alone (G-a-M). A last 
control was performed by incubating the cells with the primary followed by the secondary antibodies (M-a-His + 
G-a-M). The latest possibly indicates the unspecific cellular staining performed by the primary antibody Mouse-
anti-Histidine tagged. This strategy is in this way not suitable for CEA interaction evaluation. 
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Evaluation of CEA recognition by Cy7.5-scFv and 
functionalized PLGA-FITC nanoparticles by FACS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Preliminary study of the CEA recognition ability of scFv-Cy7.5 and of functionalized NPs made 
with PLGA-FITC polymer were evaluated by flow cytometry analysis (FACS) in SW480 cells. A CEA 
expressing cells (SW480) were incubated with the anti-CEA single-chain variable fragment (scFv) stained 
with the NH2-Cy7.5 (scFv-Cy 7.5). To note, the anti-CEA scFv was previously linked to the NH2-Cy 7.5 through 
two-step carbodiimide crosslinking reaction. As controls, the cells were incubated in complete medium 
(Unstained) or with the NH2-Cy 7.5 probe alone (Cy 7.5). To evaluate the impact of the functionalization ratio 
of NPs in the CEA recognition, SW480 cells were also incubated PLGA-FITC NPs functionalized with several 
ratios of scFv (NPs FITC 1:5, NPs FITC 1:2.5 and NPs FITC 1:1). As controls, cells were incubated with non-
functionalized NPs (NPs FITC 1:0) or first incubated with scFv to saturate the sites for CEA binding, followed 
by functionalized NPs at 1:5 scFv ratio (scFv + NPs 1:5). The NPs functionalization was made with scFv 
previously reduced with TCEP. The data is inconclusive due to cross contamination. 
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Physical-chemical characterization of functionalized 
nanoparticles  
 
Table 13. Characterization of functionalized nanoparticles at several scFv ratios and conjugation efficiency (CE) 
determination by ELISA direct method. 
Nanoparticles 95 PLGA5004A : 5 PLGA-PEG-Maleimide, pH 7.4, TCEP reduction 
 
Hydrodynamic 
diameter (nm) 
Polydispersity 
Index 
Zeta Potential 
(mV) 
Conjugation 
Efficiency (%) 
Naked NPs 200 ± 2 0.168 ± 0.025 -9.2 ± 0.3 --- 
NP 1 PLGA-PEG-Mal : 5 scFv 237 ± 6 0.259 ± 0.035 -23.4 ± 1.3 1.0 ± 0.6 
NP 1 PLGA-PEG-Mal : 2.5 scFv 315 ± 7 0.340 ± 0.034 -24.0 ± 1.3 1.2 ± 0.9 
NPs 1 PLGA-PEG-Mal :1 scFv 343 ± 5 0.344 ± 0.044 -26.6 ± 1.3 4.9 ± 0.6 
NPs 1 PLGA-PEG-Mal : 0.4 scFv 272 ± 15 0.322 ± 0.048 -24.7 ± 1.9 --- 
NPs 1 PLGA-PEG-Mal : 0.2 scFv 307 ± 14 0.411 ± 0.050 -28.4 ± 2.3 --- 
NP 1 PLGA-PEG-Mal : 0 scFv 292 ± 14 0.328 ± 0.043 -25.7 ± 1.8 --- 
 
A B 
Figure 21. Enzyme-linked immunosorbent assay (ELISA) of different formulations. (A) The ELISA was the 
methodology first selected for the anti-scFv detection at the surface of functionalized NPs. Non-functionalized 
NPs (NPs w/o scFv) and functionalized NPs at several scFv ratios (NPs 1.1, NPs 1:0.4, NPs 1:0.2) were 
evaluated. As expected, the functionalized NPs at higher scFv ratio (NPs 1:1) obtained higher detection signal. 
(B) This strategy was also applied to quantify the anti-CEA scFv conjugation efficiency by direct method at the 
nanoparticles’ surface. The non-functionalized nanoparticles (NP_1:0) and functionalized NPs at several scFv 
ratios (NP_1:1, NP_1:2.5, NP 1:5) were evaluated and the results of conjugation efficiency are summarized in 
table X. To note, the NPs functionalization was made with scFv previously reduced with TCEP. This method 
was not further followed to quantify the conjugation efficiency of functionalized nanoparticles, due to the time-
consuming optimization process. 
 104 
 
Cytotoxicity evaluation by metabolic activity assay (MTT) and 
LDH release assay 
 A 
B 
Figure 22. Evaluation of the toxicity of the nanoformulations and of free siRNA. (A) The metabolic activity 
assay, MTT (A), and the LDH release assay (B) were performed by incubating SW480 cells with several 
concentrations of the siRNA complex-loaded NPs functionalized with anti-CEA scFv at 1:0.4 ratio (0.01 nM, 
0.1 nM, 1 nM, 2.5 nM and 10 nM). The siRNA complex corresponds to spermidine/MACC1 siRNA at 3:1 N/P 
ratio. These concentrations were selected once the in vitro silencing of MACC1 occurred efficiently with 100 
nM of MACC1 siRNA further diluted to 10 nM final concentration in the cells. As controls, the free siRNA 
(free siRNA), non-functionalized and empty nanoparticles (Empty & Naked NPs), empty and functionalized 
NPs (NPs w/ scFv) and nanoparticles loaded with the siRNA complex were incubated at the same stablished 
concentrations. Due to the very low practical drug loading of siRNA complexes, the high concentration (10 
nM) was only applied for the free siRNA, because it required a concentration of nanoparticles not capable 
to be dispersed in the small volume of cellular incubation.  Importantly, the high variance between the values 
obtained for the both experiments invalidate the analysis of the results. 
